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SUMMARY 
 The flower heads of Chrysanthemum morifolium have been used as traditional 
medicine as well as a beverage for centuries in many Asian countries. Recently, it was 
found that the water extract of chrysanthemum significantly inhibited tumor growth in 
mice, suggesting the anti-tumor potential of this herbal plant. To investigate the anti-
tumor properties of chrysanthemum and its major active components, we conducted 
the following studies: 1) identification of the major active components of the water 
extract of chrysanthemum; 2) evaluation of the anti-tumor effects of the major active 
components; 3) investigation of the combined effects of luteolin, its main flavonoid, 
with cancer therapeutic agents in vitro and in vivo. 
 Initially, we applied a bioassay-driven fractionation strategy, and sequentially 
obtained four fractions from chrysanthemum. Flavonoids were then identified as the 
major components in the fraction showing the most potent cytotoxicity against human 
cancer cells. Further studies showed that the flavonoids extracted from chrysanthemum 
exerted significant cytotoxic effect on several human cancer cells via inducing 
caspase-dependent apoptosis. 
 Among a number flavonoids identified, luteolin is one of the most abundant 
found in chrysanthemum. In this study, we focused on the combined effect of luteolin 
with several cancer therapeutic agents, including tumor necrosis factor (TNF), TNF-
related apoptosis-inducing ligand (TRAIL) and cisplatin. 
 First, we found that luteolin significantly sensitized TNFα-induced apoptosis in 
a number of cancer cell lines. The sensitization was due to the inhibitory effect by 
luteolin on TNFα-induced activation of nuclear transcription factor-kappaB (NF-κB). 
As a result, luteolin suppressed the expression of NF-κB targeted anti-apoptotic genes, 
 xii
including A20 and cellular inhibitor of apoptosis protein-1 (c-IAP1), and augmented 
and prolonged c-Jun N-terminal kinase (JNK) activation.  
 Next, we found that luteolin significantly sensitized the apoptosis induced by 
TRAIL in TRAIL-resistant cancer cells. Such sensitization was achieved through 
down-regulation of X-linked inhibitor of apoptosis protein (XIAP), which was due to 
enhanced XIAP ubiquitination and proteasomal degradation. Further, we demonstrated 
that inhibitory effect of luteolin on protein kinase C (PKC) contributed to the XIAP 
down-regulation. In addition, our data reveal a novel function of PKC in cell death: 
PKC activation may stabilize XIAP and thus suppress TRAIL-induced apoptosis. 
 Third, we examined the effect of luteolin on the anti-cancer activities of 
cisplatin, a potent DNA damaging agent that has been widely used as a cancer 
chemotherapeutic in clinic. Our data showed that luteolin was able to enhance the 
apoptosis-inducing effect of cisplatin. Interestingly, p53 played a critical role in the 
apoptosis induced by combination of luteolin and cisplatin. We found that the rapid 
elevation of p53 protein level was due to stabilization effect of luteolin by decreasing 
MDM2 protein. Furthermore, combined treatment of luteolin and cisplatin induced 
significant p53 and Bax mitochondrial translocation as well as Bax conformation 
change. Finally, the anti-cancer potential of a combination of luteolin and cisplatin was 
investigated in a xenograft nude mice model. We found that luteolin could 
significantly enhance the anti-cancer activity of low dose of cisplatin by elevating p53 
protein. 
          In conclusion, the present study provides a new insight of the anti-tumor 
property of chrysanthemum and its major active component, luteolin. The evidence 
from both in vitro and in vivo experiments clearly demonstrates the anti-tumor 
potential of luteolin as a chemo-sensitizer in cancer therapy. 
 xiii
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1.1   CHRYSANTHEM MORIFOLIUM 
1.1.1 General introduction 
 Chrysanthemum morifolium Ramatuelle (also called Dendranthema morifolium 
or Hang Bai Ju in Chinese, referred as chrysanthemum hereafter in this thesis) is a 
member of the Compositae family. Its dried flower-heads have been used as a 
traditional herbal medicine in several Asian countries, such as China, Korea and Japan, 
for centuries. They have also been used as an herbal beverage in Chinese folklore and 
known as chrysanthemum tea (Figure 1.1). 
 The biological characters of chrysanthemum are “A perennial herb. 60-150 cm 
high. Stem erect, striate, hairy. Leaves alternate, petiolate, ovate or oblong, 3.5-5 cm 
long by 3-4 cm wide, variously lobed and divided. Inflorescence small head, 5 cm in 
diameter. Flowers yellowish-white. Calyxgreenish; ligulate unisexual, tubular bisexual. 
Stamens 5, syngenesious, epipetalous. Gynoecium bicarpellary, syncarpous, unicular, 
inferior; ovule one, basal placentation; style one with bifid curled stigmas whose 
receptive surfaces is on the inside. Fruit a one-seeded cypselia, crowned. Seed fills the 
fruit” (The Institute of Chinese Materia Medica, 1989). 
 Chrysanthemum is widely distributed in most habitats of China. In China, they 
are cultivated mainly in Zhejiang province along the Grand Canal. Tong Xiang City 
of this province, also referred to as the ‘City of Chrysanthemum’, produces about 
4000-5000 tons of dried chrysanthemum flowers each year, which accounts for more 
than 90% of the total chrysanthemum production in China. The plants are usually 
grown in early spring and the flowers are harvested in autumn of each year. Although 
the components of chrysanthemum may vary slightly according to the different 
cultivation environments, the flowers are processed using similar methods. After 
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Figure 1.1 Chrysanthemum morifolium Ramat (A) has been used 




steam treatment, the flowers were dried under the sun and then packed into an air-
tight plastic bag to prevent absorption of moisture.  
1.1.2 Chemical components of chrysanthemum 
 Volatile oil and flavonoids are believed to be the main active components in 
chrysanthemum. The most abundant and biologically active components flavonoids, 
in the form of glycoside derivatives, are more polar than volatile oil and hence are 
readily dissolved in water. Another group is terpenoids, which are present in the 
volatile oil. 
1.1.2.1 Flavonoids in chrysanthemum 
 Flavonoids are ubiquitous plant components with a common C6-C3-C6 
structure, consisting of two aromatic rings linked through three carbons (Figure 1.2A). 
The carbon skeleton can be regarded as being made up of a C6 fragment (A ring) and 
a C6-C3 fragment that contains a B ring. According to the variations in the 
heterocyclic C-ring, flavonoids can be further grouped into six major subclasses, 
including flavones, flavonols, flavanones, catechins, anthocyanidins, and isoflavones 
(Figure 1.2B) (Ross and Kasum, 2002).   
 Most flavonoids in plant cells are present as glycosides which are aglycons 
with sugar substitution. Sugar substitution on the flavonoid skeleton may occur 
through hydroxyl groups in the case of O-glycosides (Figure 1.2C), which is more 
common, or directly to carbon atoms in ring A as C-glycosides. The most important 
variations in their structure arise from the level of oxygenation (hydroxyl or methoxyl 
groups) and the position of attachment of ring B (flavonoids and isoflavonoids). The 
number of sugar rings substituted on the aglycone varies from one to four. All these 
render the great structure variation in flavonoids and so far more than 4000 types of 
flavonoids have been identified. 
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Figure 1.2 Structure of flavonoids
A, The skeleton of flavonoids; B, subgroups of flavonoids; C, 




Adopted from Ross and Kasum 2002
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Both flavonoid aglycons and flavonoid glycosides can be extracted from plants by 
methyl alcohol (MeOH) or ethyl acetate (EtOAc). Since flavonoid glycosides are 
more polar than flavonoid aglycons, its solubility in water is higher than that of 
aglycons. The structure of an individual flavonoid in a mixture can be identified using 
liquid chromatography (LC) and mass spectrometry (MS) (Stobiecki, 2000). 
 Flavonoids play an important role in defense of plants against microorganisms 
and insects, and act as UV protectants in plant cells (Harborne and Williams, 2000). 
These phytochemicals also affect the human and animal health because of their 
significance in the diet, which is ascribed to their antioxidant properties, estrogenic 
action and a wide spectrum of antimicrobial and pharmacological activities (Birt et 
al., 2001). The evidence comes from in vivo animal studies, in vitro cell culture 
experiments and human epidemiological studies (Hollman and Katan, 1999). For 
instance, epidemiological studies show a clear correlation between the flavonoid 
consumption and lower risk of cancer of the gastrointestinal tract (Hollman and 
Katan, 1999). A cohort study in Finland also supported that flavonoids intake in some 
circumstances may be involved in slowing cancer process and lowered cancer risks 
(Knekt et al., 1997). Several studies also suggested an inverse correlation of 
flavonoids intake with stroke and cardiovascular disease (Hollman and Katan, 1999). 
Flavonoids may block several points in the process of tumor promotion, including 
inhibiting kinases, reducing transcription factors and regulating cell cycle (Birt et al., 
2001). 
 In the last 3 decades, extensive studies have been conducted on isolation and 
identification of flavonoids in chrysanthemum. By extraction using 70 % MeOH and 
partition using hexane, CHCl3, ethanol (EtOH), n-butanol (n-BuOH), and H2O or 
similar methods, more than 12 flavonoids have been identified in chrysanthemum (Hu 
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et al., 1994; Liu et al., 2001; Lee et al., 2003; Hu et al., 2004). Most of the flavonoids 
are glycosides, which are conjugated with sugars. Based on their aglycon form, these 
flavonoids can be grouped into the following six major types: (i) luteolin (luteolin, 
luteolin-7-O-beta-D-glucoside), (ii) apigenin (apigenin-7-O-beta-D-glucoside, 
apigenin 7-O-beta-D-(4'-caffeoyl)glucuronide), (iii) acacetin (acacetin-7-O-beta-D-
glucoside, acacetin-7-O-beta-D-galactopyranoside, acacetin-7-O-(6”-rhamnosyl)-
beta-D-glucopyranoside), (iv) hesperetin (hesperetin-7-O-beta-D-glucopyranosyl (6”-
alpha-L-rhamnopyranoside, hesperetin-glucoside), (v) quercetin, and (vi) baicalin (Hu 
et al., 1994; Liu et al., 2001; Lee et al., 2003; Hu et al., 2004). 
 The flavonoid components of chrysanthemum have been proven to be 
responsible for the many pharmacological properties of this herbal plant, which will 
be discussed in more details in Section 1.1.3. However, it should be noted that the 
flavonoids present in chrysanthemum are not restricted in this plant. Most of them are 
also widely distributed in other plants, for example green tea, parsley, celery and 
berries. The studies on the bioactivities of flavonoids were extensively reviewed by 
Harborne and Williams (2000). 
1.1.2.2 Terpenoids in chrysanthemum 
 Terpenes are a class of naturally occurring chemicals derived from five-carbon 
isoprene units assembled and modified in various ways. They consist of one 
isoprenoid skeleton or of a polymer made up of several such units. According to the 
number of isoprene units that they contain, terpenes can be subdivided into several 
subclasses, including monoterpenes (C10H16, 2 isoprene units), sesquiterpenes (C15H24, 
3 isoprene units), diterpenes (C20H32, 4 isoprene units), triterpenes (C30H48, 6 isoprene 
units), tetraterpenes (C40H60, 8 isoprene units) and polyterpenes with a large number 
of isoprene units (Hanson, 2001). 
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 Terpenoids are terpenes which have substitute groups. The substitute groups 
may have varying degrees of oxygenation, such as alcoholic and ketonic, at different 
positions. The large variety of this compound makes terpenoids the largest group of 
natural products. Among the more than 23,000 terpenoids described, various 
interesting substances are already known to be present. For example, plant hormones, 
flavour, flagrances and biopolymers (latex) are terpenoids. Because many terpenoids 
are biologically active, they are also used for medical purposes. For instance, the 
antimalarial drug artemisinin and the anticancer drug paclitaxel (Taxol) are terpenoids 
with an established medical application (Linden et al., 2001) 
 Until now, more than 50 triterpenoids and several sesquiterpenoids have been 
isolated and identified in chrysanthemum (Akihisa et al., 1996). Ukiya et al. identified 
32 triterpenoids which are present as 3-O-fatty acid esters in the n-hexane soluble 
fraction and 24 triterpenoids as 3-O-palmitoyl esters in the nonsaponifiable lipid 
fraction (Ukiya et al., 2001). 
1.1.3 Pharmacological properties of chrysanthemum 
 Traditionally chrysanthemum is mainly used for common cold, fever, 
migraines, conjunctivitis, eye irritation, hypertension, ulcerative colitis, vertigo and 
ophthalmia with swelling and pain etc (Jiang, 2002). As a mixture with other herbs, it 
has been claimed to be able to relieve migraines and eye irritation, improve vision and 
cure keratitis. For instance, the effective rates against ulcerative colitis and 
hypertension are reported to be more than 90% and 80%, respectively (Liu, 1998; 
Jiang, 2002). 
1.1.3.1 Antioxidant activities 
 The antioxidant properties of flavonoids extracted from chrysanthemum could 
have been responsible for its broad pharmacological effects. It was found that its 
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water extract showed significant antioxidant activities, suggesting that the extract may 
reduce lipid peroxidation and play a role in protecting against damages to the cell 
membrane (Chen et al., 2003).  
 The water extract of chrysanthemum also possessed direct inhibitory effects 
on various free radicals (Duh, 1999). The significant correlation between phenolic 
compounds and antioxidant activity indicates that the flavonoids may contribute 
directly to the antioxidant activity of the extract. The flavonoids can also be absorbed 
into the cell membrane and hence protect the cells from the damages of free oxygen 
radicals (Duthie and Dobson, 1999).  
1.1.3.2 Anti-hypertension 
 The flavonoids of chrysanthemum have been proven to increase blood 
circulation in experimental animals, suggesting a potential role in reducing 
hypertension (Zhou, 1987). Several fractions from the ethanol extract also showed 
significant anti-myocardial ischemia and anti-arrhythmias activities in rats (Jiang et 
al., 2004).  
1.1.3.3 Anti-eye irritation 
 Aldose reductase catalyzes the reduction of glucose to sorbitol, which is 
responsible for eye irritation (Terashima et al., 1991; Matsuda et al., 2002). Hot water 
extract of chrysanthemum has been reported to inhibit rat lens aldose reductase. 
Flavones and flavone glycosides were found to be the active components (Matsuda et 
al., 2002).  
1.1.3.4 Anti-ulcerative colitis 
 Chrysanthemum water extract was found to inhibit ulcerative colitis by 
decreasing the contents of adherent glycoproteins, which are responsible for the 
adherence and communication between cells (Liu et al., 2001). 
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1.1.3.5 Anti-inflammatory activity 
 Chrysanthemum has long history for treatment of inflammation  (Yu and 
Xie, 1987). Eleven triterpene alcohols, isolated from chrysanthemum, were tested for 
their inhibitory effects on phorbal myristate acetate (PMA)-induced inflammation in 
the ears of mice. All eleven triterpene alcohols showed remarkable inhibitory effect 
with a 50% inhibitory dose at 0.1-0.8 mg per ear, which was roughly at the level 
comparable to that of indomethacin, an anti-inflammatory drug as positive control 
(Ukiya et al., 2001). Helianol, the most predominant component in the triterpene 
alcohol fraction, exhibited the strongest inhibitory effect among the 11 compounds 
tested. Since anti-inflammation activity of the inhibitors is highly related to their anti-
cancer-promoting activities, helianol is also expected to be a potent anti-tumor agent 
(Akihisa et al., 1996).  
 Flavonoids of chrysanthemum also have been showed to exert anti-
inflammatory effects (Cheng, 2005) and the mechanisms have been extensively 
studied. For example, luteolin is able to inhibit lipopolysaccharide (LPS)-induced 
release of TNF or interleukins (ILs) or directly inhibit the signaling transduction such 
as nuclear factor-kappa B (NF-κB) that mediates inflammatory responses (Xagorari et 
al., 2001; Xagorari et al., 2002; Kim et al., 2005b). The functional role of those 
molecules will be discussed in more details in Section 1.2.3. 
 Recently, extracts of chrysanthemum were investigated on their anti-
inflammatory effect in animal models. A butanol soluble fraction, which mainly 
contains flavonoids, caused a significant inhibition on the auricle edema induced by 




1.1.3.6 Anti-tumor activities 
 Recently the potential anti-tumor activity of chrysanthemum has interested 
many researchers. For instance, fifteen pentacylic triterpenes isolated from 
chrysanthemum have been screened for their anti-tumor-promoting activities. All of 
the compounds showed inhibitory effects against Epstein-Barr virus early antigen 
(EBV-EA) activation induced by the tumor promoter, PMA in Raji cell, which means 
that they can inhibit tumor promotion (Ukiya et al., 2002). The terpenoids faradiol, 
heliantriol B0, heliantriol, arnidiol, faradiol α-epoxide and maniladiol also showed 
significant inhibitory activity against almost all 60 human tumor cell lines derived 
from seven cancer types (lung, colon, melanoma, renal, ovarian, brain and leukemia) 
(Ukiya et al., 2002).  
 The anti-tumor activities of flavonoids have also been well documented. For 
example, as one of the flavonoids from chrysanthemum, luteolin has been reported to 
inhibit proliferation or induce cycle arrest or induce apoptosis in some cancer cells 
(more details in Sections 1.2.4.2, 1.2.4.3, and 1.2.4.4). The anti-tumor properties of 
luteolin can also be through inhibiting angiogenesis and metastasis (more details in 
Sections 1.2.4.5 and 1.2.4.6). 
 
1.2 PHARMACOLOGICAL MECHANISMS OF LUTEOLIN 
 Luteolin is one of the major flavonoids in chrysanthemum. As a ubiquitious 
flavonoid, luteolin has been extensively studied for its various biological effects, such 
as estrogenic and anti-estrogenic activity, anti-oxidant activity, anti-inflammation, 
anti-proliferation, anti-carcinogenesis, and anti-tumor effects. Many of these activities 
are functionally related to each other. For instance, its anti-inflammatory effects may 
also attribute to its anti-cancer effects. Anticancer property is closely related to the 
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effects on proliferation, cell cycle, apoptosis, topoisomerase and several protein 
kinases.  
1.2.1 Estrogenic and anti-estrogenic activity  
 Estrogens are hormones involved in the proliferation and differentiation of 
target cells. In response to estrogens, estrogen receptor (ER) will be activated and it 
then stimulate DNA synthesis and cell proliferation (Colditz, 2005). Flavonoids are 
naturally occurring phytoestrogens because they can bind to ER and activate its 
signaling pathway (Collins-Burow, 2000). So, it is suggested that these groups of 
natural compounds may be used to replace conventional hormones in therapy of 
menopause disorder. Luteolin possesses potent estrogenic activity at very low 
concentration (Zand, 2000), suggesting that it may be useful in hormone replacement 
therapy. 
 However, there were also reports about the anti-estrogenic effects of luteolin, 
similar to genistein, a well studied soy isflavone with both estrogenic and anti-
estrogenic properties (Wang, 1996; Han, 2002). The mechanisms behind this still 
remain controversial. A possible explanation is that flavonoids are estrogenic because 
they have a high affinity towards ER and thus activate ER if the estrogen is deficient. 
Nevertheless, their estrogenic activity is  relatively weak, 103-105 fold less than 17β-
estradiol (Murkies et al., 1998; Zand, 2000). Thus, in the presence of estradiol, 
flavonoids could possibly inhibit estrogen by competing for its receptors.  
 Since ER is one of the major risk factors in breast cancer, the anti-estrogenic 
activity of flavonoids has been suggested to be closely related to their anti-
proliferation activity and potential in breast cancer therapy and prevention. Luteolin, 
as well as other flavonoids such as daidzein, genistein and quercetin, is able to inhibit 
the proliferation-stimulating activity in MCF-7 cells caused by environmental 
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estrogens such as diethylstilbestrol, clopmiphene and bisphenol (Han, 2002). The 
suppressive effect of flavonoids suggests that these compounds have anti-estrogenic 
and anti-cancer activities. Wang and Kurzer (1998) also found that luteolin inhibits 
estradiol-induced DNA synthesis (Wang, 1998). In an in vivo test, Holland and Roy 
(1995) proved that luteolin reversed the estrogen-stimulated proliferation of 
mammary epithelial cells in female Noble rats, suggesting that it may play a 
preventive role in estrogen-induced mammary carcinogenesis (Holland and Roy, 
1995).  
 It is however important to point out that the anti-estrogenicity of flavonoids 
does not always correlate with their ER binding capacity, suggesting that alternative 
signaling mechanisms could have been involved in their antagonistic effects (Collins-
Burow, 2000). Mammalian cells contain two classes of estradiol binding sites, type I 
(Kd~1.0 nM) and type II (Kd ~20 nM), named according to their affinity 
(Markaverich, 1988). Luteolin was found to compete for estradiol binding to cytosol 
and nuclear type II sites but it did not interact with estrogen receptors (Markaverich, 
1988). In an in vivo study, injection of luteolin blocked estradiol stimulation of 
nuclear type II sites in the immature rat uterus and this correlated with an inhibition of 
uterine growth (Markaverich, 1988). Further studies also showed that luteolin could 
bind to nuclear type II sites irreversibly due to covalent attachment (Markaverich, 
1988). 
1.2.2 Antioxidant activity 
 Flavonoids are well known antioxidants and there were also many reports 
about the antioxidant effects of luteolin. Robak et al (1998) found that luteolin 
inhibits lipoxygenase activity, cyclooxygenase activity and ascorbic acid-stimulated 
malonaldehyde formation in liver lipids (Robak et al., 1988). In other reports, luteolin 
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also inhibits DNA damage induced by hydrogen peroxide or singlet molecular oxygen 
in human cells (Devasagayam et al., 1995; Noroozi et al., 1998). The glycosylated 
form of luteolin, luteolin-7-O-glucoside, demonstrates a dose-dependent reduction of 
LDL oxidation, although it is less effective than luteolin (Brown and Rice-Evans, 
1998). Studies of the copper-chelating properties of luteolin-7-O-glucoside and 
luteolin suggest that both of them act as hydrogen donors and metal ion chelators 
(Brown and Rice-Evans, 1998). Since oxidative stresses is closely related to 
mutagenesis and carcinogenesis, luteolin, as an anti-oxidant, may act as a 
chemopreventive agent to protect cells from various forms of oxidant stresses and 
thus prevent mutagenesis and carcinogenesis. 
 Although the ability of flavonoids to protect cells from the oxidative stress has 
been demonstrated, there is also increasing evidence for their pro-oxidant property 
(Cao et al., 1997; Lapidot et al., 2002; Sakihama et al., 2002; Galati and O'Brien, 
2004). It is believe that flavonoids could behave as antioxidants or pro-oxidants, 
depending on the concentration and the source of the free radicals (Cao et al., 1997). 
The pro-oxidant activity of flavonoids may be related to the ability of flavonoids to 
undergo autoxidation catalyzed by transition metals to produce superoxide anions 
(Hanasaki et al., 1994). In other reports, however, it was observed that the phenol 
rings of flavonoids are metabolized by peroxidase to form pro-oxidant phenoxyl 
radicals, which are sufficiently reactive to cooxidize glutathione (GSH) or 
nicotinamide-adenine hydrogen (NADH) accompanied by extensive oxygen uptake 
and reactive oxygen species formation (Galati et al., 2002). 
 One important understanding is that the pro-oxidant properties of flavonoids 
could contribute to their ability in induction of tumor cell apoptosis and cancer 
chemoprevention (Ueda et al., 2002). Exposure of mammalian cells to flavonoids is 
 15
accompanied by an increase in intracellular ROS levels and lipid peroxidation, which 
lead to apoptotic or necrotic cell death (Yoon et al., 2000; Morin et al., 2001; Mouria 
et al., 2002; Salvi et al., 2002; Shen et al., 2004).  
 Structure-activity relationship study on pro-oxidant cytotoxicity of flavonoids 
showed that flavonoids containing a phenol ring are generally more bioactive than 
that containing a catechol ring (Galati et al., 2002). Further studies showed that an 
increase in cytotoxicity is correlated with an increase in ease of electrochemical 
oxidation of flavonoids and their lipophilicity (Sergediene et al., 1999). Although 
luteolin has been shown to induce apoptosis in several cancer cells (section 1.2.4.3), it 
remains to be determined whether the pro-oxidant activity of luteolin is part of the 
mechanisms causing apoptotic cell death.  
1.2.3 Anti-inflammatory activity 
 Inflammation is a defense mechanism to guard against infection and help heal 
injury. During an inflammation, monocytes and macrophages become activated by 
various immune molecules, such as cytokines, or endotoxin, such as 
lipopolysaccharide (LPS), an outer membrane component of gram-negative bacteria. 
The activated macrophages will vigorously produce inflammatory molecules such as 
TNFα (Tracey and Cerami, 1994), ILs (Akira et al., 1993), free radicals and nitric 
oxide (NO) etc (Nathan and Xie, 1994), which will lead to  inflammation and turn on 
a deadly cascade of events. 
 LPS triggers the secretion of a variety of inflammatory products, such as TNF-
α (Tracey and Cerami, 1994), interleukins (Akira et al., 1993), intercellular adhesion 
molecule-1 (ICAM-1), as well as inducible nitric oxide synthase (iNOS), which 
produces excessive amounts of nitric oxide (Nathan and Xie, 1994). Production and 
release of inflammatory cytokines by LPS depends on inducible gene expression 
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mediated by the activation of transcription factor NF-κB (Baeuerle and Henkel, 1994; 
Baeuerle and Baltimore, 1996; Beuvink et al., 2005). The signals from LPS converge 
upon the IκB kinase (IKK) complex, which phosphorylates the inhibitor of NF-κB 
(IκB), causing its ubiquitination and degradation. Removal of IκB liberates NF-κB 
proteins such as p65 for nuclear translocation, binding to κB-promoter elements and 
induction of gene transcription.  
Macrophages participate in host defense and are main targets for the action of 
LPS. Pretreatment of murine macrophages RAW 264.7 with luteolin or luteolin-7-
glucoside inhibits both the LPS-stimulated TNFα and IL-6 release. Furthermore, 
luteolin abolishes the LPS-induced phosphorylation of Akt, which may link LPS 
activation to NF-κB activation (Zhou et al., 2000; Xagorari et al., 2001). However, 
overexpression of a dominant negative form of AKT does not alter LPS-induced 
TNF-α release, suggesting that inhibition of this kinase does not mediate the 
inhibitory action of luteolin (Xagorari et al., 2002). It is possible that luteolin 
interferes with LPS signaling by reducing the activation of MAPK family members 
ERK and p38, but not c-Jun N-terminal kinase (JNK) (Xagorari et al., 2002). The 
active anti-inflammatory components of Glossogyne tenuifolia were identified as 
oleanolic acid and luteolin-7-glucoside. Both of them inhibited LPS-stimulated 
inflammatory mediator production and NF-κB activation (Wu et al., 2004b). 
 Similar effects and mechanisms of luteolin on innate immunity were found in 
intestinal epithelial cells and dendritic cells. Luteolin significantly blocks LPS-
induced IκB phosphorylation and degradation, NF-κB transcriptional activity and 
intercellular adhesion molecule-1 (ICAM-1) gene expression in rat IEC-18 cells (Kim 
and Jobin, 2005). This effect is by directly inhibiting the LPS-induced IKK activity. 
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 Interestingly, although luteolin shows potent inhibition on LPS-stimulated NF-
κB transcriptional activity in Rat-1 fibroblasts, it does not inhibit either IκBα 
degradation, ,NF-κB nuclear translocation, or DNA binding induced by LPS (Kim et 
al., 2003b). Rather, luteolin prevents LPS-stimulated interaction between the p65 
subunit of NF-κB and the transcriptional coactivator CBP, suggesting that the effect 
of luteolin on NF-κB signaling varies depending on the cell types.  
 Luteolin not only inhibits LPS stimulated release of proinflammatory 
cytokines such as TNF and ILs, but also directly inhibits the signaling triggered by 
TNF or ILs. Intercellular adhesion molecule-1 (ICAM-1) is an immunoglobulin 
superfamily expressed on endothelial cells and important for adhesion of leukocytes 
and transendothelial migration (Hubbard and Rothlein, 2000). Luteolin inhibits TNF-
α-stimulated ICAM-1 expression by inhibiting IKK activity, IκBα degradation, NF-
κB DNA-protein binding, and NF-κB luciferase activity in respiratory epithelial cells 
(Hubbard and Rothlein, 2000). The inhibitory effects of luteolin on ICAM-1 
expression are also mediated by the sequential attenuation of the three MAPKs 
activities, the c-fos and c-jun mRNA expressions, and the activator protein-1 (AP-1) 
transcriptional activity (Chen et al., 2004). Through a similar mechanism, luteolin can 
inhibit TNF-alpha-induced IL-8 production in human colonic epithelial cells (Kim et 
al., 2005b).  
 Another important inflammation mediator, NO is synthesized by inducible NO 
synthase (iNOS), which is activated by LPS. Luteolin and its glycoside, luteolin-7-O-
glucoside, suppress the production of NO and prostaglandin E2 (PGE2) in LPS 
activated-mouse macrophage RAW264.7 cells (Kim et al., 1999; Hu and Kitts, 2004). 
The inhibitory effect is attributed to the suppression of both iNOS and 
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cyclooxygenase-2 (COX-2) protein expression by luteolin, without affecting the 
enzymatic activity directly (Kim et al., 1999; Hu and Kitts, 2004). 
 It should be pointed out that it seems unlikely that the inhibitory action of 
luteolin on proinflammatory cytokine production is the result of antioxidant properties. 
This is based on observations that some flavonoids with strong antioxidant properties 
are completely ineffective in reducing LPS-stimulated TNF-production (Devasagayam 
et al., 1995). A structure-activity study shows that the presence of a double bond at 
position C2-C3 of the C ring with oxo function at position 4, along with the presence 
of the OH groups at positions 3' and 4' of the B ring are required for optimal inhibition 
of LPS-stimulated TNF- release (Xagorari et al., 2001).  
 The anti-inflammatory ability of luteolin has been also evaluated in vivo. Mice 
receiving LPS exhibited high mortality after the LPS challenge. On the contrary, mice 
that had received luteolin (0.2 mg/kg, intraperitoneally) before LPS showed an 
increased survival (Kotanidou et al., 2002). Luteolin pretreatment also reduces LPS-
stimulated TNF-α release in serum and ICAM-1 expression in the liver (Kotanidou et 
al., 2002), which is in agreement with many in vitro observations. The effect of 
luteolin was also tested in an acute Chlamydia pneumoniae infection model in 
C57BL/6J mice. Luteolin was found to suppress inflammation in lung tissue that was 
caused by Chlamydia pneumoniae, however, luteolin treatment had no effect on iNOS 
but significantly decreased the expression of constitutive eNOS enzyme 
(Tormakangas et al., 2005).  
 In summary, the anti-inflammation effect of luteolin has been well 
documented. It is via not only inhibiting LPS-stimulated release of cytokines such as 
TNF and ILs but also directly inhibiting the signal transductions triggered by these 
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cytokines. Both mechanisms may attribute to the strong inhibitory effects of luteolin 
on NF-κB.  
1.2.4 Anti-cancer property 
1.2.4.1 Anti-carcinogenesis activities 
 Carcinogenesis is a long-term and multi-stage process that results from 
accumulation of mutation and dysfunction of important molecules regulating cell 
proliferation and cell death. The process of chemical carcinogenesis may be divided 
into three stages: initiation, promotion and progression. During initiation, a potential 
carcinogen is transformed into a mutagen by phase I enzymes such as cytochrome 
P450. The mutagen may react with cellular molecules such as DNA and result in 
genetic mutation. During the promotion stage, the genetic alterations will lead to 
enhanced cell proliferation and/or reduced cell death. During the promotion stage, the 
mutations are enhanced and the cells are proliferating in an uncontrolled manner 
(Pitot, 1993). 
 The inhibitory effects of flavonoids, including luteolin, on carcignogenesis 
have been well documented. In an in vivo study, it was observed that luteolin 
significantly decreased the incidence of fibrosarcoma induced by 20-
methylcholanthrene (20-MC), a strong carcinogen, in male Swiss albino mice 
(Elangovan et al., 1994). Other studies showed that, to prevent tumor development, 
different stages of carcinogenesis can be targeted by luteolin. In the initiation stage, 
luteolin were found to inhibit the metabolism of carcinogens in isolated liver 
microsomes (Buening, 1981). In another study, Huang et al (1983) found that luteolin 
inhibits the mutagenic activity resulting from the metabolic activation of benzo-
pyrene and trans-7,8-dihydroxy-7,8-dihydrobenzo-pyrene in rat liver microsomes 
(Huang, 1983). Later in 1998, Oguri et al proved that luteolin suppresses formation of 
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mutagenic and carcinogenic heterocyclic amines (Oguri, 1998). Recently, it was 
found that luteolin acts as a potent inhibitor of human cytochrome P450 (CYP) 1 
family enzymes, such as CYP1A1, CYP1A2, and CYP1B1, and thus the 
transformation of potential carcinogen into a potent mutagen product is inhibited 
(Kim, 2005). During the promotion stage, luteolin could directly scavenge the 
ROS/RNS generated by various mutagens, or by inhibiting pro-oxidant enzymes, such 
as xanthine oxidase (Nagao, 1999), myeloperoxidase (Kostyuk et al., 2003), and 
lipoxygenases (Sadik et al., 2003). In addition, luteolin can inhibit the lipid 
peroxidation induced by CCl4 (Cholbi, 1991) or by FeSO4+ cysteine in rat liver 
microsomes (Mora, 1990). 
  On the other hand, luteolin targets the enzymes involved in DNA synthesis, 
for example, DNA topoisomerases, to suppress tumor promotion. DNA 
topoisomerases are the essential enzymes that catalyze the interconversion of 
topological isomers of DNA molecules (Corbett and Berger, 2004). Acting by 
sequential breakage and reunion strands of DNA, two topoisomerases (topoisomerase 
I and topoisomerase II) are involved in many vital cellular processes such as DNA 
replication, transcription, recombination, integration and chromosomal segregation 
(Corbett and Berger, 2004). The dysfunction of these vital enzymes will result in 
DNA damage that may induce cell cycle arrest or apoptosis. Several flavonoids have 
been shown to exert their action by interacting with DNA topoisomerases and 
promoting site-specific DNA cleavage (Constantinou, 1995). Luteolin inhibits 
topoisomerase II activity of HL-60 cells by forming a luteolin- topoisomerase II-DNA 
ternary complex and then induces apoptosis in the cells (Yamashita and Kawanishi, 
2000). By inhibiting DNA synthesis and promoting topoisomerase-II-mediated 
cleavage of kinetoplast DNA minicircles, luteolin inhibits the growth of Leishmania 
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donovani promastigotes and arrest its cell cycle progression, leading to apoptosis 
(Mittra et al., 2000).  
 In addition, luteolin also strongly inhibits the catalytic activity of eukaryotic 
DNA topoisomerase I (Chowdhury et al., 2002). Luteolin intercalates directly with 
the enzyme as well as the substrate DNA to stabilize the topoisomerase-DNA 
covalent complex and thus to block the subsequent rejoining of the DNA breaks.  
1.2.4.2 Inhibition on cell proliferation 
 One character of cancerous cells is that they are undergoing rapid and 
unlimited proliferation. Proliferation requires the success of DNA synthesis and then 
cell division, which is controlled by signaling pathways triggered by growth factors, 
such as epidermal growth factor receptor (EGF), platelet-derived growth factor 
(PDGF), insulin-like growth factor (IGF), fibroblast growth factor (FGF), and 
vascular endothelial growth factor (VEGF). 
 Many flavonoids, including luteolin, were found to be able to inhibit the 
proliferation of cancer cells derived from nearly all tissues, such as human breast 
cancer cells MCF-7, human neuroblastoma cells SHEP and WAC2 (Fotsis, 1997; Han, 
2002), Raji lymphoma cells (Ramanathan, 1994), pancreatic cancer cells MiaPaCa-2 
(Lee et al., 2002), human leukemia cells HL-60 (Ko et al., 2002), hepatic stellate cells 
(Zhao, 2002), human thyroid carcinoma cell lines (Yin, 1999), human melanoma cells 
OCM-1 (Iwashita, 2000), human epidermoid carcinoma A431 (Huang et al., 1999a) 
and human prostatic tumor cells (Knowles, 2000). 
 The anti-proliferation mechanisms of luteolin have been explored extensively 
in several aspects. 
 Firstly, it is controversial whether the anti-proliferation effect of luteolin is 
dependent on endoplasmic reticulum (ER) (Ross and Kasum, 2002). Luteolin, as well 
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as several other flavonoids, suppresses the proliferation of human prostatic tumor 
cells (PC-3), androgen-independent cells, indicating that flavonoids show their anti-
proliferation activity in an androgen-independent manner (Knowles, 2000). On the 
other hand, it was found that luteolin inhibits estradiol-induced DNA synthesis in both 
estrogen-dependent MCF-7 and estrogen-independent MDA-MB-231 human breast 
cancer cells (Wang, 1997; Wang, 1998; Han, 2002). In a separate study, luteolin was 
shown to inhibit the proliferation of several human thyroid carcinoma cell lines, 
UCLA NPA-87-1 (with estrogen receptor), UCLA RO-82W-1 (with anti-estrogen 
binding site) and UCLA RO-81A-1 (lacking both estrogen receptor and anti-estrogen 
binding site), suggesting that the inhibitory activity of luteolin on cancer cell 
proliferation is not dependent on estrogen receptor or androgen receptor, but via other 
mechanisms (Yin, 1999). 
 Secondly, since luteolin is able to inhibit the activity of topoisomerases, which 
is critical for DNA synthesis (Constantinou, 1995; Mittra et al., 2000; Chowdhury et 
al., 2002), it has been suggested that luteolin inhibits cell proliferation by inhibiting 
topoisomerases and DNA synthesis (Makino, 2001).  
 Thirdly, the inhibitory effect of luteolin on cancer cell proliferation is related 
to its effects on various growth factors and their signaling pathways, including 
epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and vascular 
endothelial growth factor (VEGF). For instance, EGF activates EGF receptor which is 
a typical receptor tyrosine kinase that stimulates cell growth as well as cell migration 
through receptor phosphorylation and the subsequent activation of downstream 
signaling pathways (Zhang, 1998). Luteolin was found to inhibit the proliferation of 
pancreatic cancer cell MiaPaCa-2 and its effect is closely related to the inhibition of 
the activity of EGF receptor, but not protein synthesis (Lee et al., 2002). The same 
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group found that luteolin inhibits proliferation of human epidermoid carcinoma A431 
cells via a similar mechanism (Huang et al., 1999b).  
 PDGF is one of the principal regulators of proliferation and migration of 
vascular smooth muscle cells (VSMCs). PDGF binding to its receptor leads to its 
phosphorylation on multiple tyrosine residues. The activated PDGF receptor is 
associated with a number of proteins including the phosphatidylinositol 3'-kinase 
(PI3K), which mediates Raf-MEK-ERK transduction (Claesson-Welsh, 1994). 
Luteolin inhibits PDGF-induced proliferation and DNA synthesis of rat aortic VSMCs 
by inhibiting PDGF receptor phosphorylation (Kim et al., 2005b). As a consequence, 
luteolin significantly inhibits PDGF-induced ERK, Akt and phospholipase C (PLC)-
γ1 activation as well as c-fos gene expression (Kim et al., 2005b). These results 
suggest that the inhibitory effect of luteolin on the PDGF-induced proliferation of rat 
aortic VSMCs may be mediated by blocking phosphorylation of PDGF receptor (Kim 
et al., 2005c). 
 Another important growth factor is VEGF, which is one of the most important 
factors regulating key angiogenic responses of endothelial cells. They include 
proliferation, migration, and differentiation, as well as protection from apoptosis 
(Ferrara, 2001). In a murine xenograft model, luteolin was demonstrated to inhibit 
tumor growth and angiogenesis (Bagli et al., 2004). Furthermore, it was found that 
luteolin inhibits proliferation of human umbilical vein endothelial cells by inhibiting 
VEGF-induced PI3K activity and activation of Akt, a downstream target of PI3K. 
However, luteolin does not affect VEGF-induced ERK activation, which is considered 
important for the mitotic effects of VEGF (Bagli et al., 2004). 
 Protein kinase C is a family of serine-threonine protein kinases that regulate 
growth factor response, cell proliferation, differentiation and apoptosis (Lucas and 
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Sanchez-Margalet, 1995; Weinstein et al., 1997). It was found that PKC is inhibited 
in a concentration-dependent manner by many flavonoids including luteolin in both 
cell-free systems and intact cells (Ferriola et al., 1989). Another study showed that 
luteolin is a potent inhibitor of human mast cell activation through the inhibition of 
Ca2+ influx and PKC activation (Kimata et al., 2000). 
 Thus, it appears that luteolin is able to inhibit activity of a range of kinases, 
such as RTKs, PI3K and PKC. The question to ask is whether this inhibitory effect on 
different kinases is via a common mechanism. Apigenin, with a structure similar to 
luteolin, is also able to inhibit a wide range of kinases and this inhibitory effect is by 
competing with adenosine triphosphate (ATP) (Huang, 1996; Conseil, 1998). It 
remains to be determined whether luteolin inhibits various kinase activity through the 
same mechanism. 
 Finally, the inhibitory effect of luteolin on cell proliferation is related to its 
effect on cell cycle progression or cell death. For example, luteolin inhibits 
proliferation of human melanoma cells OCM-1 by arresting the cells at phase G1 
(Casagrande and Darbon, 2001). In human leukemia HL-60 cells, luteolin inhibits its 
proliferation at low dose and induces apoptosis at higher dose (Ko et al., 2002). 
Detailed discussion about cell cycle arrest- or apoptosis-inducing effects of luteolin 
will be covered in subsequent sections. 
1.2.4.3 Induction of cell cycle arrest 
 In eukaryotic cells, cell proliferation proceeds through DNA replication 
followed by division of nucleus and separation of cytoplasm to yield two daughter 
cells. The sequential process, called cell cycle, contains 4 distinct phases 
biochemically. G1 phase is a period when cells decide whether to start proliferation or 
to stay quiescent. Once cells decide to proliferate, their DNA will be replicated during 
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a DNA synthesis phase (S phase). The phase after DNA synthesis is called G2 phase 
which allows for the repair of DNA damage and replication errors. When there is no 
DNA damage or replication errors, the nucleus and cytoplasm will be equally divided 
into two and yield two daughter cells, which is call mitosis phase (M phase) 
(Massague, 2004). Cell cycle progression is timely regulated by cyclin-dependent 
kinases (CDKs) and their cyclin subunits (Ekholm and Reed, 2000). G1 progression 
and G1/S transition are regulated by CDK4-cyclin D, CDK6-cyclin D and later 
CDK2-cyclin E. While CDK2 controls S-phase when associated with cyclin A and 
G2/M transition is regulated by CDK1 in combination with cyclins A and B 
(Donjerkovic and Scott, 2000). Activation of CDKs is regulated by cyclin as well as 
CDK inhibitors (CKIs). Two families of mammalian CKIs have been identified: the 
INK4 family, which specifically inhibits CDK4 and CDK6, and the CIP/KIP family, 
including p21cip1/waf1, p27kip1 and p57kip2, which have a broad range of inhibition 
(Ekholm and Reed, 2000).  
 Cell cycle checkpoints have been the targets for chemotherapeutic and 
chemopreventive agents. In several in vitro experiments, flavonoids have been found 
to inhibit the proliferation of many cancer cells by arresting cell cycle progression 
either at G1 or at G2/M phase (Zi et al., 1998; Lindenmeyer et al., 2001).  
 Although luteolin has been found to inhibit cell growth and proliferation of 
many cancer cells, its effect on cell cycle distribution was found only in several cell 
lines. Luteolin arrests the cell cycle at G1 phase in the following three cancer cell 
lines: human gastric cancer HGC-27 cells (Matsukawa et al., 1993), human melanoma 
cells OCM-1 (Casagrande and Darbon, 2001) and human prostate cancer cells LNCaP 
(Kobayashi et al., 2002). The G1 cell cycle arrest induced by luteolin on OCM-1 is 
mediated by inhibiting the activity of CDK2, which is attributed to the up-regulation 
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of its inhibitors p27/kip1 and p21/waf1 (Casagrande and Darbon, 2001). On the other 
hand, luteolin was found to arrest mouse cancer cell tsFT210 at G2/M phase (Li et al., 
2005). Another study suggests that the G2/M arresting effect might be related to the 
activation of the tumor suppressor protein p53. Luteolin was also found to induce 
G2/M arrest in a non-tumor cell line C3H10T1/2CL8 due to the rapid activation of 
p53 (Plaumann et al., 1996). 
1.2.4.4 Induction of apoptosis 
 During the development, apoptosis is critical in eliminating unwanted cells in 
a specific site to form organs. Apoptosis is also critical in eliminating any damaged 
cells that may be caused by carcinogens and keep the whole organism healthy. 
Insufficient apoptosis of the damaged cells is believed to be a reason of cancer 
formation. Therefore, many cancer therapeutics work through induction of cancer cell 
apoptosis (Ghobrial et al., 2005). 
In addition to the inhibitory effect on cancer growth, luteolin is able to kill 
cancer cells by inducing apoptotic cell death. It has been reported that luteolin can 
induce apoptosis in several cancer cell lines, including human epidermoid carcinoma 
A431(Huang et al., 1999b), human leukemia HL-60 (Ko et al., 2002; Cheng et al., 
2005a) and U937 (Monasterio et al., 2004), pancreatic tumor cell MiaPaCa-2 (Lee et 
al., 2002), and human hepatoma cell HepG2 (Lee et al., 2005). 
 One possible mechanism of apoptosis-inducing effect of luteolin is that this 
flavonoid is a RTK inhibitor and it may mimic deprivation of growth factors by 
blocking the growth factor-triggered signaling pathway. The possibility was partially 
supported by the finding that apoptosis induced by luteolin in pancreatic cancer cell 
MiaPaCa-2 is concomitant with dampened EGF receptor triggered-signals (Lee et al., 
2002). 
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 Topoisomerases are essential in catalyzing sequential breakage and reunion 
strands of DNA, which is involved in many vital cellular processes such as DNA 
replication and transcription. Inhibition of topoisomerases not only suppresses DNA 
replication and cell proliferation but also caused DNA damage, which might lead to 
apoptosis. Luteolin has reported to inhibit topoisomerases II (Yamashita and 
Kawanishi, 2000) and induced apoptosis in HL-60 cells. The inhibition is through 
forming a luteolin-topoII-DNA ternary complex. Luteolin has been also proven to 
inhibit the catalytic activity of DNA topoisomerase I  (Chowdhury et al., 2002). 
Luteolin intercalates directly not only with the enzyme but also with substrate DNA. 
Further study showed that it can cause DNA damage by stabilizing the topoisomerase-
DNA covalent complex and block the subsequent rejoining of the DNA break 
(Chowdhury et al., 2002).  
 In response to DNA damage, a number of signals are activated sequentially. 
Ataxia telangiectasia mutated kinase (ATM) and ataxia telangiectasia and Rad3-
related kinase (ATR) are activated very rapidly and then activate p53, which 
eventurely leads to cell cycle arrest or apoptosis. The apoptosis mediated by p53 may 
be through either a transcription-dependent pathway, which involves the activation of 
proapoptsotic genes, or transcription–independent pathway, which involves p53 and 
Bax mitochondrial translocation (Chipuk et al., 2003; Erster et al., 2004). Plusseman 
(1996) found that luteolin, as well as apigenin and quercetin, induces apoptosis, which 
is accompanied by p53 protein accumulation and p53 transactivation (Plaumann et al., 
1996). Recently, two studies proved that change of mitochondria and Bcl-2 family 
member proteins are involved in the apoptosis induced by luteolin in cancer cells. 
Luteolin induces cleavage of the proapoptotic Bcl-2 proteins, Bax and Bak 
translocation to mitochondria and the release of cytochrome c to cytosol, whereas Fas 
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ligand remains unchanged, suggests that luteolin induced apoptosis via mechanisms 
involving mitochondria translocation of Bax/Bak (Cheng et al., 2005a; Lee et al., 
2005).  
1.2.4.5 Anti-angiogenesis 
 Angiogenesis, the generation of new blood vessels, occurs during many 
physiological processes, including development, wound healing, formation of the 
corpus luteum, endometrium and placenta (Folkman, 1995). Angiogenesis also occurs 
in some pathological processes, such as solid tumor growth and metastasis, which 
require nutrition and oxygen due to the fact that avascular tumors do not grow beyond 
a diameter of 1-2 mm (Folkman, 1995). Rapid growth of tumor and consumption of 
oxygen result in hypoxia, which activates transcription of genes such as vascular 
endothelial growth factor (VEGF) and matrix metalloproteases (MMP). In response to 
secretion of angiogenic stimuli, such as VEGF and MMP which degrade the 
extracellular matrix, the endothelial cell basal membrane is degraded by the action of 
protease and then the endothelial cells migrate and proliferate and finally organize 
into capillary tubes. Several important factors are involved in this progress. (1) VEGF 
receptor. This enzyme is one of the most potent and specific known angiogenic 
factors in vivo. It increases microvascular permeability in response to hypoxia, 
multiple growth factors, cytokines and estradiol (Benassayag et al., 2002). (2) 
Hyaluronidase. Hyaluronic acid is one of the most abundant constituents of the 
extracellular matrix and acts as a barrier to neovascularization (Trochon et al., 1997). 
Fragments of hyaluronic acid, as a result of catalytic activity of hyaluronidase, bind to 
CD44 receptor exposed on the membrane of endothelial cells and then are responsible 
for endothelial cell proliferation, migration and finally angiogenesis. (3) MMP. 
Metalloproteases also can promote angiogenesis by degrading the extracellular matrix.  
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 Transcription of the VEGF gene is enhanced under hypoxic conditions 
(Semenza, 2001). Many flavonoids have been reported to be able to inhibit hypoxia 
and hypoxia-activated downstream events (Zhou et al., 2004; Fang et al., 2005; Liu et 
al., 2005). Luteolin is also effective in inhibiting the transactivation of the hypoxia-
response element (HRE) under hypoxic conditions (Hasebe, 2003). On the other hand, 
luteolin, as a RTK inhibitor (section 1.2.4), was also found to be able to inhibit the in 
vitro angiogenesis by inhibiting VEGF activity (Fotsis, 1997; Bagli et al., 2004).  
 In addition, luteolin has been found to be a potent competitive inhibitor of 
hyaluronidase (Kuppusamy, 1990), which catalyzes  hyaluronic acid and activates 
receptors for endothial cell proliferation, migration and angiogenesis. As an inhibitor 
of several growth factors, luteolin inhibits EGF triggered MMP secretion in A431 
cells (Huang et al., 1999b). Moreover, it was shown luteolin can also directly inhibit 
MMP activity. Interestingly, kinetic analysis revealed that the inhibition of MMP by 
luteolin is non-competitive, while luteolin inhibits hyaluronidase in a competitive 
manner (Ende, 2004). 
 The anti-angiogenesis effect of luteolin was confirmed in two in vivo studies. 
Luteolin can significantly inhibit corneal angiogenesis in vivo and corneal 
neovascularization induced by fibroblast growth factor (FGF) (Joussen et al., 2000). 
Recently, in a murine xenograft model, luteolin is able to inhibit tumor growth and 
angiogenesis (Bagli et al., 2004). Furthermore, it has been shown that luteolin inhibits 
angiogenesis by inhibited VEGF-induced PI3K activity and activation of AKT (Bagli 
et al., 2004). 
1.2.4.6 Inhibition on cancer metastasis 
 In addition to rapid and continuous division and proliferation, another 
important feature of cancer cells is their ability to spread from the primary site to 
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other more distant sites. This process, called metastasis, contributes to over 90% of 
human cancer mortality. The deadly process involves several sequential steps, 
migration, invasion and adhesion, which are driven by growth factors such as EGF, 
and MMPs (Brinckerhoff and Matrisian, 2002).  
 Transactivation of the epidermal growth factor receptor (EGFR) tyrosine 
kinase activity is proposed to stimulate cell migration by regulating MMP expression. 
By blocking of the EGFR-signaling pathway, luteolin is able to reduce the level of 
phosphorylated FAK as well as the secreted MMP, which may lead to the suppression 
of cell invasion and metastasis (Huang et al., 1999b; Lee et al., 2004).  
 In addition to many growth factors, cytokines also control MMP expression. 
For example, interleukin 6 (IL6) is known as a cytokine that induces MMP-1 
expression. Luteolin is potent in inhibiting the production of IL-6 and suppressing the 
expression of MMP-1 (Kim, 2004). Since ILs production is regulated by NF-κB, it is 
possible that the inhibitory effect of luteolin on NF-κB may play a role in suppressing 
IL production and MMP expression.  Interestingly, luteolin as well its glycoside, can 
directly inhibit the activity of MMP-2 and MMP-9, in a non-competitive manner 
(Ende, 2004). 
 On the other hand, luteolin is a potent inhibitor of in vitro invasion of human 
PC-3 prostate cancer cells (Lansky, 2005). Since elevation of Focal adhesion kinase 
(FAK) activity in human carcinoma cells is associated with increased invasive 
potential, the inhibitory effect of luteolin on FAK phosphorylation may contribute to 
suppression of cell invasion ability (Huang, 2005). 
 Intercellular adhesion molecule-1 (ICAM-1) has been implicated in the 
processes of adhesion and metastasis. Luteolin was found to suppress TNF-stimulated 
ICAM-1 expression in respiratory epithelial cells. The inhibitory effect of luteolin on 
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ICAM-1 expression is mediated by inhibiting NF-κB pathway, including IKK activity, 
IκBα degradation, NF-κB DNA-protein binding, and NF-κB luciferase activity, as 
well as AP-1 transcriptional activity (Chen et al., 2004). 
 Taken together, Section 1.2.4 summarizes different aspects of the anticancer 
properties of luteolin and the main mechanisms involved. Luteolin has been proved to 
be a potent anticancer agent in a variety of cancer cells in vitro as well as in a number 
of in vivo animal models. Firstly, it can inhibit carcinogenesis at different stages: 
initiation, promotion and progress. Secondly, it can inhibit cancer cell proliferation, or 
modulate cancer cell cycle progression, or induce apoptotic cell death or suppress 
angiogenesis. Lastly, luteolin possesses strong anti-metastasis effect, an important 
property in cancer therapy to restrict the mortality of cancer. It is possible that a 
number of common mechanisms are involved in the diverse activity of luteolin on 
cancer. For example, inhibition on receptor tyrosine kinases and topoisomerases 
contributes to its inhibitory effects on carcinogenesis, proliferation, cell cycle and 
apoptosis. The inhibition on NF-κB could contribute to its anti-inflammatory, anti-
carcinogenesis, anti-angiogenesis and anti-metastasis activities.  
 
1.3 APOPTOSIS 
1.3.1 General introduction 
 Apoptosis is a tightly regulated cell death process characterized by unique 
morphological and biochemical changes including cell shrinkage, mitochondrial 
depolarization, nuclear fragmentation, chromatin condensation, membrane blebbing 
and formation of apoptotic bodies (Hengartner, 2000; Kaufmann and Hengartner, 
2001). In receiving cell death signals, which might be either intrinsic or extrinsic, 
cells will undergo a chain of biochemical changes, which are characterized by 
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dramatic changes of mitochondria, the main apoptosis mediator, and activation of 
caspase cascade, the main apoptosis executors. Activated caspase will cleave a 
number of substrates, including DNase II, caspase-activated deoxyribonuclease and 
cytoskeletal proteins which responsible for the distinct morphological changes such as 
nuclear fragmentation, chromatin condensation and cell shrinkage. The cleaved 
substances of the cells will be packed into small apoptotic bodies, which, with 
phosphatidylserine flipped to outer cell membrane, will be recognized and removed 
by phagocytes by engulfment and degradation (Savill and Fadok, 2000). So, different 
from necrosis, apoptosis does not trigger inflammation responses and exert damages 
to surrounding cells, and thus are believed to be a physiological way to eliminate a 
cell. 
1.3.2 Caspases 
 Caspases are a group of proteases which cleave its substrate proteins 
specifically on the carboxyl side of an aspartate residue (Strasser et al., 2000). Up to 
now, there are about 14 caspases have been identified in mammalian cells and more 
than half of them are directly involved in apoptosis regulation (Nicholson and 
Thornberry, 1997). Caspases are produced initially in cells in an inactive form with an 
extended N-terminal prodomain that must be cleaved during activation. According to 
their structures and functions in activation, caspases can be subdivided into two 
groups, initiator caspases and effector caspases. Initiator caspases, including caspase-
8, -10, -9 and -2, have caspase recruitment domains (CARD) or death effector 
domains (DED) which function in its activation. For example, upon death signals, 
such as Fas-FasL interaction, caspase 8 can be recruited through its DED domains to 
death receptors via an adaptor protein Fas-associating death domain protein (FADD) 
(Chinnaiyan et al., 1995). The recruitment will bring pro-caspase-8 together and 
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trigger its auto-activation through proximity-induced dimerization. Another important 
initiator caspase, caspase-9, is activated in an apoptosome comprising of pro-caspase-
9, cytochrome C, apoptotic protease-activating factor 1 (Apaf-1) and dATP (Kroemer, 
2000). Activation of effector caspase, including caspase-3, -6 and -7, requires 
activated initiator caspase which cleave effector caspase at specific internal Asp 
residues and produce its active form. The active effector caspases will act as executors 
that cleave diverse cellular substrates which lead to apoptotic cell death (Fischer et al., 
2003). For instance, cleavage of ICAD by caspase-3 liberates the active CAD 
nuclease that mediates apoptotic DNA fragmentation.  
 Interestingly, initiator caspases also serve as the substrates of active effector 
caspases. For example, active caspase-3 can cleave and activate pro-caspase-8. The 
apoptosis process can be accelerated by this positive feedback loop (Shi, 2002). 
 On the other hand, the activation of caspase is negatively regulated by anti-
apoptotic proteins (IAPs) that directly interact with caspases and inhibit their 
activation as well as activity. One of the most important anti-apoptotic proteins is X-
linked inhibitor of apoptosis (XIAP), a member of IAPs family. XIAP can inhibit the 
activation of caspase-3 and -9 as well their active forms. XIAP has a baculovirus IAP 
repeat domain (BIR) which mediates its interaction with caspase-3 or -9 (Deveraux et 
al., 1997). So, a success activation of caspase-9 requires neutralization of the 
inhibitory effect of XIAP, which is performed by SMAC/DIBLO released 
simultaneously with cytochrome C from mitochondria. Another potent anti-apoptotic 
protein is FLICE-inhibitory protein (FLIP), which specifically inhibits caspase-8 
activation. FLIP, has similar structure with pro-caspase-8 but without protease activity, 
can compete with pro-caspase-8 to be recruited to activated death receptors (Hu et al., 
1997; Irmler et al., 1997). 
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 Although it has been well established that caspases are vital mediators of 
apoptosis, there are apoptosis independent of caspases but mediated by apoptosis 
inducing factor (AIF) (Cande et al., 2002) or other proteases such as  granzyme B and 
calpain (Kroemer and Martin, 2005).  
1.3.3 Apoptosis pathways 
 Apoptosis is mediated through two signaling pathways, death receptor 
pathway (the extrinsic pathway) and mitochondrial pathway (intrinsic pathway). 
Notably, there is significant cross-talk between these two pathways. 
1.3.3.1 Death receptor-mediated apoptosis pathway 
 In the death receptor pathway, the death receptors are triggered by their 
ligands or antagonist antibodies and lead to the recruitment of adaptor molecules that 
activate the caspase cascade. Death receptors are receptors on the cell surface which 
can be specifically activated by death ligands. The death receptors are intermembrane 
proteins characterized by its extracellular domains that can be recognized by death 
ligands, and its intercellular death domains (DD), which recruit a series of proteins 
and trigger caspase activation (Itoh and Nagata, 1993). Several groups of death 
receptors have been identified such as Fas/CD95, TNFR1, DR4 and DR5. 
Accordingly, the main death ligands which can bind to death receptors include FasL 
(for Fas), TNF (for TNFR), and TRAIL (for DR4 and DR5). 
 The signal transduction of receptor-mediated apoptosis has been well 
understood using Fas/FasL as a model (Chinnaiyan et al., 1995). The binding of FasL 
to Fas will trigger trimerization of Fas, which recruits Fas associated death domain 
(FADD) through DD domain. FADD is acting as an adaptor protein with its death 
domains binding to death receptors, and its death effector domain recruiting pro-
caspase-8 and form the death-inducing signaling complex (DISC). Within the DISC, 
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pro-caspase-8 is processed by its auto-activation through proximity-induced 
dimerization. The long prodomain is cleaved and pro-caspase-8 forms intermediate 
but inactive forms, which will be cleaved further and maturate into active forms. The 
active caspase-8 will cleave its effector caspase, caspase-3, which activation is 
considered as “no-return” event during apoptosis.  
 Receptor-mediated apoptosis, however, can be triggered in the absence of 
death ligands. Under certain circumstances, cells overexpress death receptors, which 
may trigger receptor trimerization and caspase activation (Wu, 1997). 
1.3.3.2 Mitochondria-mediated apoptosis pathway 
 Mitochondria, apart from its crucial role in supplying energy, are the pivotal 
mediator of apoptosis. One of the main evidence supporting the critical role of 
mitochondria in apoptosis is that mitochondria contain an array of apoptosis 
regulatory proteins including  cytochrome c, Smac, apoptosis-inducing factors (AIFs), 
endonuclease G and HtrA2 (also known as Omi) (Kroemer, 2000). Whereas AIF and 
endonuclease G seem to be able to directly cause nuclear and DNA damage, 
cytochrome c works together with Apaf-1 and pro-caspase-9 to form a complex, 
called apoptosome, within which caspase-9 is activated and then activates the effector 
caspases that results in morphological and biochemical changes in apoptosis. On the 
other hand, Smac and HtrA2 can reverse the suppressive effects of the inhibitor-of-
apoptosis proteins (IAPs), such as XIAP, on either caspase-9 or caspase-3/7, thus 
further enhancing the activation of the effector caspases. 
 The involvement of mitochondria in apoptosis is tightly regulated by bcl-2 
family proteins, which can be either pro-apoptotic such as Bid, Bad and Bax, or anti-
apoptotic such as Bcl-2, Bcl-xL, Mcl-1 (Adams and Cory, 1998). For example, Bcl-2 
is an anti-apoptotic protein over-expressing in many cancer cells and is responsible 
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for their resistance to cell death. Down-regulation of Bcl-2 or inactivation of Bcl-2 
has been suggested to be effective in restoring the sensitivity of cancer cells to 
anticancer treatment (Bartholomeusz et al., 2005). 
 Mitochondria are also closely involved in death receptor-mediated apoptosis 
in certain types of cells. In type I cells, the presence of activated caspase-8 is 
sufficient to induce activation of effector caspases, which then act on death substrates 
in apoptosis (Wallach et al., 1999). However, in type II cells, a small amount of 
activated caspase-8, although not enough to activate the effector caspases directly, is 
sufficient to trigger a mitochondria-dependent apoptotic amplification loop (Scaffidi 
et al., 1998; Scaffidi et al., 1999). Active caspase-8 will cleave its substrate Bid and 
form a truncated Bid (tBid). tBid, together with other pro-apoptotic bcl-2 members, 
then translocates to outer membrane of mitochondria and cause cytochrome C release 
and apoptotic cell death (Li, 1998; Luo et al., 1998). 
1.3.4 Apoptosis and cancer 
 Apoptosis, as a way to eliminate unwanted cells, is crucial for development, 
organ morphogenesis, and tissue homeostasis. There is accumulating evidence 
showing that the accumulation of damaged cells in the tissue resulted from lacking of 
proper apoptosis is closely associated with tumorigenesis (Hanahan and Weinberg, 
2000). The resistance to apoptosis of cancer cells is acquired through a variety of 
biochemical changes, including over-expression or low-expression of certain 
functional proteins relevant to apoptosis. Moreover, these changes also attribute to the 
responsiveness of cancer cells to anticancer therapy. Therefore, apoptosis regulatory 
molecules are legitimate targets for anticancer treatment. 
 Apoptosis is executed by activated intracellular proteases, known as caspases, 
which are responsible for the specific apoptotic biochemical and morphological 
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changes. The activation of caspases is regulated by a fine balance with/between two 
opposite sides, i.e. proapoptotic signals that facilitate its activation and antiapoptotic 
signals that inhibit its activation. Changes at either side may perturb the balance and 
confer the cancer to be resistant or sensitive to apoptosis stimuli. For example, low 
expression of cell death receptors contributes to the resistance of some cancers (Wang 
and El Deiry, 2003). Apaf-1, a cell-death effector that acts with cytochrome c and 
caspase-9, is frequently inactivated in cancers such as malignant melanoma (Soengas 
et al., 2001). Another well known example is p53, a tumor suppressor protein, which 
activation in response to DNA damage induced by anticancer drugs will lead to cell 
cycle arrest or apoptosis. However, many cancers have mutant p53, which confers the 
cancer cell to be resistant to anticancer therapy (Koechli, 1994). Thus activation of 
p53, for example by inhibiting its interaction with MDM2 (Vassilev et al., 2004), a 
p53 antagonist, or restoration of wide type p53, for example by introducing wide type 
p53 using gene therapy (Quist, 2004), have been proved to be effective in anti-cancer 
therapy. The cancer resistance can also be acquired by over-expression of one or 
several anti-apoptotic proteins, such as Bcl-2, survivin, FLIP and IAPs (Deveraux et 
al., 1997; Deveraux and Reed, 1999). Understanding of the molecular basics of cancer 
resistance also helps to locate proper targets for activating apoptosis in cancer therapy. 
1.3.5 TNFR signaling pathway 
 TNF, a cytokine produced mainly in macrophages, was initially regarded as an 
important player in inflammation and immuno responses. Upon the activation of LPS, 
macrophages produce a number of cytokines including TNF and ILs, which can 
mediate inflammation responses through activating NF-κB (Tracey and Cerami, 1993). 
It is now well understood that TNF, through binding to it receptors, can trigger 
caspase cascade and thus function as a death ligand. The bioactivities of TNF are 
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mainly elicited by TNF receptor 1 (TNFR1), through which the following three 
distinct signaling pathways are initiated: a caspase cascade, NF-κB, and mitogen-
activated protein kinase JNK (Chen and Goeddel, 2002). 
1.3.5.1 TNFR1-mediated apoptosis 
 Comparing to that of Fas, TNFR1-induced apoptosis pathway is more 
complicated, which involves more players, formation of two complexes, and feedback 
regulations. Upon TNF binding, the trimerized TNFR1 does not directly recruit 
FADD, like in Fas signaling pathway, but first binds to an adaptor protein TNF 
receptor-associated death domain (TRADD), which then binds to cytosolic proteins 
FADD as well as receptor-interacting protein (RIP) and TNF receptor-associated 
factor 2 (TRAF2). The above molecules form a big complex (complex I), which is 
bound to membrane via TNFR1. Pro-caspase-8 is not bound to TNFR directly and not 
found in complex I (Harper et al., 2003a). However, the complex I is disassociated, 
together with FADD and pro-caspase-8, form a second complex (complex II), within 
which pro-caspase-8 is processed and activated (Chinnaiyan et al., 1995; Yeh et al., 
1998; Micheau and Tschopp, 2003). The active caspase-8 will activate caspase-3 
directly or through crosstalking with mitochondria via tBid. 
1.3.5.2 TNFR1-induced NF-κB activation 
 NF-κB is a ubiquitous transcription factor playing an important role in 
inflammation responses and cell survival regulation. It consists of heterogenous 
dimeric proteins, such as p65 and p50, which all containing a Rel homology domain 
(Karin and Delhase, 2000). In TNFR1 signaling pathway, NF-κB is activated and 
provides a negative feedback for apoptotic cell death. 
 In resting cells, NF-κB binds to inhibitor of κB (IκB) proteins and localizes in 
cytoplasm. In response to TNFα-TNFR1 ligation, the activated IκB kinase (IKK) 
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phosphorylates IκB, which results in the proteasomal degradation of IκB through 
ubiquitination. The released NF-κB then translocates from cytoplasm to nuclei and 
binds to the promoter regions of its target genes to regulate the gene expression.  
 A number of genes such as A20, IAPs, c-FLIP, TRAF1 and TRAF2 have been 
identified as NF-κB-regulated anti-apoptotic genes (Krikos et al., 1992; Wang et al., 
1998; Micheau et al., 2001). Expression of these anti-apoptotic proteins can promote 
cell survival and inhibit cell death. For example, XIAP, a member of IAPs, can 
directly bind to and inhibit the activation of caspase-9 and -3 (Deveraux et al., 1997). 
It is thus why some cancer cells are resistant to the TNF-induced apoptosis and 
inhibition of NF-κB by a transcription inhibitor (actinomycin D) or translation 
inhibitor (cycloheximide, CHX), can great facilitate TNF-induced apoptosis. 
1.3.5.3 TNFR1-induced JNK activation 
 Another branch of signaling pathway triggered by TNF-TNFR1 is JNK. Upon 
TNF-TNFR1 interaction, JNK is readily activated in a transient manner. Persistent 
JNK activation was observed in TNFα-treated cells when the NF-κB signaling 
pathway was blocked. It is known now that the crosstalk between NF-κB and JNK 
plays a role in diminishing the activated JNK. For instance, upregulation of the 
Gadd45 and XIAP by NF-κB can block the JNK activation (Tang et al., 2001; Papa et 
al., 2004). Another important mediator between JNK and NF-κB is believed to be 
ROS as many of the NF-kB target proteins function as antioxidants to remove ROS 
and to suppress JNK activation (Bubici et al., 2006). 
 In contrast to the well-established anti-apoptotic role of NF-κB, the exact 
function of JNK in TNF-mediated apoptosis remains largely controversial (Liu et al., 
1996; Natoli et al., 1997). Recently it has been demonstrated that prolonged JNK 
activation by the suppression of NF-κB activity promotes TNFα-induced apoptosis 
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(De Smaele et al., 2001; Tang et al., 2001). It appears that the exact function of JNK 
in TNF-induced apoptosis depends on a number of factors such as cell type and/or the 
presence of other signaling pathways such as NF-κB activation (Karin and Lin, 2002). 
1.3.5.4 Regulation of TNF-induced apoptosis 
 Upon TNF-TNFR interaction, in addition to the recruitment of FADD that 
activate caspase cascade, the recruitment of RIP and TRAF2 results in the activation 
of NF-κB which mainly functions as a cell survival mechanism to protect cells against 
TNFα-induced apoptotic cell death (Ting et al., 1996; Reinhard et al., 1997; Kelliher 
et al., 1998). As TNFα activates both cell death and cell survival pathways 
simultaneously, most cancer cells are resistant to TNFα-induced apoptosis and thus 
inhibition of NF-κB activation becomes a popular strategy to enhance the sensitivity 
of cancer cells to apoptosis mediated by TNF family proteins (Baldwin, 2001; 
Yamamoto and Gaynor, 2001). Various approaches have been developed, including 
the genetic disruption of NF-κB signaling pathway by overexpression of a mutant 
IκBα (Leverkus et al., 2003) and chemical inhibitors of NF-κB. Some of these 
approaches have been in clinical trial with promising results in cancer therapy. 
1.3.6 TRAIL signaling pathway 
 Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is newly 
identified member of the TNF superfamily. TRAIL elicits its function by binding to 
its receptors on the cell surface. To date, four types of receptors have been identified. 
Death receptor 4 (DR4) and death receptor 5 (DR5) have both an extracellular domain 
that binds to TRAIL, and intercellular domains with DDs that trigger caspase cascade. 
However, other two receptors, death decoy receptor 1 (DcR1) and death decoy 
receptors (DcR2), lack the functional intercellular domains. Therefore, TRAIL can 
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bind to DcR1 and DcR2 but does not trigger caspase cascade and cell death (Wang 
and El Deiry, 2003). 
1.3.6.1 TRAIL-induced apoptosis 
 The apoptosis induced by TRAIL is quite similar with that induced by FasL. 
Ligation of TRAIL to its receptors (DR4 and DR5) results in trimerization of 
receptors and clustering of intracellular death domains (DDs), which then recruit Fas-
associated death domain protein (FADD) and pro-caspase-8 to form the death-
inducing signaling complex (DISC). Caspase 8 activation within DISC subsequently 
leads to activation of effector caspases or cleavage of Bid, which then crosstalks with 
mitochondria to activate caspase-9 and -3 (Green, 2000a; Ashkenazi, 2002). 
1.3.6.2 TRAIL-induced NF-κB activation 
 The apparent difference from TNF-induced signaling is that TRAIL-DRs 
interaction does not recruit TRADD or RIP or TRAF2 that can activate the cell 
survival signal, NF-κB. However, there were several reports that, in some cell lines, 
TRAIL can trigger NF-κB activation as evidenced from the detection of NF-κB-DNA 
binding by electrophoretic mobility shift assay (EMSA), although it is much weaker 
comparing with that induced by TNF. Up to date, little is known about how TRAIL 
activates NF-κB. It suggests that PI3K/AKT might be involved in the process (Zauli 
et al., 2004). On the other hand, a recent report provided a possible explanation why 
TRAIL fails to activate NF-κB in some cells: TRAIL triggered-caspase activation 
causes the cleavage of NF-κB protein and in the presence of caspase inhibitor, TRAIL 





1.3.6.3 Regulation of TRAIL-induced cell death 
 TRAIL is a potent apoptosis inducer and might be potential in cancer therapy. 
However, its application in clinical is limited because many cancer cells are found to 
be resistant to the apoptosis induced by TRAIL. 
 The resistance of cancer cells to TRAIL has been studies extensively. It may 
attribute to the biochemical changes in the cells in a variety of ways. First, either low 
expression of DR4/DR5, or high expression of decoy receptors DcR1/DcR2 will 
render the cancer cell to be resistant to TRAIL (Sheridan et al., 1997). A number of 
anti-cancer drugs can activate DR4 or DR5 via DNA damage-activated p53 because 
DR4/DR5 is under control of transcription factor p53 (Liu et al., 2004). Thus, a 
combination of anti-cancer drug with TRAIL might be an effective anti-cancer 
therapy. Second, although TRAIL may not activate NF-κB in some cancer cells, the 
relatively high basal level of NF-κB activation may directly or indirectly inhibit 
caspase activation via an array of its anti-apoptotic genes. Many small molecules 
which can downregulate or antagonize these anti-apoptotic proteins have been shown 
to be potent in sensitizing TRAIL-induced apoptosis in both in vitro and in vivo 
experiments (McManus, 2004; Hyer et al., 2005). 
1.3.7 Cisplatin and its anti-cancer effects 
 Cisplatin (cis-diamminediachloroplatium) is a widely used anti-cancer drug. 
Since its approval in 1970’s for the treatment of genitourinary tumors, cisplatin has 
become one of the most widely used and successful drugs for the treatment of a 
variety of cancers, including ovarian, head, neck, bladder, cervical, and small cell 




1.3.7.1 Anti-cancer effects of cisplatin and mechanisms of action of p53 
. Once cisplatin enters a cell, its chloride ligand will be replaced by water 
molecules and form positively charged species that can react with nucleophilic sites 
on intracellular macromolecules such as protein, RNA and DNA (Dijt, 1988). It is 
generally accepted that the anti-cancer effect of cisplatin is mainly mediated by its 
interaction with DNA to form DNA adducts, which induce DNA damage and activate 
several signaling transduction pathways including ATR, ATM, p53, and MAPK 
(Siddik, 2003). 
 The interaction between cisplatin and DNA not only inhibits DNA replication 
and cell division, but also leads to apoptosis (Gonzalez et al., 2001). Tumor 
suppressor p53 activation is one of major factors responsible for apoptosis induced by 
cisplatin. It has been observed that cisplatin treatment can cause apoptosis in wide 
type p53 cancer cell but not in p53 deficient or mutant cancer cells (Song et al., 1998; 
Kanata et al., 2000; Tang and Grimm, 2004; Beuvink et al., 2005), suggesting that 
p53 is the key regulator for cisplatin-mediated apoptosis in cancer cells.  
 p53 is a tumor suppressor protein (Ko, 1996; Levine, 1997), which is readily 
activated by DNA damage as well as other stimuli. Activation of p53 contributes to 
the tumor suppression either by inducing cell cycle arrest, possibly providing 
opportunity for the cells to repair damaged DNA, or by inducing apoptosis in the 
injured cells. So, p53 is playing a critical role in avoiding genetic instability and acts 
as tumor suppressor protein. It is believed that the loss of p53 activity promotes 
malignant transformation, leading to the high incidence of p53 mutations in a wide 
spectrum of human cancer (Hollstein, 1991; Levine et al., 1991). 
 At present, the molecular mechanisms controlling p53 activation have been 
studied extensively. Generally, there are two regulatory mechanisms working together 
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to control the function of p53: p53 transcriptional activation and p53 stability 
(Kubbutat et al., 1997; Ashcroft and Vousden, 1999). The stability of p53 protein, a 
short-lived protein, is mainly regulated by its interaction with its transcriptional target 
mouse double minute 2 (MDM2), which act as an ubiquitin E3 ligase and promotes 
p53 ubiquitination and proteasomal degradation (Kubbutat, 1997). Meanwhile, 
MDM2 is a transcriptional target of p53 and expression of MDM2 will promote p53 
degradation to maintain the negative feedback loop. Upon DNA damage or other 
stimuli, p53 is up-regulated by transcriptional activation as well as via a number of 
mechanisms that disrupt the interaction between MDM2 and p53 and thus to increase 
p53 stability. Modifications on either p53 or MDM2 may affect their interaction. For 
instance, phosphorylation of p53 affects its interaction with MDM2 or its binding to 
DNA or its transcriptional activity (Steegenga et al., 1996). It is known that DNA 
damage-activated ATM, ATR and DNA-PK can phorphorylate p53 on Ser 15 and Ser 
37 (Shieh, 1997), Chk2 is among the kinases that contribute to phosphorylation of p53 
on serine 20 (Shieh, 1999), whereas JNK phosphorylates p53 on tyrosine 81 
(Buschmann et al., 2001). Any of above phosphorylations on p53 may affect its 
interaction with MDM2 and finally affect its stability. On the other hand, post-
translational modifications on MDM2 or inhibition of MDM2 activity or decrease of 
MDM2 protein can disrupt the interaction between p53 and MDM2 and promote the 
rapid accumulation of p53 (Ryan et al., 2001). MDM2 protein is also controlled by 
ubiquitination and proteasomal degradation (Chang, 1998). 
 One important role of p53 as a tumor suppressor is its involvement in 
apoptosis. p53 activates the caspase cascade and apoptosis mainly via an intrinsic 
pathway that involves mitochondria, a central regulator of apoptosis. The integrity of 
outer mitochondrial membrane is tightly regulated by Bcl-2 family proteins. Pro-
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apoptotic members of the Bcl-2 family, such as Bax, Bak and Bid, form channels in 
membranes and to regulate preexisting channels. Anti-apoptotic members of the 
family, such as Bcl-2 and Bcl-XL, tend to have the opposing effects on membrane 
channel formation. (Kelekar and Thompson, 1998). The pro-apoptotic functions of 
p53 can be mediated through a transcription-dependent pathway, which involves the 
activation of pro-apoptotic genes. It was shown that p53 can regulate the transcription 
of a group of pro-apoptotic proteins such as Bax (Miyashita and Reed, 1995), Noxa 
(Oda et al., 2000a), PUMA (Nakano and Vousden, 2001; Chipuk et al., 2005), DR5 
(Wu, 1997), BID (Sax et al., 2002), and CD95 (Muller et al., 1998), which elicit 
caspase cascade and apoptosis. 
 In addition to transactivation of target genes, evidence has also implicated that 
p53 can induce apoptosis via a transcription–independent way. For example, the 
apoptosis induced by p53 may be through increasing surface Fas by transporting from 
the Golgi complex (Bennett et al., 1998), or require FADD-independent activation of 
caspase-8 (Ding et al., 2000). Further, it was found that p53 protein can translocate to 
mitochondria, form complexes with Bcl-XL and Bcl-2 proteins and directly induce 
cytochrome c release (Mihara et al., 2003). Recently, it has been demonstrated that 
the apoptosis induced by p53 is mediated by Bax mitochondrial translocation and 
activation (Chipuk et al., 2003; Erster et al., 2004). In non-stimulated cells, Bax exists 
as a monomer either in the cytosol or loosely attached to the outer mitochondrial 
membrane. Upon stimulation, the cytosolic Bax translocates to mitochondria and 
inserts into the membrane. Bax oligomerizes into large complexes which are believed 
to be crucial to mitochondrial membrane permeabilization (Goping et al., 1998). The 
activated Bax on mitochondria can be distinguished by a conformational change in the 
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N-terminus that exposes the formerly buried 6A7 epitope (Desagher et al., 1999; 
Nechushtan et al., 1999) 
1.3.7.2 Regulation of cisplatin-induced apoptosis 
 Despite the success against testicular cancer, the use of cisplatin against other 
cancers is limited due to acquired or intrinsic resistance. For example, cisplatin has 
minimal activity against some common cancer types, such as colorectal cancer (Natoli 
et al., 2000). Thus, resistance is the major constraint that undermines the curative 
potential of cisplatin. 
 Efforts have been made to define the cellular and molecular mechanisms 
responsible for cisplatin resistance (Kartalou and Essigmann, 2001). The resistance 
may be through either limiting the extent of cisplatin-induced damage, for example, 
alterations in cellular pharmacology, including decreased drug accumulation, 
increased cellular thiol levels and increased repair of platinum–DNA damage. In 
addition, alterations in the cellular response to the damage also contribute to the 
resistance. Since p53 is a major mediator of the apoptosis induced by cisplatin, 
mutation of p53 or alteration of expression level of Bcl-2, Bcl-XL, Bax or MDM2 
may affect the responses to cisplatin. For example, MDM2 overexpression confers the 
cancer cells to be resistant  to cisplatin (Kondo et al., 1995). 
 Therefore, cisplatin is usually not used alone for cancer therapy. Clinically, it 
is used in combination with other anti-cancer drugs, such as etoposide (Kovnar et al., 
1990; Ardizzoni et al., 1999), bleomycin (Behnia et al., 2000) and irinotecan (Sandler, 
2002). Recently, new strategies to enhance the cytotoxicity of cisplatin has been 
investigated (Duan et al., 2001; Iwase et al., 2003; Kim et al., 2003a; Fulda and 
Debatin, 2005; Mohanty et al., 2005). For instance, downregulation of MDM2 using 
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MDM2 antisense oligonucleotides or RNA interference can enhance the sensitivity to 
cisplatin (Yu et al., 2006).  
 
 
1.4 OBJECTIVES OF THE STUDY 
 At present, many aspects of pharmacological activities of chrysanthemum 
have been well studied, including the anti-inflammatory and anti-oxidant function.. 
Preliminary results from our laboratory has shown that the water extract of 
chrysanthemum exerted significant anti-tumor effects in in vivo experiments 
(unpublished data), suggesting the anti-tumor potential of this herbal plant. However, 
the major anti-tumor components in the water extract of chrysanthemum are yet to be 
determined. It has been reported that chrysanthemum contains a wide range of 
flavonoids including luteolin, apigenin etc. However, it is currently not known how 
these flavonoids contribute the potential anti-tumor effect in chrysanthemum. 
Therefore, the goals of this study are to identify the major anti-tumor components in 
the water extract of chrysanthemum and to investigate the molecular mechanisms 
involved.  
To achieve these goals, the following studies will be conducted: 
(1) To identify the major active component(s) in the water extract of Chrysanthemum 
morifolium Ramat. 
(2) To evaluate the anti-tumor property and mechanism of the water extract of 
chrysanthemum. 
(3) To study the anti-tumor effect and mechanisms of luteolin, a major component 
found in Chrysanthemum, on human cancer cells. 
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(4) To investigate the potential synergistic effects of luteolin with known cancer 
therapeutics agents (cisplatin) or cell death ligands (TNF and TRAIL) on 
apoptosis in cancer cells and the molecular mechanisms involved. 
(5) To evaluate the synergistic anti-tumor effects of luteolin and cancer therapeutic 
agents using in vivo animal models. 
 This study will help in understanding the anti-tumor properties of 
chrysanthemum and, at a molecular level, provide evidence of the potential effects of 
this herb on cancer prevention or therapy. Furthermore, the study of combined effects 
of luteolin with other cancer therapeutic agents could provide useful insight on the 
synergistic mechanisms, and the potential application of luteolin as a chemosensitizer 
















 The dried flower heads of Chrysanthemum morifolium Ramatuelle have been 
used as a traditional herbal medicine in Asian countries for centuries. Its traditional 
usage includes treatment of common cold, fever, migraines, conjunctivitis, eye 
irritation, hypertension, ulcerative colitis, vertigo and ophthalmia with swelling and 
pain etc (Liu, 1998; Jiang, 2002). There were also reports about its other activities, such 
as anti-tumor activities (Ukiya et al., 2002). 
 Due to its multiple pharmacological properties as well as the mild fragrance, the 
flower is used popularly as herbal beverage, chrysanthemum tea. Chrysanthemum tea is 
prepared in the same way as for traditional tea. The dried flowers are infused with hot 
water for a few minutes before it is served. For clinical usage, the chrysanthemum is 
boiled with water. Therefore, the water-soluble components in the flower are more 
likely related to its pharmacological properties. 
 Recently, preliminary data from our laboratory found that the water extract of 
chrysanthemum significantly inhibited growth of transplanted tumor in nude mice (Shen 
et al, unpublished data), suggesting that the aqueous components of chrysanthemum 
may have potent anti-tumor effects. More than 50 terpenoids, identified as the main 
components of volatile oil from chrysanthemum flower, were tested on their anti-tumor 
properties (Ukiya et al., 2002). However, the anti-tumor components in the water 
extract are yet to be determined.  
 In this chapter, we attempted to identify the major water soluble anti-tumor 




2.2 MATERIALS AND METHODS 
2.2.1 Materials 
 Commercially available air-dried flower head of Chrysanthemum morifolium 
(commercial name: Hang Bai Jv) was obtained from Tong xiang city, Zhejiang 
Province, China. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT) and dimethyl formamide (DMF) were from Sigma (St. Louis, MO). Formic 
acid, ammonia solution and hydrochloric (HCl) acid were obtained from Merck 
(Darmstadt, Germany). All organic solvents and other chemical reagents used were 
analytical grade. 
2.2.2 Cell lines and cell culture 
 Human colorectal cancer cells HCT116 were purchased from the American 
Type Culture Collection (ATCC, Rockville, MD) and maintained in completed RPMI 
1640 medium supplemented with 10% fetal bovine serum (FBS), penicillin (100U/mL) 
and streptomycin (100 U/mL) at 37°C in 5% CO2. 
2.2.3 Extraction and fractionation 
 The flower head of chrysanthemum was pulverized by an electronic blender 
and kept airtight at 4OC for further use. 200g of the dried powder was boiled in 3000 
ml distilled water for 20 min and filtered through paper filter (Whatman). The same 
process was applied to the residue twice. The combined filtrate was concentrated to 
1400 ml using a rotary vacuum evaporator. 700 ml condensed filtrate was freeze-dried 
and resulted in crude water extract (Fraction A). Another 700 ml condensed filtrate 
was partitioned with 700 ml ethyl acetate (EtOAc) four times and freeze-dried 
(Fraction B), while the aqueous fraction was freeze-dried and then extracted three 
time with 250 ml 80% ethanol (EtOH). After concentrated by a rotary vacuum 
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evaporator and then freeze-dried, two fractions were obtained, the EtOH fraction 
(Fraction C), and water fraction (Fraction D) (Figure 2.1). 
2.2.4 Cytotoxicity assay  
 MTT assays were used to assess the cytotoxicity of various extracts on cancer 
cells as described previously (Yang et al., 1999). Briefly, HCT116 cells were plated 
on 96-well microplates (1 × 104 cells/well in 100 μL of medium) for 24 h. After 
discarding the medium, cells were then treated with various concentrations of extracts 
dissolved in RPMI 140 medium for 24 h. At the end of treatment, 25 μL of MTT (5 
mg/mL) was added to each well and incubated for a further 2 h. Finally, 100 μL of 
lysing buffer (50% DMF and 20% SDS, pH 4.6) was added to each well and 
incubated for another 2 h. The plate was finally read using a microplate reader (BIO-
RAD Model 3550) at a wavelength of 595 nm. Each assay was repeated 3 times. 
2.2.5 High-performance liquid chromatography-mass spectrum  
 The major components of ethyl acetate fraction were identified by reverse 
phase high performance liquid chromatography coupled with mass spectrometer (RP-
HPLC-MS). The ethyl acetate fraction was dissolved in methanol:acetic acid (95:5) 
and filtered through 0.5 μm filter before applying to HPLC-MS. Separation was 
performed on a Zorbax SB-C18 (5 μm) column (150 × 4.6 mm i.d.) from Agilent 
Technologies. The detectors are Finnigan MAT LCQ ion trap mass spectrometer 
equipped with an atmospheric pressure chemical ionization interface (APCI) and a 
diode array thermo separation product UV6000LP detector. Mobile phase: step 
gradient of 0.1% formic acid in water (A) and 0.1 % formic acid in acetonitrile (B) 
was used according to the following profile: 0–15 min, 100–77% A, 0–23 % B; 15–35 
min, 77 % A, 23 % B; 35-45 min, 77-66% A, 23-34 % B; 45-50 min, 25-0 % A, 75-
100 % B. The flow rate was 1.0 ml/min. Column temperature, controlled with a 
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column heater–cooler HP Series 1100 from Hewlett-Packard, was set at 35 °C. The 
mass scanning range of APCI detector was set in 50-1500. 
2.3. RESULTS 
2.3.1 Fractionation of chrysanthemum water extract 
 To determine the anti-tumor water-soluble components of chrysanthemum, we 
used a strategy applying a combination of bioactivity-directed fractionation and 
HPLC-MS analysis. First, we extracted the chrysanthemum flower powder using 
boiling water, which is to mimic the procedure of chrysanthemum tea preparation. 
The 200 g chrysanthemum flower power was boiled with water and half of them was 
freeze-dried and resulted in the crude water extract (Fraction A), which was about 38 
g (yielding rate 38 %) (Figure 2.1). Another half was sequentially partitioned into 
three fractions according to their polarity and resulted in EtOAc (Fraction B), EtOH 
(Fraction C) and final water extract (Fraction D). The EtOAc fraction was about 2 g 
(yielding rate 2 %) and was the minimal fraction. EtOH fraction and final water 
extract were about 5 g and 30 g, respectively.  
2.3.2 Cytotoxicity of each fraction 
 The cytotoxicity of each fraction was assessed using the MTT assay. As 
shown in Figure 2.2, the crude water extract showed a moderate cytotoxicity (IC50 = 
3.6 mg/ml) on HCT116 cancer cells. The EtOAc fraction showed a higher 
cytotoxicity (IC50 = 0.2 mg/ml), which is about ten times higher than using crude 
water extract. However, two other fractions, sequentially extracted from the leftover 
of EtOAc extraction, showed much lower cytotoxicities (IC50 > 5 mg/ml for EtOH 
fraction and IC50 > 8 mg/ml for final water fraction). These results suggest that the 
EtOAc fraction (Fraction B) contains the major anti-tumor components in the water 
extract of chrysanthemum. 
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Figure 2.1 Bioassay-directed fractionation from Chrysanthemum
The water extract of chrysanthemum was separated into four fractions, 
A, B, C and D. Details were described in Section 2.2.3
Flower Powder of Chrysanthemum
(200 g)
Boiled in water for 20 mins 3 
times 
Filtration and condensed
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Figure 2.2 Cytotoxicity of fractions from Chrysanthemum on human
colorectal cancer cells HCT116
HCT116 cells were treated with various fractions from chrysanthemum 
for 24 h. At the end of treatment, cell viabilities were determined by MTT 
assay. Cell viabilities were expressed as means of three experiments. A, 

























2.3.3 Flavonoids are the major components in EtOAc fraction 
 Flavonoids are ubiquitious in many edible plants. They consist of two 
aromatic rings linked through three carbons. Most flavonoids in plant are present as 
flavonoid glycosides, aglycone with sugar substitution (Figure 1.2) (Ross and Kasum, 
2002). 
 A common method of flavonoid extraction is using ethyl acetate. In this study, 
EtOAc fraction was separated in a C18-HPLC column with a UV detector and a MS 
detector. HPLC is able to effectively separate various flavonoids under the specific 
conditions and mass spectrum and UV spectrum provides some structure information 
of each peak such as molecular weight, major stable ions and existence of phenol ring. 
A combination of HPLC separation and MS are useful in identification of flavonoids 
from a mixture (Stobiecki, 2000). Since the EtOAc fraction was originally from a 
water extract, it was separated in a reverse phase column using a gradient solution, a 
combination of water and acetonitrile, after optimization. Figure 2.3 shows that there 
are 13 major peaks. 
 The structure of each of the 13 peaks was identified according to the 
information provided by MS and UV and made reference to available literature (Hu et 
al., 1994; Liu et al., 2001; Lee et al., 2003; Hu et al., 2004). Mass spectrum provides 
important information about the peak, in particular the molecular weight. Increasing 
the voltage of APCI will result in more fragments and provide additional information 
about its possible structure. Take peak 2 (retention time 20.23 min) as an example, the 
mass spectrum using low collision energy of APCI showed two major peaks, m/z 449 
and m/z 287.5 (Figure 2.5A). Thus, m/z 449 is the molecular weight ion peak [M+H]+ 
and its molecular weight (MW) is 448. Higher collision energy of APCI caused the 
peak m/z 449 disappeared and only peak m/z 287.5 remained (Figure 2.5B). The loss 
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of 162 (from 449 to 287.5) is evidently due to the loss of a sugar residue (C6H12O6 - 
H2O = 162). Loss of 162 resulted in a stable structure m/z 287.5. According to 
literature (Hu et al., 2004), it is putatively considered as luteolin. UV spectrum 
confirmed the existence of a phenol ring (data not shown). According to the literature, 
the sugar is established as a glucose side chain (Hu et al., 2004; Hu and Kitts, 2004). 
Thus, peak 2 is luteolin glucoside. Figure 2.5C shows the conversion from peak m/z 
449 to m/z 287 under APCI. 
 Similarly, the putative structures of other peaks were identified based on their 
mass spectrum and earlier reports (Hu et al., 1994; Liu et al., 2001; Lee et al., 2003; 
Hu et al., 2004) (Figures 2.4-2.16). Peak 8 appears to be a mixture of two flavonoids, 
one is a baicalein glucuronide and another is a hesperetin glycoside. However, the 
latter contains an unknown group attached to glucose. The structure of a small peak 
(peak 4) was not identified. In this investigation, a total of 13 flavonoids from 12 
peaks were identified. 
 The 13 flavonoids of EtOAc fraction can be classified into five groups 
according to their aglycones (Figure 2.3). Four peaks are related to luteolin, including 
luteolin-rhamonosyl-glucoside (peak 1), luteolin-glucoside (peak 2), luteolin-
glucuronide (peak 3) and luteolin-methoxyl-glucoside (peak 7). Two peaks are 
apigenin glycosides; including apigenin-glucoside (peak 6) and apigenin-methoxyl-
glucoside (peak 10). There are three hesperetin glycosides, including hesperetin-
rhamonosyl-glucoside (peak 5), heperetin-glucuronide (peak 9) and heperetin-
methoxyl-glucoside (peak 8). Two peaks are baicalein glycosides, including 
baicalein-glucuronide (peak 8) and baicalein-methoxyl-glucoside (peak 12). The last 
group consists of two acacetin-glycosides, acacetin-rhmnosyl-glucoside (peak 11) and 
acacetin-glucoside (peak 13). 
 58
RT: 17.45 - 43.67






















































Acacetin glycosidesLuteolin glycosides Apigenin glycosides
8
Baicalein glycosides
Figure 2.3 Flavonoids in the EtOAc fraction
The flavonoids in the EtOAc fraction are grouped into five groups, 
luteolin glycosides, apigenin glycosides, hesperetin glycosides, 
baicalein glycosides and acacetin glycosides. 
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Figure 2.4 Structure elucidation of peak 1, RT 18.31 min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT18.31 were shown. A, under 
low energy APCI; B, under high energy of APCI. Structure of peak 1 





Figure 2.5 Structure elucidation of peak 2, RT 20.23 min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The Mass spectrums of the peak (RT20.23min) were shown 
in A and B. A, under low energy APCI; B, under high energy of 





Figure 2.6 Structure elucidation of peak 3, RT 21.22 min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT21.22 were shown. A, under 
low energy APCI; B, under high energy of APCI. Structure of peak 3 





m/z 463 m/z 287
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Figure 2.7 Mass spectrum of peak 4, RT 22.79 min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT22.79 were shown. A, under 




Figure 2.8 Structure elucidation of peak 5, RT 23.5 min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT23.5 were shown. A, under 
low energy APCI; B, under high energy of APCI. Structure of peak 5 
and its conversion under APCI.
A
B
C Hesperdin (Hesperetin-Glucoside-Rhamnoside)     RT 23.50 min 
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Figure 2.9 Structure elucidation of peak 6, RT 25.2 min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT25.2 were shown. A, under 
low energy APCI; B, under high energy of APCI. Structure of peak 2 





Figure 2.10 Structure elucidation of peak 7, RT 23.18 min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT23.18 min were shown. A, 
under low energy APCI; B, under high energy of APCI. Structure of 





m/z 491.1 m/z 287.4
- Methoxyl-Glu (204)
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Figure 2.11 Structure elucidation of peak 8, RT 21.22 min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT21.22 were shown. A, under 
low energy APCI; B, under high energy of APCI. Structure of peak 3 
and its conversion under APCI.
A B
C
m/z 447 Baicalin m/z 271 Baicalein
-Glucuronic (176)
Baicalin (Baicalein-7-O-D-Glucuronide)        RT 27.22 min
Hesperetin-Glycoside                                 RT 27.22 min D
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Figure 2.12 Structure elucidation of peak 9, RT 28.70 min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT28.70 were shown. A, under 
low energy APCI; B, under high energy of APCI. Structure of peak 9 







Hesperetin-7-D-O-Glucuronide     RT 28.70 min 
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Figure 2.13 Structure elucidation of peak 10, RT 33.20 min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT33.20 were shown. A, under 
low energy APCI; B, under high energy of APCI. Structure of peak







Figure 2.14 Structure elucidation of peak 11, RT 36.61 min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT36.61 were shown. A, under 
low energy APCI; B, under high energy of APCI. Structure of peak





Figure 2.15 Structure elucidation of peak 12, RT 42.09min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT42.09 were shown. A, under 
low energy APCI; B, under high energy of APCI. Structure of peak
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Figure 2.16 Structure elucidation of peak 13, RT 43.08min
EtOAc fraction was separated on reverse phase-HPLC and detected 
by APCI. The mass spectrum of peak RT43.08 were shown. A, under 
low energy APCI; B, under high energy of APCI. Structure of peak






 Flavonoids are a group of phytochemicals ubiquitiously present in plants. It 
has been well documented that flavonoids possess certain anti-tumor effects, 
including flavonoids from tea (Brown, 1999; Hibasami, 2000; Kinjo et al., 2002), 
ginkgo biloba (Kim et al., 2005d), grape (Ye et al., 1999) and soybean (Kim et al., 
2004b) etc. In this study, the EtOAc extract of chrysanthemum was shown to have 
strong cytotoxicity on human cancer cells (Figure 2.2). 
 The components of this fraction were further identified using HPLC-MS and 
also made reference to various earlier reports (Hu et al., 1994; Liu et al., 2001; Lee et 
al., 2003; Hu et al., 2004). Twelve of the major peaks of this extract were identified 
as flavonoids (Figures 2.4-2.16). All are conjugated with either one or two sugar side 
chains. 
Several flavonoids, which have not been reported previously in 
chrysanthemum, are also detected in the present study. We found four luteolin 
glycosides (only 1 was reported previously), three hesperetin glycosides (2 were 
reported previously) and two baicalein glycosides (1 was reported previously). 
However, apigenin-(4'-caffeoyl)-glucuronide, which was reported earlier, was not 
found in the present study. Instead, apigenin-methoxyl-glucoside was detected. 
 In summary, the EtOAc extract was found to be the most potent in its 
cytotoxic effect on human cancer cells. The flavonoids in the EtOAc fraction can be 
divided into 5 groups according to their aglycones. They are glycosides of luteolin, 
apigenin, hesperetin, baicalein and acacetin. Among them, luteolin glycosides and 




























 The flower heads of chrysanthemum have been used as an herbal medicine as 
well as a popular beverage for centuries. Recently, it has been shown that the water 
extract of chrysanthemum exerted significant anti-tumor properties (Shen et al., 
unpublished data). In order to find out the active components of chrysanthemum 
water extract, we obtained several fractions and then tested their cytotoxicity on 
human cancer cells (Figures 2.1 and 2.2). In the most potent EtOAc fraction, 13 
flavonoids were identified as the major components (Figure 2.17). Thus, it is believed 
that chrysanthemum flavonoids are the major anti-cancer components of 
chrysanthemum water extract.  
 The anti-tumor effects of flavonoids have been well studied and extensively 
reviewed (Harborne and Williams, 2000). Many of them are capable of inhibiting 
tumor growth and/or inducing cancer cell apoptosis, which is characterized by 
characteristic morphological and biochemical changes including cell shrinkage, 
nuclear fragmentation, chromatin condensation, membrane blebbing and formation of 
apoptotic bodies (Hengartner, 2000; Kaufmann and Hengartner, 2001). In the 
previous Chapter, chrysanthemum flavonoids was shown to possess strong 
cytotoxicity in cancer cells, however, it remains to be determined whether they are 
capable of inducing apoptotic cell death in cancer cells.  
 Another important issue closely related to the biological effect of flavonoids is 
absorption. Most flavonoids in plants are conjugated with sugar substitute, named 
flavonoid glycosides. Absorption of flavonoid glycosides has been thought to occur in 
intestine after hydrolysis into their algycone forms (Griffiths and Barrow, 1972). The 
hydrolysis can be processed by microorganisms in intestine or oral cavity (Walle et al., 
2005). Once this hydrolysis occurs, the aglycones are absorbed more efficiently. 
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Recently, it was reported that flavonoid glycosides can also be absorbed directly 
(Hollman et al., 1995). In contrary, intact flavonoid glycosides was not found in 
plasma (Sesink et al., 2001). As shown in Chapter 2, most of the chrysanthemum 
flavonoids are glycosides of the five main aglycones. Luteolin glycosides and 
apigenin glycosides are the two major groups of chrysanthemum flavonoids, therefore 
luteolin and apigenin were the main focus of the subsequent studies. 
The main aim of this chapter is to examine the anti-cancer property of 
chrysanthemum flavonoid extract and its major flavonoids, luteolin and apigenin. We 
found that chrysanthemum flavonoid extract (EtOAc fraction) and luteolin are strong 
inducers of apoptosis in colorectal cancer cell COLO205 via caspase activation.  
 
3.2 MATERIALS AND METHODS 
3.2.1 Regents and chemicals 
 Luteolin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT), 4’,6-diamidino-2-phenylindole (DAPI), Propidium iodide (PI), RPMI 1640 
were obtained from Sigma (St. Louis, MO). Chrysanthemum flavonoid extract was 
prepared as described in Figure 2.1. Characterized Fetal Bovine Serum (FBS) was 
obtained from Hyclone (Logan,Utah). Apo-one Homogeneous Caspase-3/7 Assay Kit 
was obtained from Promega (Madison, WI). General caspase inhibitor z-VAD-fmk 
were purchased from Biomol (Plymouth Meeting, PA). Anti-caspase-3 antibody and 
CHAPS lysis buffer were purchased from Cell Signaling (Beverly, MA). Anti-PARP 
antibody was purchased from Pharmingen (San Diego, CA). 
3.2.2 Cell lines and cell culture 
 Human colorectal cancer cells COLO205, HCT116 and HT29 were obtained 
from American Type Culture Collection (ATCC). COLO205 cells were routinely 
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maintained at 37° C in RPMI 1640 medium containing 10% filter-inactivated fetal 
bovine serum (FBS) in an atmosphere containing 5% CO2. HCT116 and HT29 were 
maintained in McCoy 5A medium. 
3.2.3 Assessment of cell viability using MTT assay 
 Cell growth was assessed by a MTT assay as described previously in Chapter 
2 (Section 2.2.4) 
3.2.4 Assessment of apoptosis using DAPI staining 
 The cells undergoing apoptosis were evaluated by chromatin condensation and 
nuclear shrinkage using 4’,6-diamidino-2-phenylindole (DAPI) staining (Fuentes et 
al., 2003). After various designated treatments, medium was removed and cells were 
fixed with 70% ethanol at room temperature for 10 min. Cells were then stained with 
0.3 μg/mL DAPI (in PBS) at room temperature for 10 min and visualized under an 
inverted fluorescence microscope and photographed.  For quantification, 200 cells 
were counted and the percentage of apoptotic cells was calculated. 
3.2.5 Assessment of DNA content using flow cytometry.  
 After treatment, all cells were collected by trypsinization and fixed with ice-
cold 70% ethanol. Before subject to flow cytometry, ethanol was removed from the 
fixed cells and then the cells were stained with 0.5 ml propidium iodide solution for 
30 min at room temperature. 10,000 cells were counted by flow cytometer (Coulter 
Epics Elite ESP, Miami, FL, USA) using a filter with 488 nm excitation and 610 nm 
emission.  
3.2.6 Caspase 3-like activity assay 
 Apo-one homogeneous caspase-3/7 assay kit (Promega) was used to measure 
the caspase 3-like activity according to manufacturer’s protocol. Briefly, cells were 
plated on 96-well microplates. At the end of designated treatments, z-DEVD-
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Rhodamine 110 was added into the cells as substrate and continued the incubation at 
37°C for 1 h. The fluorescence intensity was then recorded using a spectrofluorimeter 
(Tecan) at excitation 485 nm and emission 535 nm. Cells treated by TNF (10ng/ml) 
with ActD (1 μg/ml) pretreatment were used as a positive control. 
3.2.7 Western blotting 
 PARP cleavage and procaspase 3 cleavage were detected by western blotting. 
Equal amount of proteins were fractionated on SDS-polyacrylamide gel in the Mini-
PROTEAN II system (Bio-Rad) and blotted onto PVDF membrane (Millipore). After 
blocked with 5% nonfat milk in TBST (10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 
0.1% Tween 20), the membrane was probed with various antibodies and developed 
with enhanced chemiluminescence (Pierce) using a Kodak Image Station (Kodak). 
 
3.3 RESULTS 
3.3.1 Cytotoxicity of chrysanthemum flavonoids on human cancer cells. 
 In Chapter 2, an EtOAc fraction was obtained from chrysanthemum water 
extract (Figure 2.1) and flavonoids have been identified as its major components 
(Figure 2.17). Further, our data showed the flavonoid fraction (Fraction B) exerted 
higher cytotoxicity than other fractions of chrysanthemum water extract (Figure 2.2), 
suggesting that flavonoids are the cytotoxic components of the chrysanthemum water 
extract. Here we aimed to further examine the cytotoxic effect of chrysanthemum 
flavonoids on various human cancer cell lines. As shown in Figure 3.1, the EtOAc 
fraction rich in chrysanthemum flavonoids exerted significant cytotoxicity on three 




3.3.2 Chrysanthemum flavonoid extract induces apoptosis in cancer cells 
 To examine whether the cytotoxicity of chrysanthemum flavonoids are due to 
induction of apoptosis, we then checked the morphological changes of HCT116 after 
24 h treatment with 0.25 mg/ml chrysanthemum flavonoids. Under a normal light 
microscope, we observed that most cancer cells rounded up after treatments (upper 
panel of Figure 3.2A). Using DAPI staining, which specifically stains DNA, we could 
see that a large portion of cells showed a chromatin condensation (lower panel of 
Figure 3.2A). The above data were quantified and presented in Figure 3.2B, 
chrysanthemum flavonoids induced around 60% and 90% apoptosis at 0.25 mg/ml 
and 0.5 mg/ml, respectively, which is consistent with the dose response pattern of the 
cytotoxicity detemined by MTT assay (Figure 3.1). Significant apoptosis was also 
observed in COLO205 and HT29 cells after the Fraction B treatment (data not shown). 
3.3.3 Chrysanthemum flavonoid causes apoptosis by inducing a caspase cascade  
 Caspases are the major executors of apoptosis (Strasser et al., 2000). To test 
whether the apoptosis induced by chrysanthemum flavonoids was through caspase 
activation, we then examined the caspase-3 activation as well as the cleavage of its 
substrate protein PARP using Western blot in HCT116 cells. The caspase-3 as well as 
PARP was cleaved significantly in cells treated with chrysanthemum flavonoids at 
0.25 mg/ml and 0.5 mg/ml (Figure 3.3).  
 More importantly, the cleavage of caspase-3 and PARP induced by 
chrysanthemum flavonoids were completely prohibited by a general caspase inhibitor, 
z-VAD-fmk (Figure 3.3), suggesting that the apoptosis induced by chrysanthemum 
flavonoids was mediated via caspase activation. 
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Figure 3.1 Cytotoxicity of EtOAc extract on human colorectal cancer cells
Human cancer cell HCT116, COLO205 and HT29 were plated on 96-well 
plates. After 24 h, the cells were treated with indicated concentration of EtOAc
extract for 24 h. At the end of treatment, cell viabilities were determined by 
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- EtOAc Extract
Figure 3.2 EtOAc extract induces apoptosis in cancer cells HCT116
A, HCT116 cells were treated with 0.5 mg/ml EtOAc fraction for 24 h, cells 
were observed under a light microscope directly (upper panel) or under UV 
after DAPI staining (lower panel); B, HCT116 cells were treated with 
indicated concentration of EtOAc fraction for 24 h, apoptotic cells were 
counted after DAPI staining.
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Figure 3.3 EtOAc extract causes apoptosis by inducing caspase
cascade in HCT116
HCT116 cells were treated with indicated concentration of EtOAc fraction 
for 24 h, cells were collected for Western blotting using anti-caspase-3 
and anti-PARP antibody. Tubulin was used as loading control 
Cleaved PARP
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3.3.4 Cytotoxicity of luteolin and apigenin in human cancer cells. 
 Our chemical assay shows only flavonoid glycosides are detected in the 
EtOAc fraction, with apigenin and luteolin as the major components. Physiologically, 
when ingested the sugar moiety of their glycosides are also likely to be removed by 
colonic bacteria and left with the aglycones. We then tested the cytotoxicity of 
luteolin and apigenin, the two major flavonoid aglycones in chrysanthemum, on 
several human colorectal cancer cell lines using the MTT assay. Both of them showed 
significant cytotoxicity in all three cancer cell lines in a concentration-dependent 
pattern (Figure 3.4). Interestingly, both of them showed stronger cytotoxicity in 
COLO205 and HCT116 cells than in HT29 cells, similar to the cytotoxicity effect of 
the chrysanthemum flavonoids extract (Figure 3.1). To be noted, luteolin showed 
stronger cytotoxicity than apigenin in all three cell lines, especially on COLO-205 
cells. Therefore in the subsequent studies we decided to focus on the anti-tumor 
properties of luteolin. 
3.3.5 Luteolin induces apoptosis in COLO205 but not in HCT116 and HT29 cells. 
 We next tested whether luteolin exerts its cytotoxicity through induction of 
apoptosis in all three cancer cell lines. Since the COLO205 cells are semi-adherent, 
we had to use flow cytometry after propidium iodide staining, instead of DAPI 
staining, to quantify the extent of apoptosis. Cells undergoing apoptosis will lose 
DNA fragments after fixation and washing. So, the hypodiploid proportion (sub-G1) 
is generally regarded as apoptotic cells (Yang et al., 2000a). As shown in Figure 3.5A, 
luteolin induced apoptosis in COLO205 cells in a dose-dependent pattern. Luteolin at 
40 μM induced more than 70% apoptotic cell death after 24 h. Under a normal light 
microscope, COLO205 cells were undergoing typical apoptosis, as judged by the cell 
shrinkage and formation of apoptotic bodies (Figure 3.6).  
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 To our surprise, luteolin treatment, even at higher doses, was unable to induce 
evident apoptosis in both HCT116 and HT29 cells (Figure 3.5B), suggesting that 
other mechanism may be involved in the cytotoxicity in these two cells. The 
molecular mechanisms involved in the cytotoxicity of luteolin on these two cell lines 
remain to further be elucidated.  
 To confirm the form of cell death induced by luteolin in COLO205 cells, we 
then tested the changes of a typical apoptosis marker, PARP cleavage. Figure 3.7A 
showed that luteolin caused significant PARP cleavage in a dose-dependent manner. 
The time course data showed that the cells started to undergo apoptosis after 18 h. 
(Figure 3.7B) 
3.3.6 Luteolin induced apoptosis in COLO205 by activating caspase-3  
 To examine whether caspase activation is involved luteolin-induced apoptosis, 
we used western blot to detect the activation of caspase-3. As shown in Figure 3.8, 
two cleaved bands (21 kDa and 17 kDa), the active forms of caspase-3, were detected 
after 18 h and 24 h treatment with luteolin. In addition, Apo-ONE caspase 3/7 
homogenous assay kit was used to detect the caspase-3-like activity. Significant 
caspase-3-like activity was detected after 18 h treatment by luteolin at 40 μM (Figure 
3.9), which was consistent with the temporal pattern of caspase-3 cleavage (Figure 3.8) 
and apoptotic cell death (Figure 3.5A). 
 Next, we pretreated the cells with a general caspase inhibitor, z-VAD-fmk and 
found that the percentage of sub-G1 cells measured by flow cytometry was almost 
completely blocked by z-VAD (Figure 3.10). In addition, z-VAD-fmk could also 
inhibit cell shrinkage and formation of apoptotic bodies induced by luteolin (data not 
shown).  Therefore, it is believed that luteolin induces apoptosis in COLO205 cells 

























Figure 3.4 Cytotoxicities of luteolin and apigenin in human cancer cells
Human cancer cell HCT116 (A), COLO205 (B) and HT29 (C) were plated on 
96-well plates. After 24 h, the cells were treated with indicated concentration of 
apigenin or luteolin for 24 h. At the end of treatment, cell viabilities were 




















































Figure 3.5 Luteolin induces apoptotic cell death in COLO205 cells but 
not in HCT116 or HT29 cells
COLO205, HCT116 and HT29 cells were plated on 24-well plates for 24 
hours prior to various treatments by luteolin. At the end of treatment, cells 
were collected by trypsinization, fixed with ice-cold 70% ethanol and 
stained with PI solution. Samples were subject to flow cytometry and 
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Figure 3.6 Morphological change of COLO205 after luteolin 
treatment
COLO205 cells were treated with 40 μM luteolin for 24 h, cells 
were observed under a light microscope.
Control Luteolin
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Figure 3.7 Luteolin induces PARP cleavage time- and dose-
dependently in COLO205 cells
A, COLO205 cells were exposed to various concentration of luteolin for 
24 h; B, COLO-205 Cells were exposed to 40 μM luteolin for indicated 
periods. Cells were collected for Western blotting. Anti-PARP antibody 
was used to detected both PARP (116 kD) and cleaved PARP (85 kD). 
ActD (1 μg/ml) with TNF (10 ng/ml) was used a positive control.
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Figure 3.8 Luteolin induces caspase-3 cleavage in COLO205 cells
COLO205 cells were exposed to 40 μM luteolin for indicated periods 
and collected for Western blotting. Anti-caspase-3 antibody was used 
to detected both pro-caspase-3 PARP (32 kD) and cleaved caspase-3 
(21and 17 kD). ActD (1 μg/ml) with TNF (10 ng/ml) was used a 
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Figure 3.9  Luteolin activates caspase-3 like activity in COLO205 
COLO205 cells were exposed to 40 μM luteolin for indicated periods and 
subject to caspase-3 like activity assay using Apo-one caspase-3 assay kit. 




Figure 3.10 z-VAD-fmk inhibits cell death induced by luteolin 
in COLO205 cells
COLO205 cells were pretreated with z-VAD-fmk (25 μM) for 30 
min before exposure to 40 μM luteolin for 24 h. Cells were then 


















 In the previous Chapter, we found that flavonoids were the major cytotoxic 
components from water extract of chrysanthemum. In this Chapter, we further 
investigated their cytotoxicity in several cancer cell lines and the mechanisms 
involved. 
 We first tested the EtOAc extract (Fraction B), a mixture of flavonoids, on 
several colorectal cancer cells. We found that this fraction at 0.25 mg/ml or 0.5 mg/ml 
showed significant cytotoxicity in all three cancer cell lines studied (Figure 3.1). Its 
cytotoxicity is similar to that of several other plant flavonoid extracts, such as ginkgo 
biloba extract (EGb761) (Kim et al., 2005d) or grape seed extract (Ye et al., 1999) 
and soybean extract (Kim et al., 2004b), although their compositions are different. 
Further studies showed that the flavonoid extract induced apoptosis in these cancer 
cells, as evidenced by chromatin condensation and PARP cleavage (Figure 3.2). The 
inhibition of a caspase inhibitor on the apoptosis further proved that the apoptosis was 
through activating caspases (Figure 3.3). 
 To be noted, the EtOAc extract exerted higher cytotoxicity in wild type p53 
cancer cells HCT116 and COLO205 than in mutant p53 cells HT29 (Figure 3.1). 
Similar results were found when luteolin and apigenin, the two major flavonoids of 
chrysanthemum, were tested (Figure 3.4). Therefore, it appears that the cytotoxic 
effect of chrysanthemum flavonoids requires the presence of a functional p53.  
 Although luteolin and apiginin are similar in their structure (luteolin contains 
one more hydroxyl group than apigenin, Figure 1.3), luteolin showed higher 
cytotoxicity than apignin in all three cell lines, especially in COLO205 cells (Figure 
3.4). In addition, as suggest by Figure 2.3, the concentration of luteolin glycosides 
was higher that that of apigenin glycosides in chrysanthemum. Therefore, it is 
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believed that luteolin plays a more important role in the anti-cancer potential of 
chrysanthemum, a fact that leads us to focus on luteolin in our subsequent studies.  
 Data from this part of our study confirmed that luteolin is capable of inducing 
apoptosis in COLO205 cells as evidenced by DNA fragmentation, PARP cleavage 
and formation of apoptotic bodies (Figures 3.5, 3.6 and 3.7). The apoptosis was 
through activating caspases as it was completely inhibited by a pan-caspase inhibitor, 
z-VAD-fmk (Figure 3.8). Such a finding is basically consistent with some earlier 
reports in which luteolin can induce apoptosis in several cancer cell lines, including 
human epidermoid carcinoma A431(Huang et al., 1999b), human leukemia HL-60 
(Ko et al., 2002; Cheng et al., 2005a) and U937 (Monasterio et al., 2004), pancreatic 
tumor cell MiaPaCa-2 (Lee et al., 2002). Interestingly, luteolin fails to induce 
apoptosis in HCT116 or HT29 cells (Figure 3.5), although the growth of both cancer 
cells was inhibited by luteolin (Figure 3.4). It is thus believed that luteolin may exert 
anti-cancer effects in various cancer cells via different mechanisms. 
 In summary, we found that both the flavonoids extract of chrysanthemum and 
luteolin, one of the major flavonoid aglycones of chrysanthemum, can induce 
apoptosis in cancer cells by activating caspases. Such a finding lays a foundation for 













LUTEOLIN SENSITIZES TUMOR NECROSIS FACTOR-ALPHA-INDUCED 







Tumor necrosis factor (TNF) is a proinflammatory cytokine with a wide 
spectrum of functions in many biological processes, including cell growth and cell 
death, development, oncogenesis, immunity, inflammatory and stress responses 
(Tracey and Cerami, 1993). The bioactivities of TNF are mainly elicited by TNF 
receptor 1 (TNFR1), via the following three distinct signaling pathways: (i) NF-κB, (ii) 
mitogen-activated protein kinase c-Jun N-terminal kinase (JNK), and (iii) a caspase 
cascade (Chen and Goeddel, 2002). Upon TNF binding, the trimerized TNFR1 first 
recruits a key adaptor protein TNF receptor-associated death domain (TRADD), 
which then binds to cytosolic proteins such as receptor-interacting protein (RIP), TNF 
receptor-associated factor 2 (TRAF2) and Fas-associated death domain (FADD). It 
has been well established that the recruitment of FADD into the signaling complex 
leads to the activation of a caspase cascade and apoptosis (Chinnaiyan et al., 1995; 
Yeh et al., 1998). On the other hand, the recruitment of RIP and TRAF2 results in the 
activation of NF-κB which mainly functions as a cell survival mechanism to protect 
cells against TNFα-induced apoptotic cell death (Ting et al., 1996; Reinhard et al., 
1997; Kelliher et al., 1998). As TNFα activates both cell death and cell survival 
pathways simultaneously, most cancer cells are resistant to TNFα-induced apoptosis 
and thus inhibition of NF-κB activation becomes a popular strategy to enhance the 
sensitivity of cancer cells to apoptosis mediated by TNF family proteins (Baldwin, 
2001; Yamamoto and Gaynor, 2001). 
NF-κB is a ubiquitous transcription factor consisting of heterogenous dimeric 
proteins containing a Rel homology domain (Karin and Delhase, 2000). In resting 
cells, NF-κB binds to inhibitor of κB (IκB) proteins and localizes in cytoplasm. In 
response to TNFα-TNFR1 ligation, the activated IκB kinase (IKK) phosphorylates 
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IκB, which results in the degradation of IκB through ubiquitination. The released NF-
κB then translocates from cytoplasm to nuclei and binds to the promoter regions of its 
target genes to regulate the gene expression. A number of genes such as A20, IAPs, 
cellular FLICE inhibitory protein (c-FLIP), TRAF1 and TRAF2 have been identified 
as NF-κB-regulated anti-apoptotic genes (Krikos et al., 1992; Wang et al., 1998; 
Micheau et al., 2001). In contrast to the well-established anti-apoptotic role of NF-κB, 
the exact function of JNK in TNF-mediated apoptosis remains largely controversial 
(Liu et al., 1996; Natoli et al., 1997). Recently it has been demonstrated that 
prolonged JNK activation by the suppression of NF-κB activity promotes TNFα-
induced apoptosis (De Smaele et al., 2001; Tang et al., 2001). It appears that the exact 
function of JNK in TNF-induced apoptosis depends on a number of factors such as 
cell type and/or the presence of other signaling pathways such as NF-κB activation 
(Karin and Lin, 2002). 
Flavonoids are a group of natural polyphenolic compounds widely distributed 
in the plant kingdom. The bioactivities of flavonoids have been extensively studied, 
including their antioxidant, anti-inflammatory and anti-cancer activities (Ross and 
Kasum, 2002). The anti-cancer activity of flavonoids has been well proven in 
epidemiological investigation and in animal studies (Birt et al., 2001;Yang et al., 
2001). Luteolin, 3’, 4’, 5, 7-tetrahydroxyflavone, is a flavonoid which is commonly 
found in many types of fruits and vegetables. We have previously identified luteolin 
as one of the major chrysanthemum flavonoids, which are responsible for the 
anticancer effects of chrysanthemum (Chapter 2). We then proved that luteolin can 
suppress the growth of several cancer cell lines (Chapter 3). It has been reported that 
luteolin can inhibit LPS-induced NF-κB activation in fibroblasts or macrophages 
(Xagorari et al., 2002; Kim et al., 2003b). As inhibition of NF-κB activation becomes 
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a popular strategy to enhance the sensitivity of cancer cells to the apoptosis mediated 
by TNF family proteins (Baldwin, 2001; Yamamoto and Gaynor, 2001), we naturally 
ask whether luteolin can synergistically enhance TNF-induced apoptosis in cancer 
cells. 
 In this chapter, we reported that luteolin significantly sensitizes TNFα-induced 
apoptosis in a number of human cancer cell lines. Such sensitization is closely 
associated with its inhibitory effect on NF-κB activation, resulting in down-regulation 
of some key anti-apoptotic genes such as A20 and c-IAP1. Luteolin pretreatment also 
leads to augmented and prolonged JNK activation induced by TNFα, a process that is 
proven to be critical in the sensitization effect of luteolin to TNFα-induced apoptosis.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Cell culture and treatment. 
 Human colorectal cancer cells COLO205, HCT116 were obtained from ATCC 
and maintained in RPMI1640 medium (Sigma) supplemented with 10% fetal bovine 
serum (FBS) (Hyclone) and antibiotics. Human cervix cancer cells HeLa (from ATCC) 
were maintained in Dulbecco’s modified Eagle’s medium (Sigma) containing 10 % 
fetal bovine serum and antibiotics. Treatment details with luteolin (Sigma) and TNFα 
(Sigma) were illustrated in figure legends. 
4.2.2 Measurement of cell death and apoptosis 
 Percentage of the hypodiploid cells or sub-G1 cells were measured as a 
general parameter for cell death as described previously (Yang et al., 2000a). Various 
approaches were used to assay the specific parameters of apoptosis, including (i) 
poly(ADP-ribose) polymerase (PARP) cleavage by Western blot; (ii) DNA 
fragmentation using agarose gel electrophoresis (McGahon et al., 1995) and (iii) 
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morphological changes after cells were stained with acridine orange (AO) and 
ethidium bromide (EB) (Lin et al., 1999).  
4.2.3 Caspase 3-like and caspase-8 activity assay 
 Apo-one homogeneous caspase-3/7 assay kit (Promega) was used to measure 
the caspase 3-like activity according to manufacturer’s protocol. Briefly, cells were 
plated on 96-well microplates. At the end of designated treatments, z-DEVD-
Rhodamine 110 was added into the cells as substrate and continued the incubation at 
37°C for 1 h. The fluorescence intensity was then recorded using a spectrofluorimeter 
(Tecan) at excitation 485 nm and emission 535 nm. For the measurement of caspase 8 
activity, cells were collected, pelleted and lysed in lysis buffer (10 mM Hepes, pH 7.4, 
42 mM KCl, 5 mM MgCl2, 1 mM DTT, and 0.1% Triton X-100). The whole cell 
lysate containing 50 μg protein was incubated with 5 µM Ac-IETD-AMC (Biomol) in 
a total volume of 200 µl of reaction buffer (50 mM HEPES, pH 7.0, 10% glycerol, 
0.1% CHAPS, 2 mM EDTA, 2 mM dithiothreitol) at 37°C for 1 h. The fluorescence 
intensity of released AMC was then quantitated using a spectrofluorimeter (excitation 
390 and emission 510 nm). Caspase activities were presented as relative values of the 
fluorescence intensity over the control group. 
4.2.4 Transient transfection  
 HeLa cells were transiently transfected with either pcDNA (Clontech), myc-
A20 (kindly provided by Dr. A Ting, Mount Sinai School of Medicine, NY), HA-c-
IAP1, CrmA, or dominant negative forms of both HA-JNKK1 and HA-JNKK2 
(kindly provided by Dr. ZG Liu, NIH), using the Lipofectamine transfection reagent 
(Invitrogen). A red fluorescent protein expression vector (pDsRed, Clontech) was co-
transfected as a transfection marker. After 24 h of transfection, the cells were 
pretreated with luteolin (40 μM × 2 h) followed by TNFα (15 ng/ml × 24 h). Cell 
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death was determined by morphological changes examined under an inverted 
fluorescent microscope. 
4.2.5 NF-κB luciferase reporter assay 
 COLO205 cells were transiently transfected with the NF-κB-dependent 
luciferase reporter construct and β-gal construct (Clontech) using the Lipofectamine 
and PLUS transfection reagent according to the manufacturer's protocol (Invitrogen). 
Luciferase activity was determined using the luciferase assay system (Promega) and 
normalized with the-galactosidase enzyme activity for transfection efficiency.  
4.2.6 Preparation of whole cell lysate, cell fractionation, immunoprecipitation 
and western blot 
 Whole cell lysate was obtained using M2 lysis buffer (20 mM Tris, pH 7.4, 
0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM dithiothreitol, 0.5 
mM phenylmethylsulfonyl fluoride, 20 mM β-glycerol phosphate, 1 mM sodium 
vanadate, and 1 µg/ml leupeptin) (Wu et al., 2002). Cytosol and nuclear fractions 
were prepared based on a protocol described previously (Kim et al., 2003b). The 
immunoprecipitation experiment was performed using CBP antibody for detecting 
CBP−p65 interaction, based on a report method (Hehner et al., 1998). For Western 
blot, equal amount of proteins were fractionated on SDS-polyacrylamide gel in the 
Mini-PROTEAN II system (Bio-Rad) and blotted onto PVDF membrane (Millipore). 
After blocked with 5% nonfat milk in TBST (10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 
0.1% Tween 20), the membrane was probed with various antibodies and developed 
with enhanced chemiluminescence (Pierce) using a Kodak Image Station (Kodak). 
4.2.7 Electrophoretic Mobility Shift Assay (EMSA) 
 The DNA binding activity of nuclear proteins was tested according to 
established method with modifications (He and Ting, 2002). NF-κB consensus 
 99
oligonucleotides (5’-AGTTGAGGGGACTTTCCCAGGC-3’ and 3’-
TCAACTCCCCTGAAAGGGTCCG-5’) (Promega) were labeled with p32-γATP 
using T4 kinase (Invitrogen). Equal amounts of nuclear protein (5 μg) were incubated 
with 100,000 cpm labeled NF−κB oligonucleotides in 5 × reaction buffer (100 mM 
HEPES/KOH, pH 7.9, 20% glycerol, 1 mM dithiothreitol, and 300 mM KCl) for 30 
min at room temperature, in the presence of 2 μg poly(dI-dC) and 2 μg bovine serum 
album in a total volume of 20 μl. The DNA-protein complexes were resolved on a 5% 
polyacrylamide gel. Gels were then dried and exposed to an X-ray film (Kodak) at –
80°C overnight. 
4.2.8 RNA extraction and RT-PCR 
 RNA extraction was carried out using a total RNA extraction kit (Purescript), 
following the instructions from the manufacturer. Five μg of total RNA from each 
sample were subjected to reverse transcription using M-MLV reverse transcriptase 
(Promega). For PCR, the amplification reaction was carried with 200 pmol of each 
primer, 200 μM of each dNTPs, and 0.5 units of Tag DNA polymerase II (Promega). 
The PCR conditions were optimized to achieve exponential amplification in which the 
PCR product formation is proportional to the starting cDNA. The primers of human 
A20 (Sonoda et al., 2000), c-IAP1, c-IAP2 (Petak et al., 2000), c-FLIPL, c-FLIPS 
(Mafune et al., 1999) and glyceraldehydes-3-phosphate dehydrogenase (G3PDH) 
(Denecker et al., 2001) were based on literature. After PCR, products were size 
fractionated using 1.8% agarose gel and visualized by ethidium bromide staining. 
4.2.9 Statistical Analysis 
 The numeric data are presented as mean ± SD from at least three sets of 
independent experiments and were examined using student’s t test. p < 0.05 was 




4.3.1 Luteolin sensitizes TNFα-induced cell death in cancer cells 
 Majority of cancer cells are resistant to TNFα without the blockage of gene 
transcription and de novo protein synthesis. In this study, human colorectal cancer 
COLO205 cells were found to be resistant to TNFα-induced cytotoxicity, as 
demonstrated by the lack of sub-G1 cells determined using flow cytometry (Figure 
4.1). Similarly, no evident cell death was observed when cells were treated with 
luteolin alone (40 μM × 12 h). We next tested the combined effect of luteolin and 
TNFα and discovered that pretreatment with luteolin (40 μM × 2 h) greatly sensitized 
and accelerated COLO205 cells to TNFα-induced cell death. As shown in Figure 4.1, 
more than 60% of cell death occurred as early as 6 h with luteolin plus TNFα. The 
sensitizing effect of luteolin on TNFα-induced cell death was also found to be dose-
dependent. Similar sensitization effect by luteolin was also found in another human 
colorectal cancer cells HCT116 and human cervix cancer HeLa cells (Figure 4.1), 
suggesting that the sensitization of luteolin to TNFα -induced cell death may apply to 
a wide spectrum of cancer types. Furthermore, we noted that the sequence of 
treatment is important. No sensitization was found when luteolin was added 2 h after 
TNFα exposure (luteolin post-treatment) (Figure 4.2), indicating that the sensitization 
effect by luteolin is probably achieved through the blockage of certain cell survival 
signals elicited by TNFα. 
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Figure 4.1 Luteolin pretreatment sensitizes TNFα-induced cell death in 
cancer cells.
Cells were pretreated with indicated concentrations of luteolin for 2 h, followed 
by TNFα (15 ng/ml) for another period of time (6 h for COLO205, or 24 h for 
HeLa and HCT116 cells). Cell death was determined by the percentage of sub-
G1 cells as described in Materials and Methods. Data are presented as means ±
SD from at least 3 independent experiments. * p<0.05 comparing to their 
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Figure 4.2 Effect of luteolin treatment sequence on sensitization.
In COLO205 cells, luteolin was administered either 2 h before (pre-
treatment) or after (post-treatment) TNFα (15 ng/ml) exposure, then 
continued the culture for another 4 h. Cell death was determined by the 
percentage of sub-G1 cells as described in Materials and Methods. Data 
are presented as means ± SD from at least 3 independent experiments. * 
p<0.05 comparing to their respective non-treated control group; # p<0.05 
comparing to the pre-treatment group. 
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4.3.2 Luteolin sensitizes TNFα-induced cell death through apoptosis 
 To further investigate the apoptosis induced by luteolin and TNFα, we then 
examined the morphological changes using AO/EB staining under a fluorescent 
microscope (Salghetti et al., 1999). In COLO205 cells combined treatment of luteolin 
and TNFα resulted in evident cell shrinkage, cell membrane blebbing, chromatin 
condensation, and formation of apoptotic body at the early stage of cell death (data 
not shown), indicating that luteolin plus TNFα induces typical apoptotic cell death in 
this cell line. To confirm the above observations, we further analyzed two 
biochemical hall-markers of apoptosis: PARP cleavage and DNA fragmentation. 
While neither luteolin nor TNFα alone caused PARP cleavage or DNA fragmentation, 
luteolin pretreatment caused PARP cleavage (Figure 4.3A) and DNA fragmentation 
(Figure 4.3B) in cells treated with TNFα in a dose-dependent manner. The extent of 
these changes was comparable to cells treated with actinomycin D (ActD) plus TNFα. 
It is well known that ActD and cycloheximide (CHX) are general gene transcription 
and de novo protein synthesis inhibitors, respectively, which enhance TNFα-induced 
cell death via unspecific blockage of anti-apoptotic gene expression. To test whether 
luteolin acts through a similar mechanism, we examined the changes of the protein 
level of c-myc, a short half-life protein in the cell (Strasser and Newton, 1999). As 
shown in Figure 4.4, ActD and CHX but not luteolin reduced the c-myc protein 
content, indicating that luteolin is not a general gene expression inhibitor, but may act 
via other mechanisms.  
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Figure 4.3 Luteolin and TNFα induce typical apoptosis in COLO205 
cells. 
COLO205 cells were pre-treated with indicated concentrations of luteolin 
for 2 h followed by TNFα (15 ng/ml) treatment for additional 6 h. ActD (1 
μg/ml) pretreatment (1 h) was used as a positive control in both 
experiments. PARP cleavage was detected by Western blot (A). DNA
fragmentation was examined by agarose gel electrophoresis (B).
A
B
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TNF           - +        - +         +         +         +         +
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Lu                     - +            - -
ActD                 - - +            -
CHX                  - - - +
c-myc
Tubulin
Figure 4.4 Effect of luteolin on c-myc protein level in 
COLO205 cells.
Changes of c-myc protein level in COLO205 cells treated with 
luteolin (40 μM), ActD (1 μg/ml) or CHX (10 ng/ml) for 6 h was 
detected by Western blot. The content of tubulin was used as a 
loading control.
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4.3.3 Luteolin-induced sensitization to TNFα is associated with enhanced 
caspase-8 activation 
 Caspase activation is the central machinery in apoptosis and TNFα mediates 
apoptotic cell death via the cell death receptor pathway initiating from caspase-8 
activation (Baldwin, 2001; Yamamoto and Gaynor, 2001). In this study, no caspase-8 
activation was found in COLO205 cells treated with either luteolin or TNFα alone, 
while luteolin pretreatment markedly enhanced caspase-8 cleavage as well as caspase-
8 activity in TNFα-treated cells (Figures 4.5 and 4.6). Similar pattern was also 
observed in subsequent activation of caspase-3. To confirm the role of such a caspase 
cascade in apoptosis mediated by luteolin plus TNFα, we tested the effect of a specific 
caspase-8 inhibitor (z-IETD-fmk) as well as a general caspase inhibitor (z-VAD-fmk) 
on cell death induced by luteolin plus TNFα. Both inhibitors effectively blocked cell 
death (Figure 4.7), PARP cleavage (Figure 4.8 upper panel) and DNA fragmentation 
(Figure 4.8 lower panel) in cells treated with luteolin plus TNFα, in concomitant with 
caspase-8 and caspase-3 inhibition (Figure 4.5). Similar results were also found in 
HeLa cells and HCT116 cells treated with luteolin plus TNFα (data not shown). These 
results thus indicate that the apoptosis induced by luteolin plus TNFα is mediated via 
a caspase cascade initiated from caspase 8 activation.  
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Figure 4.5 Effect of luteolin and TNFα on caspase.
COLO205 cells were pretreated with 40 μM luteolin for 2 h and then 
treated with TNF (15 ng/ml) for indicated hours. Cells were collected 
for detection of caspase-8 and caspase-3 activation by specific anti-
caspase-8 and caspase-3 antibodies (Cell Signaling), recognizing the 
pro- and cleaved caspase-8, and the cleaved caspase-3, respectively. 
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Figure 4.6 Effect of luteolin and TNFα on caspase activity.
COLO205 cells were pretreated with 40 μM luteolin for 2 h and then 
treated with TNF (15 ng/ml) for indicated period.  Cells were collected for 
detection of caspase-8 and caspase-3 activity using their respective 
substrates (Ac-IETD-AMC and z-DEVD-Rhodamine 110). * p<0.05 





















Lu                  - +           - +           - +
TNF               - +            - +           - + 
z-VAD-fmk - - +          +           - -
z-IETD-fmk - - - - +           +    
Figure 4.7 Effect of caspase inhibitors on luteolin and TNFα-
induced apoptosis.
COLO205 cells were first treated with either z-VAD-fmk (25 μM) or z-
IETD-fmk (25 μM) for 30 min, followed by luteolin (40 μM) for 2 h, 
and then TNFα (15 ng/ml) for another 6 h. Cell death was evaluated by 
flow cytometry after PI staining. * p<0.05 comparing to their respective 
non-treated control group  (student's t test). # p<0.05 comparing to 
luteolin and TNF-treated group  (student's t test).
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TNF                    - +         - +          - +   
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Figure 4.8 Effect of caspase inhibitors on luteolin and TNFα-induced 
apoptosis.
COLO205 cells were first treated with either z-VAD-fmk (25 μM) or z-
IETD-fmk (25 μM) for 30 min, followed by luteolin (40 μM) for 2 h, and 
then TNFα (15 ng/ml) for another 6 h. Cells were collected for detection 
of PARP cleavage by Western blot (upper panel) and DNA 
fragmentation by agarose electrophoresis (lower panel).
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4.3.4 TNFα-induced NF-κB activation is inhibited by luteolin 
 NF-κB is the main cell survival pathway elicited by TNFα. It has been well 
established that inhibition of NF-κB signaling pathway sensitizes TNFα-induced cell 
death (Kim et al., 2003b). Luteolin has recently been shown to inhibit LPS-induced 
NF-κB activation in fibroblasts, a mechanism involved in its anti-inflammatory 
activity (Hehner et al., 1999). Here in order to understand the underlying mechanism 
responsible for the sensitization effect of luteolin to TNFα-induced apoptosis, we 
systematically tested the effects of luteolin on various phases of NF-κB signaling 
pathways triggered by TNFα. First, we examined the inhibitory effect of luteolin on 
NF-κB transcriptional activity in COLO205 cells by using the NF-κB luciferase 
reporter assay. As shown in Figure 4.9, treatment with TNFα significantly enhanced 
NF-κB transcriptional activity and luteolin pretreatment markedly suppressed the 
transactivation of NF-κB induced by TNFα. A similar inhibitory effect was found 
with parthenolide, a known specific inhibitor of IKK (Karin and Ben-Neriah, 2000). 
In order to exclude the possibility that the reduced luciferase activity by luteolin is 
due to its direct inhibition on luciferase enzyme activity, we performed luteolin post-
treatment: cells were first treated with TNFα (15 ng/ml) for 2 h followed by luteolin 
(40 μM) treatment for another 2 h. It is rather interesting to find that luteolin post-
treatment failed to inhibit the transactivation of NF-κB induced by TNFα, suggesting 
that luteolin does not suppress NF-κB post-transcriptionally and pose no direct 
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Figure 4.9 Luteolin inhibits TNFα-induced NF-κB transcriptional 
activity. 
COLO205 cells were co-transfected with NF-κB-dependent luciferase
reporter construct and β-galactosidase construct. The cells were then treated 
with luteolin pretreatment or post-treatment (40 μM × 2 h), followed by 
TNFα (15 ng/ml) for 2 h. Luciferase activity was expressed as fold increased 
over control after normalized with β-galactosidase enzyme activity. 
Pretreatment with pathenolide (PN, 20 μM × 2 h) was used as a positive 
control. Data are presented as means ± SD from at least 3 independent 
experiments. * p<0.05 comparing to the non-treated control group  (student's t 
test). # p<0.05 comparing to the TNF-treated group  (student's t test).
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 The activation of NF-κB requires a series of upstream events including 
degradation of IκBα, NF-κB nuclear translocation and NF-κB-DNA binding (Kim et 
al., 2003b). To define the mechanism by which luteolin inhibits NF-κB activation, we 
sought to define whether luteolin affects these upstream events. As shown in Figure 
4.10, IκBα degradation and p65 nuclear translocation induced by TNFα in COLO205 
cells were inhibited by parthenolide but not by luteolin. As shown in Figure 4.11, p65 
was found to be main NF-κB component in TNFα-stimulated cells (supershift assay). 
Luteolin pretreatment also failed to influence NF-κB-DNA binding activity detected 
using EMSA (Figure 4.11), while it was completely abolished by parthenolide. 
Similar results were obtained when HeLa cells were tested (data not shown). It thus 
appears that luteolin may affect TNFα-induced NF-κB activation via interfering the 
transcriptional machinery, similar to its inhibitory effect on LPS-activated NF-κB 
transcription in fibroblasts (Gerritsen et al., 1997). 
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Figure 4.10 Effect of luteolin pretreatment on IκBα degradation and 
p65 nuclear translocation in COLO205 cells. 
COLO205 cells were pretreated with luteolin (40 μM × 2 h) or PN (20 μM
× 2 h), followed by TNFα (15 ng/ml) for 30 min. Cells were collected and 
fractioned to obtain cytosolic fraction and nuclear fraction. The levels of 
IκBα in cytosol and p65 in nuclear fraction were detected by Western blot. 
Tubulin and Histone were used as loading control for cytosol and nuclear 
fraction, respectively. 
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Figure 4.11 Effect of luteolin pretreatment on NF-κB-DNA binding 
activity. 
COLO205 cells were pretreated with or without luteolin (40 μM) or PN (20 
μM) for 2 h, followed by TNF (15 ng/ml) for 30 min. The cytosol and 
nuclear fraction were prepared as described in Materials and Methods. NF-
κB-DNA binding activity was determined by EMSA.
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4.3.5 Luteolin inhibits TNFα-activated NF-κB by interfering with CBP-p65 
interaction 
 It is known that transcriptional activation of NF-κB requires participation of a 
number of coactivators including cAMP response element-binding protein (CBP) 
(Kim et al., 2003b). We next examined whether luteolin affects the interaction 
between p65 and CBP. As shown in Figure 4.12, TNFα markedly enhanced CBP–p65 
interaction and the interaction was significantly inhibited by luteolin pretreatment, 
suggesting that luteolin inhibits TNFα-induced NF-κB activation via interfering with 
p65-CBP interaction. Such action of luteolin was found to be similar to its inhibitory 
effect on LPS-activated NF-κB transcription in fibroblasts (Wang et al., 1998; He and 
Ting, 2002).  
4.3.6 p65 expression protects the cell death induced by luteolin and TNFα 
 To further confirm the involvement of p65–CBP interaction in luteolin-
mediated suppression on NF-κB activation, HeLa cells were transiently transfected 
with a p65-GFP expression vector. As shown in Figure 4.13A and B, p65 
overexpression significantly overturned the sensitization effect of luteolin and 
protected against cell death. The above observation also suggests that NF-κB (p65) 
serves as the molecular target for the sensitization activity of luteolin on TNFα 
induced apoptosis. 
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Figure 4.12 Effect of luteolin on CBP-p65 interaction
COLO205 cells were pretreated with 40 μM luteolin for 2 
h followed by TNF (15 ng/ml) for 30 min. Cell lysate was 
co-immunoprecipited by anti-CBP antibody (Santa Cruz) 
and then detected by Western blot using anti-p65 antibody 
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Figure 4.13 Effect of p65 overexpression on cell death induced by 
luteolin and TNF
A, HeLa cells were transiently transfected with pcDNA and GFP or p65-
GFP for 24 h. Cells were then treated with luteolin (40 μM × 2 h) 
followed by TNF (15 ng/ml × 24 h). B, quantification of the cell death in 
A by counting the percentage of dead cells among those transfected cells 
in total 200 randomly selected transfected cells. Data are presented as 
means ± SD from 3 independent transfection experiments. * p<0.05 




4.3.7 Luteolin suppresses the expression of NF-κB anti-apoptotic target genes 
A20 and c-IAP1 
 The anti-apoptotic function of NF-κB is depending on the expression of its 
anti-apoptotic target genes. Here we further tested whether luteolin pretreatment 
influences the expression level of those genes. As shown in Figure 4.14, TNFα 
markedly upregulated the expression of A20 and c-IAP1, while luteolin pretreatment 
significantly reduced their expression level. In contrast, no significant changes of c-
IAP2, c-FLIPL and c-FLIPS were noted in cells treated with TNFα or luteolin. Both 
A20 and c-IAP1 are important anti-apoptotic molecules (De Smaele et al., 2001; Tang 
et al., 2001) and their reduced expression levels caused by luteolin pretreatment are 
likely to contribute to the sensitization effect by luteolin to TNFα-induced apoptosis.  
4.3.8 JNK activation contributes to the sensitization effect of luteolin to TNFα-
induced apoptosis 
 Although the exact role of JNK in TNF-induced apoptosis is largely 
controversial, some recent studies have suggested that inhibition of NF-κB resulted in 
sustained JNK activation and apoptosis (Bennett et al., 2001). Here we examined the 
effect of luteolin pretreatment on TNFα-induced JNK activation. TNFα alone caused 
a rapid and transient activation of JNK in COLO205 cells, demonstrated by the 
increased level of JNK (Figure 4.15, upper panel) and c-Jun phosphorylation (Figure 
4.15, lower panel), with a peak level at 30 min. Although luteolin alone had little 
effect on JNK, luteolin pretreatment significantly augmented and prolonged JNK 
activation (both JNK and c-Jun phosphorylation). Similar augmentation effect of 
luteolin on TNFα-mediated JNK activation was also found in HeLa cells (data not 
shown).  
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Figure 4.14 Luteolin pretreatment down-regulates expression 
of NF-κB anti-apoptotic target genes. 
COLO205 cells were treated with TNFα (15 ng/ml) for 30, 60 or 
120 min, with or without luteolin pretreatment (40 μM × 2 h). The 
mRNA level of various NF-κB target genes were examined using 
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Figure 4.15 Luteolin pretreatment leads to augmented and 
prolonged JNK activation induced by TNFα. 
COLO205 cells were first pretreated with SP600125 (20 μM ×
30 min), followed by luteolin (40 μM × 2 h) and then TNFα
(15 ng/ml) for indicated periods. Cells were collected for 
detection of JNK activation by enhanced level of both JNK and 
c-Jun phosphorylation by Western blot. 
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 In order to understand the role of JNK activation in apoptosis induced by 
luteolin and TNFα, we next assessed the effect of a synthetic JNK inhibitor, 
SP600125 (Muzio et al., 1997), on JNK activation and cell death in COLO205 cells 
treated with luteolin plus TNFα. As expected, pretreatment with SP600125 prevented 
luteolin plus TNFα induced JNK activation (Figure 4.15). More importantly, it almost 
completely blocked the catalytic cleavage of caspase-8 and its downstream effector 
caspase-3, as well as PARP cleavage (Figure 4.16), suggesting that JNK activation is 
required for caspase-8 activation and apoptotic cell death induced by luteolin plus 
TNFα.  
4.3.9 Ectopic expression of A20, c-IAP1 and dominant negative forms of JNKK1 
and JNKK2 prevents apoptosis induced by luteolin plus TNFα 
 The above data collectively demonstrate that the reduced expression of anti-
apoptotic genes A20 and c-IAP1, as well as the augmented activation of JNK may 
contribute to the apoptosis induced by luteolin plus TNFα (Figures 4.14 and 4.16). 
We then used genetic approaches to further establish the causative link between these 
events. HeLa cells were transiently transfected with either myc-A20 or HA-c-IAP1 
expression vector together with a red fluorescence protein construct (pDsRed) as a 
transfection marker. In addition, a vector expressing a viral protein cytokine response 
member A (CrmA), which is known to be a specific caspase-8 inhibitor (Davis, 2000), 
were included as a positive control. As shown in Figure 4.17, the successfully 
transfected cells emitted strong red fluorescence as seen under a fluorescence 
microscope. Following combined treatments with luteolin and TNFα, most of the cells 
transfected with pDsRed and pcDNA died. A quantitative analysis counting the 
percentage of cell death among transfected cells was also carried out (Figure 4.18). 
CrmA Over-expression offered a complete protection against apoptotic cell death 
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induced by the combined treatments of luteolin and TNFα, confirming the earlier 
finding that such apoptosis is mediated by caspase-8 activation (Figures 4.7 and 4.8). 
In addition, the over-expression of either A20 or c-IAP1 protein significantly 
protected cell death induced by luteolin plus TNFα, although to a lesser extent than 
that of CrmA (Figure 4.18). 
 It has been well established that TNFα-mediated JNK activation is regulated 
by two upstream MAPK kinases: JNKK1 and JNKK2 (Ueda et al., 2003). The 
effectiveness of dominant negative forms of JNKK1 and JNKK2 were proven in 
HeLa cells when they successfully blocked TNF-mediated JNK activation using JNK 
kinase assay (data not shown). Here cells with successful HA-JNKK1(DN)+HA-
JNKK2(DN) transfection became largely resistant to apoptosis induced by 
luteolin+TNFα. Such findings, together with the pharmacological evidence from 
SP600125 (Figure 4.15), strongly suggesting that JNK plays a critical role in the 
sensitization effect of luteolin on TNFα-induced apoptosis.  
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Figure 4.16 SP600125 Inhibits caspase 8 and caspase 3 
activation and PARP cleavage in cells treated with luteolin 
and TNFα. 
COLO205 cells were first pretreated with SP600125 (20 μM ×
30 min), followed by luteolin (40 μM × 2 h) and then TNFα
(15 ng/ml) for another 6 h. Western blotting was performed to 
detect caspase-8, caspase-3 and PARP cleavage. Tubulin was 
used as loading control 
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Figure 4.17 Ectopic expression of A20, c-IAP1 and 
JNKK1(DN)+JNKK2(DN) protects cell death induced by luteolin 
and TNFα. 
HeLa cells were transiently transfected with either pcDNA, CrmA, HA-
c-IAP1, myc-A20 or HA-JNKK1(DN)+JNKK2(DN), together with 
pDsRed as a transfection marker. After 24 h, the cells were treated with 
luteolin (40 μM) for 2 h followed by TNFα (15 ng/ml) treatment for 
another 24 h. Cell death was then evaluated by morphological changes 
under a fluorescent microscope and those successfully transfected cells 
were in bright red. 







































Control                      Lu+TNF
Figure 4.18 Ectopic expression of A20, c-IAP1 and 
JNKK1(DN)+JNKK2(DN) protects cell death induced by 
luteolin and TNFα (Quantification).
Cells were treated as in Figure 5.17, quantification of cell death 
was conducted by counting the percentage of dead cells among 
those transfected cells in a total of randomly selected 200 
transfected cells. Data are presented as means ± SD from 2 
independent transfection experiments. * p<0.05 comparing to the 
group with pcDNA transfection.
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4.4 DISCUSSION 
 Luteolin is a common flavonoid found in human diet. Previous studies have 
demonstrated the anti-cancer property of luteolin. For instance: it is capable of 
preventing 7,12-dimethylbenz[a]anthracene (DMBA)- and 12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced mouse skin cancer (Huang et al., 
1999b; Casagrande and Darbon, 2001; Ko et al., 2002) or inducing cell cycle arrest 
and apoptosis in some human cancer cells in vitro (Strasser and Newton, 1999). In 
this study, we provided evidence that luteolin sensitizes TNFα-induced apoptosis in 
human colorectal and cervical cancer cells. Such sensitization is achieved via its 
inhibitory effect on NF-κB activation, which in turn results in reduced expression of 
anti-apoptotic NF-κB targets genes (A20 and c-IAP1), as well as augmented and 
prolonged JNK activation. Data from this study thus reveal a novel function of 
luteolin and enhance the value of luteolin as a useful anti-cancer agent. 
 There are several features in the sensitization effect of luteolin to TNFα-
induced cell death. First, the sensitization is mainly achieved through enhanced 
activation of caspase-8, the initial caspase in the death receptor signaling pathway to 
induce typical apoptosis (Muzio et al., 1997). Such notion is supported by the strong 
inhibitory effects on cell death offered by z-IETD-fmk, a synthetic caspase-8 inhibitor 
(Figures 4.7 and 4.8) as well as by over-expression of CrmA (Figures 4.17 and 4.18), 
a powerful and specific caspase-8 inhibitor (Baldwin, 2001; Kucharczak et al., 2003). 
In contrast, the contribution from mitochondria to the sensitization process by luteolin 
is believed to be insignificant based on the marginal inhibitory activity of a caspase-9 
inhibitor on apoptosis (data not shown). Second, although luteolin sensitized TNFα-
induced apoptosis in a similar pattern as ActD (Figure 4.3), they apparently act 
through different mechanisms. Luteolin did not block the expression level of c-myc as 
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ActD or CHX did (Figure 4.4), indicating that luteolin is not a general gene 
expression inhibitor, but rather works through a specific mechanism. Third, the 
sensitization effect of luteolin is depending on luteolin administration schedule and 
luteolin post-treatment failed to exert significant sensitization to TNFα-induced 
apoptosis (Figure 4.2), suggesting that the sensitization effect of luteolin may be 
associated with the blockage of anti-apoptotic gene expression elicited by TNFα.  
 NF-κB activation is the principal cell survival signaling triggered by TNFα 
through TNFR1. The anti-apoptotic function of NF-κB is achieved through up-
regulation of its anti-apoptotic target genes (Kim et al., 2003b). Therefore, we 
reasoned that luteolin sensitizes TNFα-induced apoptosis via its inhibitory effect on 
the NF-κB signaling pathway. Such a hypothesis is strongly supported by the finding 
that luteolin pretreatment efficiently blocked the transactivation of NF-κB determined 
by NF-κB luciferase assay (Figure 4.9). Meanwhile, post-treatment with luteolin did 
not inhibit NF-κB transactivation and subsequently failed to exert any sensitization 
effect (Figure 4.2). We also attempted to evaluate the effect of luteolin on upstream 
signaling events of NF-κB activation. To our surprise, luteolin did not affect IκBα 
degradation, p65 nuclear translocation and p65-DNA binding (Figures 4.10 and 4.11). 
Such findings are basically similar to the effect of luteolin on LPS-induced NF-κB 
activation in rat fibroblasts (Xagorari et al., 2001). In contrast, Dhanalakshmi et al. 
reported that, in macrophages, luteolin inhibited LPS-induced NF-κB activation via 
preventing IκBα degradation (Dhanalakshmi et al., 2002). Different cell types used in 
those studies may explain the different responses to the same stimulus.  A number of 
flavonoids are capable of inhibiting the NF-κB signaling pathway but distinct 
mechanisms are involved. Silibinin can directly inhibit IKKα kinase activity and 
subsequently block phospho-IκBα degradation and NF-κB translocation (Farah et al., 
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2003; Kim et al., 2003b). In contrast, both apigenin and flavopiridol suppress TNFα-
stimulated NF-κB transcriptional activity, without affecting IκBα degradation 
(Gerritsen et al., 1997), which is similar to the effect of luteolin found in this study.  
 Then how does luteolin inhibit NF-κB transactivation? Since transcriptional 
activation of NF-κB requires participation of a number of coactivators including 
cAMP response element-binding protein (CBP) (Gerritsen et al., 1997), we next 
examined the effect of luteolin on the CBP-p65 interaction, which is known to be 
required for p65 transcriptional activation (Kim et al., 2003b). Luteolin significantly 
inhibited TNFα-induced CBP-p65 interaction (Figure 4.12), which is similar to its 
effect on LPS-induced CBP-p65 interaction (Kim et al., 2003b). At present, it is not 
clear how luteolin interrupts CBP-p65 interaction. In the context of LPS signaling, 
luteolin might induce JNK and c-jun activation and thus sequester transcriptional 
coactivators (Krikos et al., 1992; Wang et al., 1998; Micheau et al., 2001). In this 
study, luteolin alone had only marginal effect on JNK activation (Figure 4.16) 
Furthermore, SP600125 (specific JNK inhibitor) failed to restore the suppressed NF-
κB transactivation by luteolin (data not shown), suggesting that JNK activation is 
unlikely to be an important factor contributing to the inhibitory effect of luteolin on 
NF-κB activation. Based on the observation that p65 overexpression could overturn 
the cell death induced by luteolin and TNF (Figure 4.13), it is possible that luteolin 
may inhibit p65-CBP interaction by targeting p65, although the exact mechanism 
responsible for such action remains to be further identified. 
 Among various anti-apoptotic genes regulated by NF-κB, a number of them 
such as c-IAP1, c-IAP2, c-FLIPL, c-FLIPS and A20 have been well characterized to 
specifically inhibit caspase-8 activation (Krikos et al., 1992). As shown in Figures 4.5, 
4.6, 4.7 and 4.8, luteolin sensitizes TNFα-mediated cell death via enhanced caspase-8 
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activation. We thus postulated that luteolin may augment caspase-8 activation by 
relieving the suppressive effects of those molecules. Among the NF-κB target genes 
tested, the expression of A20 and c-IAP1, which was up-regulated by TNFα, were 
found to be markedly suppressed by luteolin (Figure 4.14). More importantly, the 
ectopic expression of either A20 or c-IAP1 conferred significant protection against 
apoptosis induced by the combined treatment of luteolin with TNFα (Figure 4.17). 
Zinc finger protein A20 is a NF-κB inducible gene (Song et al., 1996; Lademann et 
al., 2001). The important function of A20 includes its strong inhibitory effect on 
TNFα-mediated apoptosis (Lee et al., 2000). The A20 deficient cells are highly 
susceptible to apoptotic cell death induced by TNFα (He and Ting, 2002). A recent 
study revealed that A20 is capable of interrupting the recruitment of TRADD and RIP 
into TNFR1, thus blocking both caspase-8 (cell death) and the NF-κB (cell survival) 
pathways (Li et al., 2002). On the other hand, c-IAP1, but not c-IAP2, is also found to 
be an important modulator in the sensitization effect of luteolin to TNFα-induced 
apoptosis, although to a lesser extent than that of A20. Despite the high sequence 
similarity between c-IAP1 and c-IAP2, different specificities have been identified 
regarding their effects on apoptosis. For instance, c-IAP1, but not c-IAP2, is capable 
of directing the ubiquitylation of TRAF2 in TNF signaling (De Smaele et al., 2001; 
Tang et al., 2001).  
 One intriguing issue in TNF signaling is the role of JNK in TNF-mediated 
apoptosis. Recently, several lines of evidence have demonstrated that inhibition of 
NF-κB leads to prolonged JNK activation, which promotes TNFα-induced apoptosis 
(De Smaele et al., 2001; Tang et al., 2001). In this study, luteolin pretreatment also 
augmented and prolonged TNFα-mediated JNK activation (Figure 4.15). Since 
luteolin alone has little effect on JNK, such augmentation is most likely due to the 
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potent inhibitory of luteolin on TNFα-induced NF-κB transactivation (Figure 4.9). 
Suppressed NF-κB activation and subsequently diminished XIAP or GADD45b 
expression in luteolin-treated cell could account for the enhanced JNK activation 
(Tournier et al., 2000). By using both genetic and pharmacological approaches, we 
provided convincing evidence that the augmented and prolonged JNK activation plays 
a critical role in apoptosis triggered by luteolin and TNFα (Figures 4.16 and 4.17). 
The exact mechanism for JNK-mediated apoptosis may vary depending on the 
cellular context and the nature of stimuli. In UV-induced apoptosis, JNK is an 
important component in mitochondrial apoptotic pathway (Deng et al., 2003). On the 
other hand, a recent study by Deng et al showed that JNK is required to relieve the 
inhibition imposed by TRAF2-c-IAP1 on caspase-8 activation triggered by TNFα. 
This newly identified role of JNK in TNFα-induced apoptosis helps to explain our 
observation that a specific JNK inhibitor (SP600125) prevented caspase-8 activation 
in cells treated with luteolin plus TNFα (Figure 4.17).  
 In conclusion, in this part of study we have highlighted a novel function of 
luteolin by demonstrating that luteolin interferes with the TNF signaling pathway and 
markedly sensitizes human cancer cells to TNFα-induced apoptosis. Such 
sensitization is closely associated with the inhibitory effect of luteolin on NF-κB 
activation, resulting in down-regulation of some key anti-apoptotic genes such as A20 
and c-IAP-1, as well as augmented and prolonged JNK activation induced by TNFα. 
Therefore, the strong sensitization effect of luteolin to TNFα-mediated apoptosis in 
human cancer cells suggests that luteolin are valuable as chemopreventive and 












LUTEOLIN SENSITIZES TUMOR NECROSIS FACTOR- RELATED 
APOPTOSIS INDUCING LIGAND (TRAIL)-INDUCED APOPTOSIS IN 
HUMAN CANCER CELLS 
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5.1 INTRODUCTION 
 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a 
member of the TNF superfamily (Wang and El Deiry, 2003). TRAIL is an ideal 
therapeutic agent for cancer treatment because it has been shown to be a potent 
apoptosis inducer in a wide variety of cancer and transformed cells without damaging 
most normal cells. TRAIL induces apoptosis through binding to its receptors on cell 
surface. To date, four types of receptors have been identified: death receptor 4 (DR4) 
and death receptor 5 (DR5) as death receptors and DcR1 and DcR2 as decoy receptors 
(Wang and El Deiry, 2003). Ligation of TRAIL to its receptors results in trimerization 
of receptors and clustering of intracellular death domains (DDs), which then recruit 
Fas-associated death domain protein (FADD) and caspase 8 to form the death-
inducing signaling complex (DISC). Caspase 8 activation within DISC subsequently 
activates executor caspase 3, which in turn cleaves its substrates and eventually 
induces apoptosis (Green, 2000a; Ashkenazi, 2002). On the other hand, activation of 
caspase 3 by caspase 8 can be greatly facilitated through mitochondrial amplification 
pathway, in which activated caspase 8 cleaves the proapoptotic Bcl-2 family member 
Bid into truncated Bid (tBid). Translocation of tBid together with other pro-apoptotic 
Bcl-family members promotes release of cytochrome C and SMAC/DIABLO from 
mitochondria, leading to caspase 3 activation and apoptosis (Green, 2000a; Jiang and 
Wang, 2004).  
However, the potential application of TRAIL in cancer therapy is limited as 
many cancer cells are found to be resistant to the cytotoxicity of TRAIL. The 
resistance may be due to low expression of pro-apoptotic molecules (DRs or caspase 
8) or high expression of anti-apoptotic molecules (DcRs, FLIP, IAPs, Bcl-2) (Wang 
and El Deiry, 2003). Thus, combination TRAIL with other agents has been a 
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promising strategy to potentiate the cytotoxicity of TRAIL and its therapeutic 
applications (Bagli et al., 2004; Huerta-Yepez et al., 2004; Rosato et al., 2004; von 
Haefen et al., 2004). 
 In previous chapter, we have found that luteolin greatly sensitizes TNF-
induced cell apoptosis via inhibition of NF-κB and sustained and augmented 
activation of c-jun N-terminal kinase (JNK). We here demonstrated that luteolin also 
sensitizes TRAIL-induced apoptosis in various human cancer cells. Interestingly, such 
sensitization is achieved via enhanced XIAP ubiquitination and proteasomal 
degradation. Furthermore, our study demonstrates that the enhanced XIAP 
ubiquitination and degradation are likely due to suppressed protein kinase C (PKC) 
activation by luteolin. Data from this study thus present a novel function of luteolin as 
a potential anti-cancer agent. 
 
5.2 MATERIALS AND METHODS 
5.2.1 Reagents and Plasmids  
 Luteolin, 4'-6-Diamidino-2-phenylindole (DAPI) were purchased from Sigma 
(St Louis, MO). Human recombinant TRAIL was from R&D Systems (Minneapolis, 
MN) and was dissolved in 1% BSA as stock solution (50 μg/ml). The following 
reagents were from Calbiochem (San Diego, CA): pan caspase inhibitor z-VAD-fmk, 
caspase 8 inhibitor z-IETD-fmk, caspase 3 inhibitor z-DEVD-fmk, phorbol-12-
myristate-13-acetate (PMA), general PKC inhibitor bisindolylmaleimide I (BIM), PI3 
kinase inhibitor LY-294002 (LY) and Wortmannin (Wort), and proteasome inhibitor 
MG132, PSI and PSII. Flag-XIAP expression vector was a generous gift from Dr. 
Colin Duckett (University of Michigan, Ann Arbor, MI). Anti-caspase-8, anti-
caspase-3, anti-Bcl-2, anti-Bcl-xL, anti-Bid, and anti-phospho-substrate (Ser)-PKC 
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and anti-ubiquitin antibodies were from Cell Signaling Technology (Beverly, CA). 
The anti-XIAP and anti-PARP antibody were from BD Transduction Laboratories 
(San Diego, CA). Anti-FLIP, anti-c-IAP-1, anti-c-IAP-2, anti-Mcl-1, anti-mouse-
FITC, and anti-tubulin antibodies were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA). Anti-DR4, anti-DR5, anti-DcR1 and anti-DcR2 were from R&D. 
5.2.2 Cell culture and treatments  
 Human cervical cancer cells HeLa, human liver cancer cells HepG2 and 
human colorectal cancer cells HT29 were from ATCC and human nasopharyngeal 
cancer cells CNE1 was obtained from Sun Yet-sat University (Guangzhou, China). 
HeLa, HepG2 and CNE1 were maintained in DMEM medium (Sigma) with 10 % 
FBS (Hyclone). HT29 were maintained in RPMI-1640 medium with 10 % FBS. 
5.2.3 Apoptosis assessment-DAPI staining  
 The cells undergoing apoptosis were evaluated by chromatin condensation, 
nuclear shrinkage and formation of apoptotic bodies, all visualized with 4’,6-
diamidino-2phenylindole (DAPI) staining (Fuentes et al., 2003). After various 
designated treatments, medium was removed and cells were fixed with 70% ethanol at 
room temperature for 10 minutes. Cells were then stained with 0.3 μg/mL DAPI (in 
PBS) at room temperature for 10 minutes and visualized under an inverted 
fluorescence microscope and photographed.  
5.2.4 Colony formation assay  
 Cancer cells (HT29, HeLa and HepG2) were plated on 6-well plates (5,000 
cells/well) for 24 hours followed by various treatments. After 3 weeks, the survival 
clones were stained by 0.5 % crystal violet for 1 hour and photos were taken using 
digital camera (Mangan et al., 2004). 
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5.2.5 Transient transfection  
 HeLa cells were transiently transfected with either pcDNA or Flag-XIAP, 
using the Lipofectamine transfection reagent (Invitrogen, Carlsbad, CA). A red 
fluorenscent protein expression vector (pDsRed, Clontech Inc. Palo Alto, CA) was co-
transfected as a transfection marker. After 24 h of transfection, the cells were 
pretreated with luteolin (40 μM × 2 hours) followed by TRAIL (1 ng/ml × 6 hours). 
Cell death was determined by morphological changes examined under an inverted 
fluorescent microscope. 
5.2.6 Immunoprecipitation and western blot  
 At the end of treatment, cells were collected by scrapping and then washed 
with ice-cold PBS twice. Cells were lysed in lysis buffer [50 mM Tris HCl (pH7.4), 
150 mM NaCl, 1 mM EDTA and 1 % TRITON X-100] for 1 hour on ice. The 
supernatant was collected after centrifugation at 20,000 × g for 15 minutes. Each 
sample was added with 0.5 μg anti-XIAP body BD Biosciences Pharmingen (San Jose, 
CA) and 50 μL protein A/G agarose beads (Roche Molecular Biochemicals, 
Indianapolis, IN) and rotated overnight at 4°C. The beads were washed four times 
using ice-cold PBS buffer and then eluted using SDS-sample buffer before subject to 
western blot analysis. For Western blot, equal amount of proteins were fractionated on 
SDS-polyacrylamide gel in the Mini-PROTEAN II system (Bio-Rad, Hercules, CA) 
and blotted onto PVDF membrane (Millipore, Bedford, MA). After blocked with 5% 
nonfat milk in TBST [10 mM Tris-HCl (pH 7.5), 100 mM NaCl and 0.1% Tween 20], 
the membrane was probed with various antibodies and developed with enhanced 




5.2.7 RNA extraction and reverse transcription-PCR 
 RNA extraction was carried out using a total RNA extraction kit Purescript 
(Gentra Systems Inc., Minneapolis, MN), following the instructions from the 
manufacturer. Five μg of total RNA from each sample were subjected to reverse 
transcription using M-MLV reverse transcriptase (Promega, Madison, IL). For PCR, 
the amplification reaction was carried with 200 pmol of each primer, 200 μM of each 
dNTPs, and 0.5 units of Tag DNA polymerase II (Promega). The PCR conditions 
were optimized to achieve exponential amplification in which the PCR product 
formation is proportional to the starting cDNA. The primers of human XIAP (Asselin 
et al., 2001), DR4, DR5, DcR1, DcR2 (Abdollahi et al., 2003), and glyceraldehydes-
3-phosphate dehydrogenase (G3PDH) (Mafune et al., 1999) were based on literature. 
PCR products were size-fractionated using 1.8% agarose gel and visualized by 
ethidium bromide staining. 
5.2.8 Immunostaining for detection of death receptors  
 Cell surface expression of DR4, DR5, DcR1, and DcR2 were analyzed by 
indirect staining with primary mouse anti-human DRs (R&D systems), followed by 
FITC-conjugated rabbit anti-mouse IgG (Kim et al., 2004a). Briefly, cells were first 
stained with saturating amounts of anti-DR4, anti-DR5, anti-DcR1, or anti-DcR2 on 
ice for 30 min. After washing, cells were reacted with FITC-conjugated anti-mouse 
IgG on ice for another 30 min (Shao et al., 2004). Negative control cells were stained 
with the same FITC-conjugated secondary antibody. Cells were then subject to flow 





5.2.9 Statistical analysis  
 The numeric data are presented as mean ± SD from at least three sets of 
independent experiments. The differences among different groups were examined 
using a student's test and p < 0.05 was considered statistically significant. 
 
5.3 RESULTS 
5.3.1 Luteolin sensitizes cancer cells to TRAIL-induced apoptosis  
 We have recently shown that luteolin was able to sensitize TNF-induced 
apoptosis in human cancer cells (Chapter 4). Here we further assessed the effect of 
luteolin on TRAIL-induced cell death. First we tested the cytotoxicity of TRAIL on 
human cancer cell lines originated from various tissues, including human live cancer 
cell HepG2, human colorectal cancer cell HT29, human nasopharyngeal cancer cell 
CNE1 and human cervical cancer cell HeLa. Some cancer cells were found to be 
TRAIL-resistant. For instance, up to as high as 200 ng/mL TRAIL exerted no 
significant cytotoxicity on HepG2, HT29 or CNE1 cells even after 24 hours treatment. 
In contrast, HeLa cells were sensitive to as low as 5 ng/mL TRAIL (Figure 5.1). 
Luteolin (40 μM) alone did not induce cell death in any of these cells. However, when 
the cells were pretreated with luteolin for 2 hours followed by a non-cytotoxic 
concentration of TRAIL for as short as 6 hours, all the four cell lines tested underwent 
dramatic apoptotic cell death (Figure 5.2). Figure 5.3A shows the chromosome 
condensation in HeLa cells treated with luteolin and TRAIL. These data suggest that 
luteolin pretreatment not only markedly sensitizes TRAIL-resistant cancer cells, but 
also significantly expedites the cell death process. To test the long term effect of 
luteolin and TRAIL on cancer cell growth, the colony formation assay was performed 
using HT29 cells. As shown in Figure 5.3B, luteolin (40 μM) alone reduced HT29 
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colony size evidently, although it was not cytotoxic in the short term apoptosis assay 
(Figures 5.1 and 5.2). However, a combination of luteolin and TRAIL completely 
suppressed cancer cell growth and colony formation. Similar results were also found 
in HeLa and HepG2 cells (data not shown). 
5.3.2 Luteolin facilitates TRAIL-initiated caspase-3 maturation  
 TRAIL-induced apoptosis is mainly executed by the extrinsic cell death 
receptor pathway, involving caspase-8 as the initiator caspase and caspase-3 as the 
executor. Here we examined the effect of luteolin on TRAIL-initiated caspase cascade. 
As shown in Figure 5.4, TRAIL alone induced obvious caspase-8 cleavage, producing 
both p44 and p23. While luteolin alone had no effect on caspase-8 activation, luteolin 
pretreatment greatly promoted TRAIL-induced caspase-8 activation, as evidenced by 
the enhanced cleavage of pro-caspase-8 p55 to its intermediate form p44 and further 
to its active form p23. We next examined the pattern of caspase-3 activation. In cells 
treated with TRAIL alone for 6 hours, there was only slight cleavage of caspase-3, 
producing its inactive fragment p21 (Figure 5.4). Although luteolin alone did not 
cause any change of caspase-3, its pretreatment followed by TRAIL led to the 
complete cleavage of caspase-3, resulting in formation of the active form p17. This 
result indicates that luteolin, in combination with TRAIL, facilitates the maturation of 
caspase-3. Similar caspase changes were also observed in CNE-1, HT29 and HepG2 
cells (data not shown). Finally, we found that only combined treatment with luteolin 
and TRAIL resulted in evident PARP cleavage, downstream of caspase-3 activation 
and a hall marker for apoptosis (Figure 5.4), which is consistent to cell death results 

























Figure 5.1 Sensitivity of human cancer cells to TRAIL-induced 
apoptosis. 
CNE1, HT29, HeLa and HepG2 cells were treated with various 
concentrations of TRAIL for 24 h. At the end of treatment, cells
were stained with DAPI and examined under an inverted fluorescent 
microscope. The result was presented as the percentage of cells with 
evident nuclear condensation in 200 randomly selected cells.
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Figure 5.2  Luteolin sensitizes human cancer cells to TRAIL-induced 
apoptosis
Cells were first pretreated with indicated concentration of luteolin for 2 h, 
followed by treatment with a subtoxic concentration of TRAIL for another 
6 h (1 ng/ml for HeLa and CNE1, 5 ng/ml for HT29 and HepG2). At the 
end of treatment, cells were stained with DAPI and examined under an 
inverted fluorescent microscope. The result was presented as the
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 142
Cont rol Lu +  TRAI L
B
Figure 5.3  Luteolin sensitizes human cancer cells to TRAIL-induced 
apoptosis. 
A, apoptotic morphological changes in HeLa cells with combined 
treatment of luteolin (40 μM× 8 h) and TRAIL (1 ng/ml× 6 h). Top: 
cells pictured under a normal light microscope; bottom: the cells with 
DAPI staining under an inverted fluorescence microscope. B, colony 
formation assay. HT29 cells were plated on six-well plates (5,000 
cells/well) and treated with luteolin alone (40 μM), TRAIL alone (1 
ng/mL), or their combination for 3 weeks. The survival clones were 






Figure 5.4  Luteolin and TRAIL induces caspase activation.
HeLa cells were treated with TRAIL (1 ng/ml) for the indicated 
periods with or without the presence of luteolin pretreatment (40 μM
× 2 h). Cells were collected and subjected to Western blot for 
detection of the cleavage of caspase-8, caspase-3 and PARP. 
TRAIL(h)      - - 1     3       6      1      3      6













We then used various caspase inhibitors to confirm the role of the observed caspase 
cascade in the cell death induced by luteolin and TRAIL. Figures 5.5 and 5.6 show 
that z-DEVD-fmk (a caspase-3 inhibitor), z-IETD-fmk (a caspase-8 inhibitor) and z-
VAD-fmk (a pan caspase inhibitor) completely blocked caspase-3 activation and cell 
death induced by luteolin and TRAIL. One interesting finding here is that z-DEVD-
fmk, the specific inhibitor of caspase-3, also abrogated caspase-8 cleavage in cells 
treated with luteolin and TRAIL, indicating the presence of a caspase-8 and caspase-3 
positive feed back loop (Shi, 2002). 
 In certain cells, TRAIL has been demonstrated to induce apoptosis via the 
intrinsic mitochondrial pathway via caspase-8-mediated Bid cleavage (Shi, 2002). 
However, in this study we found that a caspase-9 inhibitor did not offer significant 
protection against luteolin and TRAIL-induced apoptosis (data not shown). Therefore, 
it is believed that luteolin enhances TRAIL-induced apoptosis mainly by utilizing the 
cell death receptor pathway. 
5.3.3 Luteolin does not alter expression of death receptors 
          It has been reported that modulation of surface expression of death receptors 
could sensitize cells to TRAIL-induced apoptosis (Gibson et al., 2000; Nagane et al., 
2000). We then tested the changes of various TRAIL death receptors after luteolin 
treatment by using immunofluorescence staining for the cell surface protein level and 
RT-PCR for their mRNA level. However, it was found that luteolin treatment did not 
alter the surface expression of death receptors (DR4, DR5, DcR1 or DcR2) (Figure 
5.7). mRNA level of death receptors does not change either after luteolin treatment 
(Figure 5.8), suggesting that luteolin promotes caspase activation via other 
mechanisms 
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Figure 5.5 Effect of caspase inhibitors on caspase activation 
induced by luteolin and TRAIL.
HeLa cells were pretreated with z-IETD-fmk (25 μM), z-DEVD-
fmk (25 μM) or z-VAD-fmk (25 μM) for 30 min, then cells were 
treated with a combination of luteolin (40 μM × 8 h) and TRAIL (1 
ng/ml × 6 h). Cells were collected for measuring caspase-3 and 
caspase-8 cleavage by Western blot. 
Lu+TRAIL - +         +          +          +
Z-IETD-fmk - - +          - -
Z-DEVD-fmk - - - +          -










Figure 5.6  Effect of caspase inhibitors on cell death induced 
by luteolin and TRAIL.
HeLa cells were pretreated with z-IETD-fmk (25 μM), z-DEVD-
fmk (25 μM) or z-VAD-fmk (25 μM) for 30 min, then cells were 
treated with a combination of luteolin (40 μM × 8 h) and TRAIL 
(1 ng/ml × 6 h). The percentage of apoptosis was evaluated using 


















Lu+TRAIL - +         +          +          +
Z-IETD-fmk - - +          - -
Z-DEVD-fmk - - - +          -
Z-VAD-fmk - - - - +
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Figure 5.7 Effect of luteolin on expression level of various TRAIL 
death receptors. 
HeLa cells were treated with 40 μM luteolin for 6 h, then collected and 
washed prior to immunostaining using respective first antibody to 
DR4, DR5, DcR1 and DcR2, followed by FITC-conjugated secondary 
antibody. Cells were analyzed by flow cytometry and the histogram 
were representative from 3 independent experiments. Open frame 









Lu                  - +            - +
TRAIL            - - +             +
Figure 5.8  Effect of luteolin and TRAIL on death 
receptor  mRNA level.
HeLa cells were treated with luteolin (40 μM) for 2  h 
followed by TRAIL (1 ng/ml) 2 h. Or cells were treated 
with luteolin alone 4 h or TRAIL alone 2 h. Cells were 
then collected for detection of mRNA level of DR4, DR5, 
DcR1 and DcR2 using RT-PCR. 
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5.3.4 NF-κB is not involved in the sensitization of luteolin  
 On the other hand, NF-κB is a potent anti-apoptotic factor in TNF-induced 
apoptosis (Wang et al., 1998; Yamamoto and Gaynor, 2001). In previous chapter, we 
have found that luteolin sensitized TNF-induced cell death through inhibition of NF-
κB. Although TRAIL-induced NF-κB activation has been observed in certain cells 
(Zauli et al., 2004), in this study NF-κB is unlikely to be important in the sensitization 
activity of luteolin on TRAIL-induced-apoptosis, based on the finding that either 
TRAIL or luteolin did not change NF-κB luciferase activity (Figure 5.9). In contrast, 
luteolin pretreatment successfully blocked the TNF-induced NF-κB transcriptional 
activation. Such a finding is consistent with an earlier report that sensitivity to 
TRAIL-induced apoptosis is not significantly modulated by transfection of dominant 
negative mutants of IKKβ or IκBα (Leverkus et al., 2003). 
5.3.5 XIAP down-regulation contributes to the sensitized cell death  
 It has been well documented that a number of cellular proteins are important 
regulators in apoptosis via inhibition of the caspase cascade. Those proteins include 
FLIP, c-IAP, Bcl-2, Bcl-xL and XIAP, which are known to be regulated by NF-κB at 
the transcriptional level (Deveraux and Reed, 1999; Micheau et al., 2001; Yamamoto 
and Gaynor, 2001). In search of the molecular mechanisms which may be involved in 
the sensitization activity of luteolin, we tested the changes of these proteins in cells 
treated with TRAIL with or without luteolin pretreatment. The protein levels of FLIP, 
c-IAP1, c-IAP2, Bcl-2 and Bcl-xL remained constant among various treated groups 
(Figure 5.10). This finding is basically consistent with the earlier observation that 
TRAIL or luteolin is unable to affect NF-κB transcriptional activity in HeLa cells 
(Figure 5.9). Interestingly, the protein levels of two anti-apoptotic proteins, Mcl-1 and 
XIAP, significantly decreased as cells undergoing apoptosis (Figure 5.11A). However, 
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the decrease of Mcl-1, but not XIAP, was reversed in the presence of z-VAD-fmk, a 
pan caspase inhibitor, indicating that the reduction of Mcl-1 protein level is the result 
of caspase activation (Herrant et al., 2004), while XIAP down-regulation is caspase-
independent. Figure 5.11B demonstrates the dose-dependent pattern of XIAP down-
regulation in cells treated with luteolin and TRAIL, which is consistent with the dose-
dependent pattern of cell death observed above (Figure 5.2). Luteolin-dependent 
reduction of XIAP protein level was also observed in two other TRAIL-resistant cell 
lines (HT29 and HepG2) (data not shown). 
 To further confirm the role of XIAP in the cell death induced by luteolin and 
TRAIL, we examined whether XIAP overexpression will protect the cell death. HeLa 
cells were transiently transfected with either wild-type XIAP plasmid (Flag-XIAP) or 
an empty vector (pcDNA). Red fluorescence protein plasmid (pDsRed) was used as a 
transfection marker. In pcDNA-transfected cells, almost all cells died after luteolin 
and TRAIL treatment based on the morphological changes. In contrast, most XIAP-
overexpressing cells remained alive while those non-transfected cells underwent cell 
death (Figures 5.12 and 5.13). The above results thus strengthen our argument that 




























TNF        -         -        +        +        -          -  
TRAIL     -         -        -         -         +         + 
Lu          -         +        -         +        -         +
Figure 5.9 Effect of TRAIL and luteolin on NF-κB
transcriptional activity. 
Three human cancer cells were transfected with NF-κB-luciferase
construct and β-galactosidase construct for 24 h, followed by TNF 
(15 ng/ml × 2 h) or TRAIL (1 ng/ml × 2 h for HeLa and CNE1, 25 
ng/ml × 4 h for HT29) in the presence or absence of luteolin 
pretreatment (40 μM × 2 h). NF-κB luciferase activity was 
normalized by β-galactosidase activity and expressed as folds over 
the control. 
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Figure 5.10 Effect of luteolin and TRAIL on expression of anti-
apoptotic proteins. 
HeLa cells were treatment with TRAIL (1 ng/ml) for indicated 
periods with or without presence of luteolin pretreatment (40 μM × 2 
h). Cells were collected for detection of FLIPL, c-IAP1, c-IAP2, Bcl-
2 and Bcl-xL protein level by Western blot. Tubulin was used as a 
loading control. 
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Figure 5.11  Down-regulation of XIAP in cells treated with 
luteolin and TRAIL. 
A, HeLa cells were first pretreated with z-VAD-fmk (25 μM ×
30 min), then cells were treated with TRAIL (1 ng/ml) for 
indicated periods with or without luteolin pretreatment (40 μM
× 2 h). Cells were collected for detection of Mcl-1 and XIAP 
by Western blot. B, HeLa cells were treated with indicated 
concentrations of luteolin for 2 h, followed by TRAIL (1 ng/ml) 
for additional 6 h and then cells were collected for detection of 
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Figure 5.12 Ectopic expression of XIAP protects cell 
death induced by luteolin and TRAIL.
HeLa cells were transiently transfected with either pcDNA or 
Flag-XIAP-Wt, together with pDsRed as a transfection
marker. After 24 h, the cells were treated with a combination 
of luteolin (40 μM × 8 h) and TRAIL (1 ng/ml × 6 h). Cell 
death was then evaluated by morphological changes under a 
fluorescent microscope and those successfully transfected 
cells were in bright red. 





Figure 5.13 Ectopic expression of XIAP protects cell death 
induced by luteolin and TRAIL (Quantification).
Cells were treated as described in Figure 6.12. Cell death was 
quantified by counting the percentage of dead cells among 200 
randomly selected transfected cells. Data are presented as means ±
SD from 3 independent transfection experiments. * p<0.05 
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5.3.6 XIAP down-regulation is mediated by ubiquitination and proteasomal 
degradation  
 The down-regulation of XIAP could be due to modulation at either 
transcriptional or post-transcriptional level. In order to elucidate the molecular 
mechanism involved, we first measured the XIAP mRNA level using RT-PCR. As 
shown in Figure 5.14, either luteolin, TRAIL, or their combined treatment did not 
alter the XIAP mRNA level up to 4 h, suggesting that the XIAP is mainly regulated 
post-transcriptionally.  
 In order to determine whether the decreased XIAP level is due to proteasomal 
degradation, here we tested the effects of proteasome inhibitors on XIAP protein level. 
As shown in Figure 5.15A, MG132 (1 μM), PSI (5 μM) or PSII (5 μM) completely 
abolished the XIAP down-regulation induced by luteolin and TRAIL. The effect of 
MG132 was also found to be dose-dependent; and a low concentration of MG132 (0.1 
μM) only partially prevented XIAP degradation (data not shown). Since XIAP is 
probably the most potent apoptosis inhibitor, the stabilization of XIAP would render 
cells resistant to apoptosis induced by luteolin and TRAIL. Such a hypothesis was 
supported by the results shown in Figure 5.15B that the three proteasome inhibitors 
were able to completely prevent cell death induced by luteolin and TRAIL. It is thus 
believed that the down-regulation of XIAP protein through proteasomal degradation is 
the underlying mechanism in the sensitization effect of luteolin on TRAIL-induced 
apoptosis. Similar results were also found in other cell lines such as HT29 and HepG2 
(data not shown). 
 It is known that XIAP has ubiquitin protease ligase (E3) activity and the 
autoubiquitination and degradation is an important mechanism for regulating the 
XIAP function in apoptosis (Yang et al., 2000b; Zhang et al., 2004). Here we further 
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examined whether treatment with luteolin and TRAIL promotes XIAP ubiquitination 
by directly measuring XIAP ubiquitination. It was found that the combined treatment 
of luteolin and TRAIL significantly enhanced the level of ubiquitylated XIAP in 
HeLa cells in the presence of proteasome inhibitor MG132 (Figure 5.16). In 
consistent, the level of total protein ubiquitination was also increased by luteolin and 
TRAIL in the presence of MG132. Similar results were also in HT29 and HepG2 cells 
(data not shown). The above results thus clearly demonstrate that luteolin and TRAIL 
promotes XIAP degradation by enhancing its ubiquitination.  
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Figure 5.14  Effect of luteolin and TRAIL on XIAP 
mRNA level.
HeLa cells were treated with luteolin (40 μM), or TRAIL (1 
ng/ml) or a combination of both for indicated periods. Cells 
were collected for detection of XIAP mRNA level using RT-
PCR. G3PDH was used as a loading control.
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Lu+TRAIL - +             - +            +             +
MG132            - - +             +            - -
PSI                  - - - - +              -
PSII                 - - - - - +
XIAP
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Lu+TRAIL - +                   - +                  +  
MG132          - - +                    - -
PSI                - - - +                   -
PSII               - - - - +
Figure 5.15 XIAP down-regulation is through proteasomal degradation 
in cells treated with luteolin and TRAIL. 
A, HeLa cells were pretreated with proteasome inhibitor MG132 (1 μM), 
PSI (5 μM), or PSII (5 μM) for 1 h, followed by combined treatment of 
luteolin (40 μM × 8 h) and TRAIL (1 ng/ml × 6 h). XIAP protein level was 
determined by Western blot. B, HeLa cells were treated as described in A 
and the percentage of apoptotic cell death was evaluated by DAPI staining.
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Figure 5.16 A combination of luteolin and TRAIL promotes XIAP 
ubiquitination. 
HeLa cells were pretreated with proteasome inhibitor MG 132 (1 μM) for 
2 h before combined treatment with luteolin (40 μM) and TRAIL (1 
ng/mL) for another 2 h. Cell lysate was used for immunoprecipitation with 
anti-XIAP antibody, followed by Western blot using anti-ubiquitin 
antibody.
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5.3.7 PI3K/AKT is not involved in cell death induced by luteolin and TRAIL 
 Previous studies have shown that the PI3K-AKT pathway plays a protective 
role in TRAIL-induced apoptosis (Thakkar et al., 2001) and one of the mechanisms is 
that AKT phosphorylates and stabilizes XIAP by inhibiting its ubiquitination (Dan et 
al., 2004). On the other hand, it is known that phorbol 12 myristate 13 acetate (PMA) 
is capable of protecting cells from TRAIL-induced apoptosis (Harper et al., 2003b). 
In our study, PMA pretreatment also completely prevented luteolin and TRAIL 
induced cell death (Figure 5.17).  
 It has been well established that PMA stimulates a series of downstream 
signals including PI3K-AKT, MAPK and PKC (Thakkar et al., 2001; Harper et al., 
2003b). We examined the involvement of each signaling pathway in the protective 
activity of PMA using various specific inhibitors. The two PI3K inhibitors (LY and 
Wort) failed to reverse the protective effect of PMA (Figure 5.17). Similar negative 
results were also found with a JNK inhibitor (SP600125), a p38 inhibitor (SB203580), 
or an ERK inhibitor (PD98059) (data not shown). The effectiveness of these two 
inhibitors on the PI3K/AKT pathway was confirmed in PMA-stimulated cells (Figure 
5.18A). We also found that either TRAIL or luteolin alone or their combination has 
no effect on AKT activation (Figure 5.18B). Therefore, the above data indicate that 
neither the PI3K-AKT nor the MAPK pathway plays a critical role in the protective 
effect of PMA against the apoptosis induced by luteolin and TRAIL. 
 
5.3.8 PKC activation blocks XIAP degradation and prevents the cell death 
induced by luteolin and TRAIL  
 It has been reported that PKC activation plays a protective role against 
TRAIL-induced apoptosis (Harper et al., 2003b). Here we attempted to explore the 
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possible role of PKC in luteolin and TRAIL-induced apoptotic cell death. First, BIM, 
a general PKC inhibitor, is capable of abolishing the protective effect of PMA on 
luteolin and TRAIL-induced cell death (Figure 5.19A), suggesting that the protective 
effect of PMA is mediated via PKC activation. Second, we asked whether PKC 
activation is associated with changes of XIAP protein level. As shown in Figure 
5.19B, PMA pretreatment completely prevented XIAP degradation in cells treated 
with luteolin and TRAIL. Moreover, such an effect by PMA on XIAP was completely 
abolished by BIM, thus suggesting that PMA-mediated PKC activation is able to 
stabilize XIAP and subsequently prevent apoptosis. The effectiveness of BIM on PKC 
activation was confirmed by the overall PKC activity which was assessed using an 
anti-phospho (Ser)-PKC substrate antibody by Western blot (Tanaka et al., 2003). As 
expected, PMA readily activated PKC and this activation was completely blocked by 
BIM but not LY and Wort (Figure 5.20), clearly suggesting that the protective effect 



















Lu+TRAIL - - +          +          +         +
PMA               - +           - +          +         +
LY                  - - - - +          -
Wort - - - - - +
Figure 5.17  Effect of PMA on the cell death induced by 
luteolin and TRAIL.
HeLa cells were pretreated with either 10 μM LY or 0.5 μM
Wort for 30 min, followed by treatment with PMA (80 ng/ml 
× 30 min) and finally with a combination of luteolin (40 μM
× 8 h) and TRAIL (1 ng/ml × 6 h). Cell death was evaluated 
by DAPI staining.
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Figure 5.18  Effect of luteolin and TRAIL on PI3K/AKT 
pathway. 
A, HeLa cells were pretreated with LY (10 μM) or Wortmannin (1 
nM) for 60 min followed by PMA (80 nM) treatment for 1 h. Cells 
were collected for detection of activation of AKT by Western blot 
using anti-phospho 473-AKT. Total AKT level was used as loading 
control. B, HeLa cells were pretreated with luteolin for 2 h followed 
by TRAIL for 1 h. Cells were collected for detection of activation of 
AKT by Western blot using anti-phospho 473-AKT. Total AKT level 



















Lu+TRAIL - +                 +                  +
PMA                 - - +                  +
BIM                  - - - +
Figure 5.19  PKC activation protects cell death and XIAP down-
regulation induced by luteolin and TRAIL. 
A, HeLa cells were first pretreated with 10 μM BIM for 30 min, 
followed by treatment with PMA (80 ng/ml × 30 min), and finally 
with combined treatment of luteolin (40 μM × 8 h) and TRAIL (1 
ng/ml × 6 h). Cell death was evaluated by DAPI staining. B, HeLa
cells were treated as in panel A and XIAP protein level was detected 
by Western blot. Tubulin was used as a loading control.
Tubulin
XIAP
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PMA           - - +             +              +




PMA           - +           +           +           +
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Figure 5.20  Effect of LY, Wort and BIM on PMA-induced 
PKC activation.
HeLa cells were pretreated with either 10 μM BIM, 10 μM LY or 
0.5 μM Wort for 30 min, followed by treatment with PMA (80 
ng/ml × 30 min). Cells were collected for detection of PKC 
activation by Western blot using anti-phospho (Ser)-PKC substrate 
antibody.  Tubulin was used as a loading control.
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5.3.9 PKC inhibition promotes XIAP down-regulation and apoptosis in TRAIL- 
treated cells  
 As the above data on PKC were all obtained from cells stimulated with PMA, 
next we examined whether the sensitization activity of luteolin also involves PKC 
without the presence of PMA. An earlier report showed that TRAIL activates PKC in 
one pancreatic adenocarcinoma cell line (PancTuI) but marginally in another 
(Colo357 cells) (Trauzold et al., 2001), suggesting the effect of TRAIL on PKC is 
cell-type specific. In this study, there was considerable degree of basal PKC activation 
in the control HeLa cells and marginal PKC activation by TRAIL. In contrast, luteolin 
pretreatment markedly reduced both the basal PKC and PKC activation by TRAIL, 
which is similar to the effect of BIM (Figure 5.21). These data thus support the 
hypothesis that luteolin sensitizes TRAIL-induced apoptosis through PKC inhibition. 
 To confirm the role of PKC in XIAP stability and the possible mechanisms 
involved, we further tested the effect of BIM on XIAP protein level in cells treated 
with TRAIL. Combined treatment of BIM and TRAIL significantly down-regulated 
XIAP level, a process not affected by z-VAD-fmk (data not shown), but prevented by 
MG132 (Figure 5.22A), which is similar to effect of luteolin on TRAIL-induced 
XIAP down-regulation as shown earlier (Figures 5.11A and 5.15A). Furthermore, 
similar to the sensitization activity of luteolin, BIM also significantly enhanced 
TRAIL-induced cell apoptosis (Figure 5.22B). Similar results were found in TRAIL-
resistant cells (HT29 and HepG2, data not shown). Therefore, data from this part of 
our study demonstrate that PKC activation plays a protective role in TRAIL-induced 
apoptosis via stabilization of XIAP and that luteolin may act as a PKC inhibitor to 
sensitize cancer cells to TRAIL-mediated apoptotic cell death. 
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Figure 5.21  Effect of luteolin on PKC activation. 
HeLa cells were first pretreated with luteolin (40 μM) or BIM 
(10 μM) for 30 min, followed by TRAIL (1 ng/ml for 1 h). 
Cells were then collected for detection of PKC activation by 
Western blot using anti-phospho (Ser)-PKC substrate antibody. 
Tubulin was used as a loading control
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Lu                      - +           - +            -
























TRAIL       - +           - +          +
BIM          - - +          +          +
MG132      - - - - +
A
B
TRAIL              - +             - +            + 
BIM                  - - +           +            + 
MG132             - - - - +
XIAP
Tubulin
Figure 5.22  A combination of PKC inhibition and TRAIL 
enhances XIAP degradation and cell death.
A, HeLa cells were pretreated with BIM (10 μM), and/or MG132 (1 
μM) for 30 min, followed by TRAIL (1 ng/ml × 6 h). XIAP protein 
level was detected by Western blot. Tubulin was used as a loading 
control. B, cells were treated as described in panel A and cell death 
was evaluated by DAPI staining. 
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5.4 DISCUSSION 
 TRAIL is a potent therapeutic agent due to its unique property of killing 
cancer cells by apoptosis but sparing normal cells. However, many cancer cells are 
found to be resistant to TRAIL, thus limiting its clinical application. A number of 
factors may be involved in the resistance, including modified expression of surface 
death receptors or changes of anti-apoptotic proteins (Wang and El Deiry, 2003). One 
effective strategy to overcome TRAIL resistance is to combine TRAIL with other 
anti-cancer agents (Gibson et al., 2000; Nagane et al., 2000; Huerta-Yepez et al., 
2004; Rosato et al., 2004; von Haefen et al., 2004). We demonstrated in an earlier 
study that luteolin sensitized TNF-induced apoptosis in cancer cells (Chapter 4). We 
here reported that luteolin also sensitizes TRAIL-induced apoptosis in a number of 
cancer cells. Such sensitization effect of luteolin is probably achieved via inhibition 
on PKC activation, promotion of XIAP ubiquitination and proteasomal degradation, 
which then removes the blockage on caspase and enhances apoptosis. 
 Data from this study have demonstrated that the sensitization activity of 
luteolin on TRAIL-induced apoptosis is mainly executed through the cell death 
receptor pathway and luteolin sensitizes TRAIL-induced apoptosis via enhanced 
caspase-3 maturation (Figures 5.4 and 5.5). It was reported that luteolin upregulated 
DR5 protein level in HeLa cells only after 12 h (Horinaka et al., 2005). This is 
consistent of our finding that luteolin treatment did not alter the expression level of 
TRAIL death receptors (DR4 and DR5) or its decoy receptors (DcR1 and DcR2) in 6 
h (Figures 5.7 and 5.8), suggesting that the slow increase of DR5 level unlikely 
contributes to the rapid sensitized cell death (4 h). We then went on to screen the 
changes of other apoptosis regulatory proteins after luteolin and TRAIL treatment. 
Among many anti-apoptotic proteins tested, we found that XIAP was significantly 
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down-regulated by combined treatment of luteolin and TRAIL, but not by their 
individual treatment (Figure 5.11). More importantly the XIAP down-regulation was 
caspase-independent, indicating the down-regulated XIAP level is upstream of 
caspase-3 activation. XIAP, a member of IAP family, is probably the most potent 
apoptosis inhibitory protein and plays important roles in cell survival. XIAP is 
characterized by baculoviral IAP repeat (BIR) domains, which can inhibit caspase-3 
and caspase-9 activity by direct binding (Deveraux et al., 1997; Deveraux and Reed, 
1999; Riedl et al., 2001). In this study, it appears that luteolin sensitizes TRAIL-
induced apoptosis by targeting XIAP to remove the blockage on caspase-3 activation 
and cell death. Such a hypothesis was further supported by the fact that over-
expression of XIAP protein offers complete protection against luteolin and TRAIL-
induced apoptosis (Figures 5.12 and 5.13).  
 We further examined the possible mechanisms contributing to the reduced 
XIAP protein level in cells treated with luteolin and TRAIL. Since either luteolin, 
TRAIL or their combined treatment had no effect on the XIAP mRNA level (Figure 
5.14), the reduced XIAP protein level is most probably the result of enhanced post-
transcriptional degradation. The effect of luteolin is apparently different from that of 
flavopiridol which acts synergistically with TRAIL by suppression of XIAP gene 
transcription (Rosato et al., 2004). It is known that the RING finger domain of XIAP 
has ubiquitin protease ligase (E3) activity and is responsible for its autoubiquitination 
and degradation after an apoptosis stimulus (Yang et al., 2000b). Here we tested 
whether luteolin and TRAIL promote XIAP ubiquitination and subsequent 
proteasomal degradation., the three proteasome inhibitors offered complete protection 
against both XIAP degradation (Figure 5.15A) and cell death (Figure 5.15B) in cells 
treated with luteolin and TRAIL. By performing XIAP immunoprecipitation and 
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ubiquitin western blot analysis, we then provided direct evidence showing that the 
level of ubiquitylated XIAP was enhanced in cells treated with luteolin and TRAIL. It 
is thus believed that the decreased XIAP protein level is mediated via ubiquitination 
and proteasomal degradation, a process crucial for deciding the susceptibility to 
apoptosis induced by luteolin and TRAIL in cancer cells.  
 One interesting finding in this study is that PMA pretreatment completely 
blocked the XIAP down-regulation and apoptotic cell death induced by luteolin and 
TRAIL (Figure 5.17). PMA is a potent inducer for a number of important cell 
signaling pathways, including the PI3K-AKT pathway (Hah et al., 2003). It has been 
reported that AKT activation stabilizes XIAP through enhanced phosphorylation and 
suppressed ubiquitination and proteasomal degradation (Dan et al., 2004). It has also 
been noted that over-expression of active AKT render TRAIL-sensitive cells to be 
resistant (Chen et al., 2001; Nesterov et al., 2001). In this study, pretreatment with the 
two PI3K inhibitors (LY or Wort) did not alter the cell sensitivity to TRAIL-induced 
apoptosis (Data not shown). No evident change of AKT activation was found in cells 
treated with either luteolin, TRAIL alone or their combination (Figure 5.18B). 
Moreover, LY or Wort failed to abrogate the protection effect of PMA against 
apoptosis induced by luteolin and TRAIL (Figure 5.17). Therefore, it appears that the 
PI3K-AKT pathway is not an important factor in luteolin and TRAIL-mediated XIAP 
down-regulation and apoptosis.  
 We next turned our attention to the possible involvement of PKC in luteolin 
and TRAIL-mediated XIAP and apoptosis since PMA is also known to be a potent 
stimulus for both classical and novel PKC activation (Tanaka et al., 2003). In this 
study we first confirmed that PKC activation contributes to the protective effect of 
PMA against luteolin and TRAIL-induced apoptosis by the following observations: (i) 
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PMA activates PKC (Figure 5.20) and (ii) a general PKC inhibitor (BIM) prevents 
PKC activation and abolishes the protective effect of PMA (Figure 5.22). It has been 
reported that PKC activation plays a protective role in TRAIL-induced apoptosis 
(Harper et al., 2003b). The protective effects of PKC against TRAIL-induced 
apoptosis could be achieved through interfering with DISC formation (Harper et al., 
2003b) or disrupting proteolytic cleavage of procaspase-8 (Meng et al., 2002) or 
affecting caspase-8-mediated Bid cleavage (Sarker et al., 2002). Here, we propose a 
novel mechanism to illustrate the anti-apoptotic function of PKC: PKC activation is 
associated with decreased XIAP proteasomal degradation and increased stability. 
Such a hypothesis is supported by the findings that PMA pretreatment prevents XIAP 
down-regulation while BIM reverses the effect of PMA on XIAP protein level in cells 
treated with luteolin and TRAIL (Figure 5.22). The suggested close linking between 
PKC activation and XIAP level indicates that there might be a positive correlation 
between the basal PKC level and XIAP level among cells with different sensitivity. 
However, we did not find any correlation after comparing the basal PKC and XIAP 
level among both TRAIL-sensitive cells and TRAIL-resistant cells (data not shown). 
It is possible that the basal level PKC activity and XIAP are not the only determining 
factors in the cellular response to TRAIL. It is known that phosphorylation of XIAP 
by some other protein kinases such as AKT protects XIAP from ubiquitination and 
proteasomal degradation (Dan et al., 2004). It is thus possible that PKC acts through a 
similar mechanism to stabilize XIAP. Thus, a number of important questions remain 
to be further investigated. For instance, does XIAP serve as the direct substrate for 
PKC? If so, which specific PKC subunit is involved? Further studies on these topics 
will certainly shed lights on the underlying mechanisms controlling TRAIL resistance 
and sensitivity in cancer cells. 
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 It was reported that certain flavonoids, including luteolin, inhibited PKC 
activity in some in vitro cell-free systems (Ferriola et al., 1989; Agullo et al., 1997). 
In this study, luteolin was found to significantly block both the basal PKC activation 
in control cells and the enhanced PKC activation in TRAIL-treated cells (Figure 5.21). 
Furthermore, the general PKC inhibitor (BIM) mimics the effect of luteolin: 
pretreatment with BIM down-regulated XIAP protein level in the presence of TRAIL 
(Figure 5.22A) and greatly caused apoptosis (Figure 5.22B). Therefore it is likely that 
luteolin acts as a PKC inhibitor to facilitate XIAP degradation and to promote 
TRAIL-mediated apoptosis. However, it is still not clear how luteolin inhibits PKC 
activity. Through the structure analysis, it has been hypothesized that flavonoids 
might interfere with the binding of PKC to calcium or diacylglycerol (DAG), but not 
directly interacting with the functional domain of PKC protein (Ferriola et al., 1989). 
Interestingly, although either luteolin or BIM could effectively suppress the basal 
PKC activation in control cells, they failed to cause any evident reduction of basal 
XIAP protein level. It thus suggests that PKC-induced modification of XIAP has no 
effect on its stability or expression, but likely acts on the recognition process by the 
proteosomal degradation pathway. Further study on PKC activation and XIAP 
ubiquitination and degradation is obviously required to address this issue.  
 Taken together, we discovered a novel anti-cancer function of luteolin. 
Luteolin sensitizes TRAIL-induced apoptosis in human cancer cells via inhibition on 
PKC activation and promotion of XIAP degradation (Figure 5.23). Understanding of 
such an effect of luteolin supports its potential therapeutic application in overcoming 
TRAIL resistance, especially in those cancers with elevated level of PKC activation. 
In addition, we also reveal a novel function of PKC in TRAIL-mediated apoptosis: 
PKC may protect the cell death by blocking XIAP ubiquitination and degradation 
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although a firm biochemical link between PKC and XIAP ubiquitination and 
degradation remains to be further established.   
 
 176
Figure 5.23  Illustration of the pathways involved in the 































Cisplatin (cis-diamminediachloroplatium) and its derivatives are among one of 
the most effective anticancer drugs used clinically in the treatment of solid tumors, 
including ovarian, testicular, cervical, and small cell lung cancers (Loehrer, 1984). 
The anti-cancer effect of cisplatin is mainly depending on its DNA damaging activity, 
via its direct interaction with DNA to form DNA adducts (Dijt, 1988). Subsequently, 
several signaling transduction pathways are activated, including ataxia telangiectasia 
mutated kinase (ATM); ataxia telangiectasia and rad3-related kinase (ATR), p53, 
mitogen-activated protein kinases (MAPKs). Among them, p53 activation is one of 
major factors responsible for the apoptosis induced by cisplatin (Siddik, 2003). It has 
been observed that cisplatin can cause apoptosis in wild type p53 cancer cells but not 
in p53 deficient or mutant cancer cells, suggesting that p53 is the key regulator for 
cisplatin-mediated apoptosis in cancer cells (Song et al., 1998; Kanata et al., 2000; 
Tang and Grimm, 2004; Beuvink et al., 2005).  
 p53 is a short-lived tumor suppressor protein (Ko, 1996; Levine, 1997). Its 
stability is mainly regulated by its interaction with its transcriptional target mouse 
double minute 2 (MDM2). Acting as an ubiquitin E3 ligase, MDM2 interacts with 
p53 directly and promotes its ubiquitination and proteasomal degradation. Hence, p53 
level is kept at a low level in p53 wild type cancer cells (Kubbutat, 1997). Upon the 
DNA damage caused by cisplatin, p53 is up-regulated via increased p53 stability 
which is achieved through disrupting the interaction between MDM2 and p53. For 
example, DNA damage-activated ATM, ATR and DNA-PK can phosphorylate p53 on 
Ser 15 and Ser 37 (Shieh, 1997); Chk2 contributes to phosphorylation of p53 on serine 
20 (Shieh, 1999); whereas JNK phosphorylates p53 on tyrosine 81 (Buschmann et al., 
 179
2001). Phosphorylation on p53 affects its interaction with MDM2 or its binding to 
DNA or its transcriptional activity (Steegenga et al., 1996). 
 One important role of p53 as a tumor suppressor is its involvement in 
apoptosis. p53 activates caspase cascade and apoptosis mainly via an intrinsic 
pathway that involves mitochondria, a central regulator of apoptosis. The integrity of 
outer mitochondrial membrane is tightly regulated by Bcl-2 family proteins. Pro-
apoptotic members of the Bcl-2 family, such as Bax, Bak and Bid, form channels in 
membranes to regulate the release of pro-apoptotic proteins from mitochondria. On 
the other hand, anti-apoptotic members of the Bcl-2 family, such as Bcl-2 and Bcl-XL, 
tend to block the above process. (Kelekar and Thompson, 1998). Activation of p53 
can perturb the balance of Bcl-2 family proteins and favour the release of cytochrome 
C, SMAC, AIF, and EndoG from mitochondria to cytosal through openings on outer 
mitochondria membrane (Green, 2000b; Schuler and Green, 2001).  
 In Chapter 4 and 5, we have discovered that luteolin was capable of sensitizing 
apoptotic cell death induced by TNF or TRAIL in various human cancer cells, 
suggesting the potential therapeutic value of luteolin in cancer therapy. The resistance 
by tumor cells to cisplatin is one of the major limitations in cisplatin chemotherapy 
(Kartalou and Essigmann, 2001; Siddik, 2003). Furthermore, it would be of interest to 
find out whether luteolin, a common flavonoid that could be found in plants, could 
have a synergistic anti-cancer effect with a commonly used chemotherapeutic agent. 
In this part of our study, we aimed to evaluate the effect of luteolin on the 
chemotherapeutic efficacy of cisplatin, using both in vitro cell culture and in vivo 
cancer cell xenograft model. We reported here that luteolin significantly enhanced the 
anti-cancer effects of cisplatin by sensitizing cisplatin-induced apoptosis. The 
molecular mechanism responsible for this enhancement activity is found to be closely 
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related to the p53-controlled cell death pathway: luteolin is capable of stabilizing p53 
and promoting the activity of the pro-apoptotic Bcl-2 family member Bax at the site 
of mitochondria. Results from this study provide new evidence for the potential 
application of luteolin as a chemosensitizer in cancer therapy. 
 
6.2 MATERIALS AND METHODS 
6.2.1 Reagents and chemicals 
 Luteolin, 4'-6-Diamidino-2-phenylindole (DAPI), cisplatin, camptothecin, 
doxorubicin and anti-Bax 6A7 antibody were all purchased from Sigma (St Louis, 
MO). Pan-caspase inhibitor z-VAD-fmk was from Calbiochem (San Diego, CA). 
Anti-caspase 3, anti-Bcl-2, anti-Bcl-xL, anti-Bid, anti-p53 and anti-ubiquitin 
antibodies were from Cell Signaling Technology (Beverly, CA). Anti-Bax antibody 
was from Chemicon (Temecula, CA). Anti-XIAP antibody was from BD transduction 
laboratories (San Diego, CA). Anti-tubulin and anti-MDM2 antibody was obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA). Fluorescin (FITC)-labeled 
synthetic siRNA (scrambled siRNA and p53 siRNA) were from QIAGEN (Valencia, 
CA).  
6.2.2 Cell culture and treatments 
 Human liver cancer cells HepG2 and Hep3B, and human colorectal cancer 
cells HT29 and HCT116 were from American Type Culture Collection (ATCC, 
Manassas, VA) and human nasopharyngeal cancer cells CNE1 was obtained from Sun 
Yet-sat University (Guangzhou, China). HepG2, HCT116 and CNE1 were maintained 
in DMEM medium (Sigma) with 10 % FBS (Hyclone, Logan, UT). HT29 cells were 
maintained in Mcoy5A medium with 10 % FBS. 
6.2.3 Apoptosis assessment-4’,6-diamidino-2phenylindole staining 
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 The cells undergoing apoptosis were evaluated by chromatin condensation, 
nuclear shrinkage and formation of apoptotic bodies, all visualized with 4’,6-
diamidino-2phenylindole (DAPI) staining (Fuentes et al., 2003). After various 
designated treatments, medium was removed and cells were fixed with 70% ethanol at 
room temperature for 10 minutes. Cells were then stained with 0.3 μg/mL DAPI (in 
PBS) at room temperature for 10 minutes and visualized under an inverted 
fluorescence microscope and photographed.  
6.2.4 RNA interference 
 HCT116 cells were transfected with scrambled siRNA labeled with FITC or 
p53 siRNA using the Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, 
CA). The knockdown efficiency was confirmed by western blotting.  
6.2.5 Immunoprecipitation, cell fractionation and Western blot 
 Cells were lysed in Chaps lysis buffer [150 mM NaCl, 10 mM HEPES (pH 7.4) 
and 1 % Chaps] for 1 hour on ice. The supernatant was collected after centrifugation 
at 20,000 × g for 15 minutes. Each sample was added with 0.5 μg anti-Bax 6A7 
antibody or anti-MDM2 antibody and 50 μL protein A/G agarose beads (Roche 
Molecular Biochemicals, Indianapolis, IN) and rotated overnight at 4°C. The beads 
were washed four times using ice-cold PBS buffer and then eluted using SDS-sample 
buffer before subject to western blot analysis (Izeradjene et al., 2005). For cell 
fractionation, treated cells were suspended in 100 μl of buffer (20 mM HEPES, 10 
mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 0.1 mM 
phenylmethylsulfonyluoride, 250 mM sucrose, pH 7.5), homogenized by a syringe 
with a 27-guage needle for 15–20 times. The lysate was centrifuged at 1000 g for 10 
min to spin down the intact cells and nuclear. The supernatant was further centrifuged 
at 15 000g for 1 h to obtain cytosolic fraction. For Western blot, equal amount of 
 182
proteins were fractionated on SDS-polyacrylamide gel in the Mini-PROTEAN II 
system (Bio-Rad, Hercules, CA) and blotted onto PVDF membrane (Millipore, 
Bedford, MA). After blocked with 5% nonfat milk in TBST [10 mM Tris-HCl (pH 
7.5), 100 mM NaCl and 0.1% Tween 20], the membrane was probed with various 
antibodies and developed with enhanced chemiluminescence (Pierce, Rockfold, IL) 
using a Kodak Image Station (Kodak, Rochester, NY). 
6.2.6 RNA extraction and real time-PCR 
RNA extraction was carried out using a total RNA extraction kit Purescript 
(Gentra Systems Inc., Minneapolis, MN), following the instructions of the 
manufacturer. Five μg of total RNA from each sample were subjected to reverse 
transcription using M-MLV reverse transcriptase (Promega, Madison, IL). Real-time 
PCR was carried out with QuantiTect SYBR Green PCR kit (QIAGEN, Valencia, CA) 
using 2 μL cDNA in a 20 μL final volume. Quantitative PCR was performed using an 
Opticon real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA) for 45 
cycles. A threshold cycle (CT) value, corresponding to the PCR cycle number at 
which fluorescence was detected above threshold, was calculated using Opticon 
analysis software (Bio-Rad Laboratories, Hercules, CA). The data was expressed as 
the fold increase after normalization using G3PDH. The primers of p53, 
glyceraldehydes-3-phosphate dehydrogenase (G3PDH) (Mafune et al., 1999) and 
human MDM2 (Wu et al., 2004a) were based on literature. 
6.2.7 In vivo nude mice xenograft experiment 
 To assess the effect of luteolin on the anti-cancer efficacy of cisplatin under in 
vivo condition, we used a nude mice xenograft model. The protocol was approved by 
the University Institutional Animal Care and Use Committee (IACUC). Briefly, 
female Balb/c nude mice of 5-6 weeks old, about 20 g were purchased from the 
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Animal Resources Centre (Murdoch, Australia) and maintained in SPF facility. The 
mice were inoculated subcutaneously in the two sides of flank with 107 HCT116 cells 
in a volume of 100 μL of PBS (Brattain et al., 1981). One week post-inoculation, 
mice bearing with visible tumors were randomly assigned to four experimental groups 
(six mice per group): vehicle (PBS), luteolin (40 mg/kg body wt), cisplatin (1.25 
mg/kg body wt) and luteolin (40 mg/kg body wt) plus cisplatin (1.25 mg/kg body wt). 
The dose of cisplatin we used was much lower than that in other studies ranging from 
3 mg/kg to 6 mg/kg (Hofmann et al., 1990; Okamoto et al., 2001; Goto et al., 2004). 
The dose of luteolin was based on our preliminary study and was comparable with 
that of other flavonoids used in vivo (Hofmann et al., 1990). The treatment was 
administered through i.p. three times per week (every Monday, Wednesday and 
Friday) with close monitoring of the general conditions of the animals. After three 
weeks, all mice were sacrificed by CO2 inhalation, the tumors were isolated and 
tumor weight and size were measured.  
6.2.8 Immunohistochemistry for p53 staining 
 p53 expression in tumor was evaluated by immunohistochemical staining. The 
tumor tissues obtained above were fixed in buffered formalin (10%) for paraffin 
sectioning. The p53 protein level was detected by immunohistochemistry with light 
counterstaining using haematoxylin. The cell thus stains brown in a positive and blue 
in a negative case. 
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6.3 RESULTS 
6.3.1 Luteolin enhances cisplatin-induced caspase-dependent apoptosis in human 
cancer cells  
 Many cancer cells are resistant to cisplatin-induced apoptosis (Kartalou and 
Essigmann, 2001; Siddik, 2003). As shown in Figure 6.1, all three cancer cells, 
HepG2, CNE-1 and HCT116 cells were rather refractory to cisplatin: only small 
fraction of cells (<5%) were apoptotic when treated with 10 μg/mL of cisplatin for 24 
h. Luteolin alone at 40 μM did not induce evident apoptosis in any of these cells. 
However, pretreatment with luteolin for 2 h significantly enhanced cisplatin-induced 
apoptosis in all three cancer cells. Apoptotic cells were evaluated by DAPI staining 
which shows typical chromatin condensation in apoptotic cells, as illustrated in Figure 
6.2.  
The apoptosis induced by luteolin and cisplatin was further examined by 
detection of PARP cleavage and caspase activation, the two hall markers of apoptosis. 
Caspase-3 is the main downstream effector caspase and PARP is one of its major 
substrates (Boulares et al., 1999). In HCT116 cells, either luteolin or cisplatin alone 
caused no caspase-3 or PARP cleavage (Figure 6.3). However, their combination led 
to evident cleavage of caspase-3 and PARP, which is consistent with the cell death 
evaluated by DAPI staining (Figure 6.1). Furthermore, the cleavage of PARP and 
caspase 3 were inhibited by a pan-caspase inhibitor, z-VAD-fmk (Figure 6.3), 
























Cisplatin - - 2          5         10         2           5        10
Luteolin     - +           - - - +          +          +
Figure 6.1  Luteolin enhances cisplatin-induced apoptosis in cancer 
cells. 
Cells were pre-treated with luteolin for 2 h (40 μM for HCT-116 and CNE-
1, 20 μM for HepG2) and then treated with indicated concentrations of 
cisplatin (μg/ml) for another 24 h. Cells were fixed with 70% ethanol for 5 
min and then stained with 0.3 μM DAPI for 10 min. Apoptotic cells were 
counted according to their morphologic changes under a fluorescence 





Figure 6.2 Luteolin enhances cisplatin-induced apoptosis in 
HCT116 cells. 
HCT116 cells were treated with cisplatin (10 μg/ml) for 24 h with or 
without luteolin (40 μM× 2 h) pretreatment. Cells were fixed with 
70% ethanol for 5 min and then stained with 0.3 μM DAPI for 10 min. 
Pictures were taken under an inverted fluorescence microscope with 
UV stimulation 
 187
Luteolin     - +           - +           +
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Figure 6.3 A combination of luteolin and cisplatin causes 
caspase activation 
HCT116 cells were treated with luteolin (40 μM × 2 h) 
followed by cisplatin (10 μg/ml) for 24 h, with or without the 
presence of z-VAD-fmk (25 μM, 30 min pretreatment). Cells 
were then collected for detection of PARP and caspase 3 using 
Western blot. Tubulin was used as a loading control. 
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6.3.2 Luteolin and cisplatin elevate p53 protein level 
            To elucidate the possible mechanism involved in the sensitization effect of 
luteolin on cisplatin-induced apoptosis, we first examined the changes of several 
important apoptosis regulatory proteins, such as XIAP, Bcl-2, Bcl-XL and Bax in cells 
treated with luteolin and cisplatin. However, none of them demonstrated any 
significant changes in HCT116 cells (Figure 6.4). Since cisplatin is known to activate 
p53 via DNA damage and p53 is the key regulator for cisplatin-mediated apoptosis in 
cancer cells (Siddik, 2003), we next examined the change of p53 protein in HCT116 
cells treated with luteolin, cisplatin, or their combination. As shown in Figure 6.4, 
luteolin or cisplatin alone is capable of enhancing p53 protein level significantly. 
More importantly, combined treatment of luteolin and cisplatin further increased the 
p53 protein level, especially at 12 and 18 h after treatment, suggesting that p53 may 
play an important role in promoting luteolin and cisplatin-induced apoptosis. 
 
6.3.3 Luteolin does not enhance cisplatin-induced apoptosis in mutant p53 cells  
          To further test the involvement of p53 in apoptosis induced by combined 
treatment of luteolin and cisplatin, we compared the responses of cells with different 
genetic features of p53. As shown in Figure 6.5, luteolin plus cisplatin induced 
significant apoptosis in HepG2  and HCT116 cells, both of them are with wild type 
p53 (Boyer et al., 2004). In contrast, luteolin plus cisplatin failed to induce evident 
apoptosis in Hep3B or HT29 cells with a mutant p53. Therefore, it is believed that 
induction of apoptosis by luteolin and cisplatin is dependent on the presence of 
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Figure 6.4 A combination of luteolin and cisplatin elevates p53 
protein level
HCT116 cells were treated with cisplatin (10 μg/ml) for the indicated 
period with or without the presence of luteolin pretreatment (40μM×
2 h). Cells were collected for detection of p53,XIAP, Bcl-xL, Bax and 








Figure 6.5 A combination of luteolin and cisplatin does not 
cause apoptosis in mutant p53 cancer cells
Cells were pre-treated with luteolin for 2 h (40 μM for HCT-116 
and HT29, 20 μM for HepG2 and Hep3B) and then treated with 
cisplatin (10 μg/ml) for another 24 h. Cells were fixed with 70% 
ethanol for 5 min and then stained with 0.3 μM DAPI for 10 min. 
Pictures were taken under an inverted fluorescence microscope 
with UV stimulation.
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6.3.4 p53 knockdown abolishes the apoptosis induced by luteolin and cisplatin 
 In order to further confirm the role of p53 in apoptosis induced by luteolin and 
cisplatin, we knocked down p53 protein in HCT116 cells using the technique of RNA 
interference. The transfection efficiency of siRNA was higher than 90%, as monitored 
by a FITC-labeled siRNA (data not shown). The knockdown efficiency was 
confirmed by Western blot. As shown in Figure 6.6, luteolin plus cisplatin elevated 
p53 protein level in cells transfected with scrambled siRNA, which does not target 
any gene. The p53 protein level was significantly reduced in cells transfected with 
p53 siRNA. We then examined the apoptosis rate induced by luteolin and cisplatin 
after various siRNA transfections. Luteolin plus cisplatin caused significant apoptotic 
cell death in cells transfected with scrambled siRNA (Figure 6.7), which is similar to 
the cell death in non-transfected cells (Figure 6.1). However, p53 knockdown 
significantly reduced the number of apoptotic cells induced by luteolin and cisplatin. 




Lu+Cisplatin - +              - +
Scrambled siRNA p53 siRNA
p53
Figure 6.6 p53 RNA interference
HCT116 cells were transfected with scrambled siRNA labeled 
with FITC, or p53 siRNA for 24 h, then cells were treated with 
luteolin (40 μM) for 6 h and cells were collected for detection 























Figure 6.7 p53 RNA interference suppresses the apoptosis induced
by luteolin and cisplatin in HCT116 cells
HCT116 cells were transfected with scrambled siRNA or p53 siRNA for 
24 h, then were treated with luteolin (40 μM× 2 h) followed by 
cisplatin (10 μg/ml × 24 h). The cells were fixed with 70% ethanol 
and stained with 0.3 μM DAPI for 10 min. Apoptotic cells were counted. 
Column, mean of three independent experiments; bar, SD. 
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6.3.5 Luteolin elevates p53 by increasing its protein stability 
 One important finding from Figure 6.4 is that luteolin alone can elevate p53 
protein level significantly and rapidly. In the presence of luteolin, significant increase 
of p53 protein was found as early as 3 h, which is much faster than the changes 
induced by cisplatin. Such a kinetic difference suggests that luteolin and cisplatin 
promotes p53 protein accumulation via different mechanisms. To elucidate the 
mechanisms of p53 elevation by luteolin, we first examined the effect of luteolin on 
p53 mRNA level. However, luteolin did not affect p53 mRNA level at 1, 3, or 6 h 
(Figure 6.8), when p53 protein was significantly elevated (Figure 6.4), suggesting that 
the rapid elevation of p53 protein level by luteolin is not regulated at transcriptional 
level.  
 p53 is a short half-life protein, which is degraded rapidly once it is synthesized. 
We then examined the p53 stability in the presence of luteolin. In cells treated with 
cycloheximide (CHX), a de novo protein synthesis inhibitor to block p53 protein 
synthesis, the p53 protein was rapidly degraded, showing a half-life of around 15 min 
(Figure 6.9). On the other hand, luteolin can significantly prolong the half-life of p53 
to about 60 min, suggesting that luteolin promotes p53 protein stabilization. 
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Figure 6.8 Luteolin does not affect p53 mRNA level in HCT116 cells
HCT116 cells were treated with luteolin (40 μM) for indicated period. 
Cells were collected for detection of MDM2 mRNA level using real
time PCR. G3PDH was used for normalization.
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Figure 6.9 Luteolin elevates p53 stability in HCT116 cells
HCT116 cells were treated with luteolin (40 μM) or vehicle for 30 min 
followed by cycloheximide (CHX) (1 µg/ml) for the indicated period. 
Cells were collected for detection of p53 and tubulin using Western blot.
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6.3.6 Luteolin increases p53 protein stability by inhibiting MDM2 and disrupting 
their interaction 
 Stability of p53 protein is mainly regulated by its interaction with its 
transcriptional target mouse double minute 2 (MDM2), which acts as an ubiquitin E3 
ligase and promotes p53 ubiquitination and proteasomal degradation (Kubbutat, 1997; 
Chi et al., 2005). We then investigated the effect of luteolin on the interaction 
between p53 and MDM2 using immunoprecipitation. In vehicle-treated cells, there 
was an interaction between p53 and MDM2, which is supposed to mediate p53 
ubiquitination and degradation. However, the interaction was significantly disrupted 
by luteolin (Figure 6.10). 
 One important finding from the data presented in Figure 6.10 is that luteolin 
treatment reduced the MDM2 protein level. We thus decided to examine the time 
course of MDM2 protein level change after luteolin treatment. Interestingly, MDM2 
protein level decreased after 3 or 6 h treatment of luteolin (Figure 6.11), which 
occurred at the same when p53 protein was elevated (Figure 6.4). These findings 
suggest that luteolin stabilizes p53 protein level by decreasing MDM2 protein and 
disrupting its interaction with p53.  
 To elucidate the mechanism of MDM2 protein down-regulation by luteolin, 
we then tested whether MDM2 was regulated at transcriptional level. Figure 6.12 
shows that luteolin significantly decreased MDM2 mRNA level at as early as 1 h, 
which was earlier than the protein level change (Figure 6.11). As expected, evident 
reduction of MDM2 mRNA level was found in cells treated with actinomycin D 
(ActD), a transcription inhibitor. However, cisplatin did not appear to affect the 










Figure 6.10 Luteolin disrupts the p53-MDM2 interaction in 
HCT116 cells
HCT116 cells were treated with luteolin (40 μM) or vehicle for 6 
h. Cell lysate was immunoprecipated with anti-p53 antibody, 
followed by Western blot using anti-MDM2 antibody. 1 % input 
lysate was subjected to Western blot to detect MDM2 and tubulin.
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MDM2
Luteolin (h)         - 1           3            6 
Tubulin
Figure 6.11 Luteolin decreases MDM2 protein level
HCT116 cells were treated with luteolin (40 μM) for 
indicated period. Cells were collected for detection of 
MDM2 protein level using Western blot. Tubulin was used as 
a loading control. 
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Luteolin (h)     - 1              3               6              - -
ActD                - - - - +               -














Figure 6.12 Luteolin decreases MDM2 mRNA level
HCT116 cells were treated with luteolin (40 μM) for indicated period 
or actinomycin D (ActD 1 μg/ml) for 6 h or cisplatin (µg/ml) for 12 h. 
Cells were collected for detection of MDM2 mRNA level using real
time PCR. G3PDH was used for normalization.
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6.3.7 Luteolin and cisplatin induces p53 and Bax mitochondrial translocation 
 Since the apoptosis induced by luteolin and cisplatin was not prevented by a 
specific caspase 8 inhibitor, z-IETD-fmk (data not shown), suggesting that the 
apoptosis is unlikely to be executed via the extrinsic death receptor pathway, but 
rather the intrinsic mitochondrial pathway. This speculation was confirmed by the 
finding that cytochrome c release to cytosol was caused by a combination of luteolin 
and cisplatin (Figure 6.13).  
 Recent evidence suggests that apoptosis mediated by p53 could involve its 
mitochondrial translocation (Chipuk et al., 2003; Erster et al., 2004). To test whether 
this is the case in luteolin and cisplatin combined treatment, we carried out 
mitochondrial fraction. The complete separation was confirmed by the absence of 
tubulin in mitochondria fraction. Figure 6.14 shows that both luteolin and cisplatin 
caused p53 translocation to mitochondria, whereas the combination treatment of 
luteolin and cisplatin induced an even more extensive p53 mitochondrial translocation. 
 The p53 mediated transcription-independent apoptosis requires the 
involvement of another partner, Bax (Chipuk et al., 2003). Although the total protein 
level of Bax was not increased by either luteolin, cisplatin or their combination 
(Figure 6.4), Bax translocation to mitochondria was significant in the presence of 
luteolin. For the combined treatment, the translocation was even more significant 
(Figure 6.14). 
 It is known that the pro-apoptotic function of Bax requires its transformational 
changes (Park et al., 2002). The activated Bax on mitochondria can be distinguished 
by a conformational change in the N-terminus that exposes the formerly buried 6A7 
epitope (Desagher et al., 1999; Nechushtan et al., 1999). We thus used a specific 
antibody, anti-Bax 6A7, to pull down the active form of Bax and detect it using 
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Western blot. As shown in Figure 6.15, the Bax transformation was increased by 
either luteolin or cisplatin. More importantly, Bax was further activated when 
cisplatin was treated together with luteolin. The above observations suggest that the 
enhanced p53 and Bax mitochondrial translocation, as well as enhanced Bax 
transformation, contribute to enhanced apoptotic cell death induced by combined 
treatment of luteolin and cisplatin. 
6.3.8 Luteolin enhances the anti-cancer effect of cisplatin in vivo  
 To evaluate the potential of luteolin as a sensitizer of cisplatin in vivo, we 
tested the combined anti-cancer effect of the two agents on HCT116 xenografted nude 
mice. As shown in Figures 6.16 and 6.17, the tumor in vehicle-treated mice grew very 
fast and increased to about 1.2 g after 3 weeks. Low dose of cisplatin (1.25 mg/kg 
body weight) alone slightly suppressed the tumor growth and luteolin (40 mg/kg body 
weight) alone did not affect much the tumor growth. However, tumor weight was 
significantly reduced by the combined treatment. In several mice, the tumor was 
almost invisible (Figure 6.16). Therefore the in vivo evidence confirms that luteolin 
can significantly enhance the anti-cancer effect of cisplatin.  
6.3.9 Luteolin enhanced the anti-cancer effect of cisplatin in vivo by elevating p53  
 To explore the mechanisms involved in the in vivo anti-cancer effect by 
luteolin and cisplatin, the tumor tissue were fixed and stained with anti-p53 antibody 
using immunohistochemistry. In vehicle treated mice, the expression of p53 was only 
marginal (Figures 6.18 and 6.19). Although both cisplatin and luteolin could 
significantly increase the expression of p53 protein, their patterns are different. About 
50% of the cells were found over-expressing p53 in cisplatin-treated mice and the p53 
level was moderate in those cells. In contrast, the p53 protein level in luteolin-treated 
mice was much higher than that in cisplatin-treated mice, although the number of 
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positive cells was less. It is noted that in mice with combined treatment of luteolin and 
cisplatin, more than 80% cancer cells were stained positive and the p53 protein level 
was also significantly higher than the individual treatment. Such a finding is basically 
consistent with in vitro data (Figure 6.4). 
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Cyto C
Luteolin     - +           - +
Cisplatin - - +           +
Tubulin
Figure 6.13 A combination of luteolin and cisplatin induces 
cytochrome c release to cytosol
HCT116 cells were treated with luteolin (40 μM × 2 h) 
followed by cisplatin (10 μg/ml) for 18 h. Cells were then 
collected and cytosol was fractioned for detection of cytochrome
c using Western blot. Tubulin was used as a loading control.
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Figure 6.14 Luteolin and cisplatin induced p53 and bax 
mitochondrial translocation
HCT116 cells were treated with luteolin (40 μM) or cisplatin
(10 μg/mL) or their combination for 12 h. Cells were collected 
and mitochondria fractions were obtained to detect p53 and Bax 
using Western blot. Anti-MnSOD was used as a loading control 
and anti-tubulin was used to prove the absence of cytosal 
proteins. 
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Figure 6.15 Luteolin and cisplatin induced bax mitochondrial 
translocation
HCT116 cells were treated with luteolin (40 μM) or cisplatin (10 
μg/mL) or their combination for 12 h. Cells were collected and 
cell lysate was used for immunoprecipitation using anti-Bax (6A7) 
antibody, followed by Western blot using anti-Bax antibody. Bax 






Figure 6.16  Luteolin enhances the anti-cancer effect of cisplatin in 
vivo
Six-eight weeks Balc/B nude mice (about 20 g) were inoculated with 
107 HCT116 cells in 100 μl PBS. After one week, mice bearing tumor 
were treated with PBS as vehicle, or luteolin (40 mg/kg), or cisplatin
(1.25 mg/kg), or luteolin (40 mg/kg) with cisplatin (1.25 mg/kg), 
through i.p. injection (3 times per week) for 3 weeks. At the end of 
















Vehicle      Cisplatin Luteolin      Lu+Cisplatin
Figure 6.17  Luteolin enhances the anti-cancer effect of cisplatin in 
vivo (Quantification)
Tumor weights (g) of mice treated in Figure 6.16 were measured. 
Column, mean of tumor weight; bar, SD. Six mice in one group. 
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Vehicle Cisplatin
Luteolin Luteolin + Cisplatin
Figure 6.18  Luteolin and cisplatin elevate p53 protein level in vivo
Tumor samples from the mice treated in Figure 6.16 were fixed by buffered 
formalin for paraffin sectioning, p53 expression was evaluated by 
immunohistochemistry after counter staining. The representative field for 
p53 expression was photographed. The p53 positive cell stains brown and 
























Luteolin        - - +                     +
Cisplatin - +                      - +
Figure 6.19  Luteolin and cisplatin elevate p53 protein level in vivo
(Quantification)
The percentages of p53 positive cells in Figure 6.18 were counted in 





 Cisplatin is widely used to treat a variety of tumors. However, resistance to 
this drug is a major limitation for its clinical use (Kartalou and Essigmann, 2001; 
Siddik, 2003). Therefore, treatment together with other agents is a strategy to enhance 
the anti-cancer potential of cisplatin (Duan et al., 2001; Iwase et al., 2003; Kim et al., 
2003a; Fulda and Debatin, 2005; Mohanty et al., 2005). Here we reported that a 
natural flavonoid, luteolin can enhance the anticancer potential of cisplatin through a 
novel mechanism, stabilizing p53 protein and causing p53 and Bax mitochondrial 
translocation. 
 As shown in our early studies, luteolin could sensitize TNF and TRAIL-
induced apoptosis in a variety of human cancer cells (Chapters 4 and 5). We thus 
further examine whether luteolin has a synergistic effect when combined with anti-
cancer drugs, such as cisplatin. 
 As shown in Figure 6.1, several human cancer cells are resistant to cisplatin, 
while luteolin, at its non-toxic concentration, significantly enhanced cisplatin-induced 
apoptosis (Figure 6.3). Moreover, this sensitization effect was only observed in p53 
wild type HCT116 and HepG2 cells, but not in p53 mutant cells such as Hep3B and 
HT29 (Figure 6.5). The critical role of p53 status was further supported by the 
following observations: (i) the significant elevation of p53 protein (Figure 6.4), (ii) 
knockdown of p53 by siRNA offered significant protection against apoptosis induced 
by a combined treatment of luteolin and cisplatin (Figures 6.6 and 6.7). 
 To be noted, the increase of p53 protein by luteolin is rapid, occurred as soon 
as 3 h after treatment (Figure 6.4). It has been previously reported that luteolin can 
activate p53 in p53 wild type cancer cells (Plaumann et al., 1996), but the mechanism 
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was not known. It is possible that luteolin can inhibit topoisomerase I (Mittra et al., 
2000; Chowdhury et al., 2002) to cause DNA damage (Leung et al., 2005). However, 
this could not explain the significant and rapid elevation of p53 protein within 3 h, 
since cisplatin, a typical DNA-damaging agent, could only elevate p53 protein after 6 
h in HCT116 (Figure 6.4). Further, we showed that the rapid p53 elevation is not 
dependent on p53 mRNA increase (Figure 6.8) but through stabilizing of this short-
lived protein (Figure 6.9). p53 stability is mainly regulated by its interaction with 
MDM2 protein, which interacts with p53 directly and promotes its ubiquitination and 
proteasomal degradation. In this study, we demonstrated that the rapid p53 
accumulation by luteolin is through decreasing MDM2 protein (Figure 6.11) and 
disrupting the MDM2-p53 interaction (Figure 6.10). In Chapter 5, we reported that 
luteolin, in the presence of TRAIL, promoted XIAP ubiquitination and proteasomal 
degradation without affecting its mRNA level. Here we tested whether luteolin also 
affected MDM2 protein via a similar mechanism. Very interestingly, we found that 
luteolin decreased MDM2 mRNA level (Figure 6.12) but did not promote MDM2 
ubiquitination (data not shown). Since MDM2 is one of the target gene of the 
transcriptional factor p53, it was expected to see that luteolin caused elevation of 
MDM2 mRNA and protein level corresponding with the marked increase of total p53 
protein level (Figure 6.4) induced by luteolin. Conversely, we found that MDM2 
mRNA level decreased after luteolin treatment, suggesting that luteolin may either 
suppress the transcriptional activity of p53 or adversely affect MDM2 mRNA stability. 
The exact mechanism remains to be further investigated. 
 There were reports that the anti-cancer effect of cisplatin largely depends on 
the p53 status of the tumors (Song et al., 1998; Kanata et al., 2000; Tang and Grimm, 
2004; Beuvink et al., 2005). It has been demonstrated that the resistance to cisplatin 
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could be overcome by enhancing or restoring the wild type p53 in p53 mutant cancer 
cells (Song et al., 1997). The apoptosis induced by p53 is mainly mediated by the 
mitochondria pathway, a central regulator of apoptosis. In response to death stimuli 
including p53 activation, cytochrome C and SMAC are released from mitochondria to 
cytosal and facilitate the caspase activation and nuclear fragmentation (Green, 2000b). 
The cytochrome c release is not present in either luteolin or cisplatin treated cells 
(Figure 6.13). A combined treatment of luteolin and cisplatin led to the release of 
cytochrome c to cytosol prior to apoptosis, indicating the involvement of 
mitochondria in the apoptosis.  
 Generally there are two pathways in p53-mediated apoptosis: the transcription 
dependent and transcriptional activity-independent pathway. In the former, p53 could 
enhance the transcription of some pro-apoptotic proteins, such as Bax, Noxa and 
PUMA (Miyashita and Reed, 1995; Attardi et al., 2000; Oda et al., 2000b; Yu et al., 
2001). However, in this study we did not observe the elevation of Bax after the 
combined treatment. On the contrary, we found that the mRNA level of MDM2 and 
p21, two downstream genes regulated by p53, reduced, indicating that the p53 
transcription-dependent pathway may not be involved in the apoptosis induced by 
luteolin and cisplatin. Currently there is accumulating evidence suggesting that p53-
mediated apoptosis is independent of its transcriptional activity, a process mainly 
involving mitochondrial translocation of p53 and some pro-apoptotic Bcl-2 family 
members such as Bax (Chipuk et al., 2003; Erster et al., 2004; Arima et al., 2005). In 
non-stimulated cells, Bax exists as a monomer either in the cytosol or loosely attached 
to the outer mitochondrial membrane. Although Bax total protein level was not 
affected in the present study (Figure 6.4), we observed that luteolin alone could 
induce translocation of p53 and Bax to mitochondria (Figure 6.14). In contrast, 
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cisplatin alone only induced marginal p53 and Bax mitochondrial translocation. The 
combined treatment of luteolin and cisplatin further enhanced p53 and Bax 
mitochondrial translocation as well as Bax transformation, suggesting the importance 
of such changes.  
 In this part of our study, the anti-cancer effect of combined treatment of 
luteolin and cisplatin was further examined using in vivo xenograft model. The dose 
of cisplatin used in this study was much lower than that in other studies (Hofmann et 
al., 1990; Okamoto et al., 2001; Goto et al., 2004). In our study, cisplatin at 1.25 
mg/ml only slightly suppressed the tumor growth (Figures 6.16 and 6.17). 
Immunohistochemisty showed that the p53 protein was elevated by cisplatin treatment, 
which is consistent with the in vitro data (Figure 6.4). The p53 protein level was also 
elevated by luteolin. Interestingly, luteolin plus cisplatin markedly elevated the p53 
protein level and significantly inhibited the tumor growth (Figures 6.16, 6.17, 6.18 
and 6.19). This in vivo finding suggests that luteolin can enhance the anti-tumor effect 
with a low dose of cisplatin by elevating p53.  
 In conclusion, we found that luteolin, a major flavonoid in chrysanthemum, 
can significantly enhance the anti-cancer effect of cisplatin. The enhancement is 
through decreasing MDM2 mRNA as well as protein level, disrupting the p53-MDM2 
interaction, thus to stabilize p53 protein, leading to mitochondrial translocation of p53 
and Bax, and eventually apoptotic cell death. Data from both the in vivo and in vitro 
experiments provide convincing evidence to support the potential application of 











DISCUSSION AND CONCLUSION 
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 Chrysanthemum morifoium is a common traditional herbal medicine for 
treatment of fever, eye irritation and hypertension, etc in many Asian countries (Jiang, 
2002). The main pharmacological activity of chrysanthemum includes its anti-
inflammatory and anti-oxidant function (Yu and Xie, 1987; Chen et al., 2003). 
Preliminary data from our laboratory have found that the water extract of 
chrysanthemum significantly inhibited the growth of xenografted tumor in nude mice 
(Shen et al., unpublished data), suggesting the potential anti-cancer property of 
chrysanthemum.  
 Many types of active components identified in chrysanthemum have been 
found to own potential anti-cancer function. For instance, more than 50 terpenoids 
identified from chrysanthemum have been shown to possess anti-tumor effects in a 
number of cancer cell lines (Ukiya et al., 2001; Ukiya et al., 2002). However, 
terpenoids are unlikely the active components in the water extract due to their 
insolubility in water. On the other hand, flavonoids are a group of phytochemicals 
ubiquitiously present in plants, and their anti-tumor effects have been well 
documented (Ross and Kasum, 2002). A dozen of flavonoids have been identified 
from chrysanthemum (Hu et al., 1994; Liu et al., 2001; Lee et al., 2003; Hu et al., 
2004). As flavonoids are mostly water soluble, thus are expected to be present in the 
water extract of chrysanthemum. Therefore, it was of interest to determine whether 
those flavonoids are responsible for the anti-cancer potential of chrysanthemum. 
 Apoptosis is a type of cell death characterized by specific morphological and 
biochemical changes (Hengartner, 2000). Insufficient apoptosis is believed to be one 
of the causes of tumor formation (Hanahan and Weinberg, 2000). Thus, induction of 
apoptosis in cancer cells has been an established strategy in cancer therapy. Apoptosis 
is mediated mainly through two signaling pathways, the extrinsic death receptor 
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pathway and intrinsic mitochondrial pathway. In the death receptor pathway, the 
death receptors are triggered by their ligands, such as TNFα and TRAIL, leading to 
the recruitment of adaptor molecules that activate the caspase cascade (Chen and 
Goeddel, 2002). In the mitochondrial pathway, cell death signals converge on 
mitochondria, causing the release of an array of apoptosis regulatory proteins such as 
cytochrome c and SMAC that activates the caspase cascade (Kroemer, 2000). The 
role of mitochondria in apoptosis is mainly mediated by the Bcl-2 family proteins in 
response to a variety of cell death stimuli, including DNA damaging agents or cancer 
therapeutics such as cisplatin.  
 One of the important issues in cancer therapy is resistance. Some cancer cells 
acquire the resistance to apoptosis through a variety of biochemical changes. For 
example, the rapid activation of NF-κB pathway by TNFα will trigger the expression 
of a series of anti-apoptotic proteins, including A20, XIAP and c-IAPs, etc (Krikos et 
al., 1992; Wang et al., 1998; Micheau et al., 2001). These anti-apoptotic proteins can 
then suppress the caspase cascade triggered by TNFα or TRAIL to block apoptosis. 
For example, XIAP can directly interact with caspase-3 to inhibit its activation and 
activity (Deveraux et al., 1997). It is known that cisplatin induces cancer cell 
apoptosis mainly through activating p53 (Siddik, 2003). Thus, high expression of 
MDM2 protein, which suppresses p53 protein level, may cause cancer cells to be 
resistant to cisplatin (Kondo et al., 1995). Therefore, it was important to seek effective 
strategies to overcome the resistance in cancer therapy. 
 As one of the major flavonoids of chrysanthemum (Chapter 2), luteolin has 
been demonstrated to possess a variety of activity, including antioxidant, anti-
inflammation, inhibition of cell proliferation, induction of cell cycle arrest or 
apoptosis, inhibition of topoisomerases and protein kinases, and suppression of 
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metastasis and angiogenesis (see more detailed discussion in Section 1.2). To be noted, 
some of these effects are closely related to the ability of luteolin in modulating the 
activation and function of NF-κB and p53. Luteolin has been demonstrated to block 
LPS-induced NF-κB transcriptional activity in macrophages (Xagorari et al., 2002), 
Rat-1 fibroblasts  (Kim et al., 2003b) and rat IEC-18 cells (Kim and Jobin, 2005). In 
addition, luteolin activates wild type p53 in several cells (Plaumann et al., 1996). It is 
thus postulated that luteolin may interfere with the cell death signaling pathway 
elicited by TNF, TRAIL and cisplatin to modulate the apoptotic cell death process. 
 The main objectives of this study are to investigate the anti-tumor property of 
chrysanthemum and its major flavonoids, luteolin. The whole study included the 
following investigation: 1) identification of the major anti-tumor components of the 
water extract of chrysanthemum, (presented in Chapter 2); 2) evaluation of the anti-
tumor effects of the major active components, (presented in Chapter 3); 3) 
investigation of the combined effects of luteolin with cancer therapeutic agents, 
including TNF, TRAIL and cisplatin (presented in Chapters 4, 5 and 6). 
7.1 Flavonoids are the major anti-tumor components of chrysanthemum water 
extract 
To investigate the major anti-tumor components in the water extract of 
chrysanthemum, we obtained a crude water extract (Fraction A) and then partitioned 
it into three fractions according to their polarity (Figure 2.1). The bioassay showed 
that the EtOAc fraction were the most potent in inhibiting cancer cell growth (Figure 
2.2). Its cytotoxicity was much higher than that of the crude chrysanthemum water 
extract and other two fractions, suggesting that EtOAc fraction contains the major 
cytotoxic components of the water extract of chrysanthemum.  
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Further chemical assays suggested that there are 13 flavonoids in the EtOAc 
fraction and all of them are conjugated with sugar substitutes. We found that the 
chrysanthemum flavonoids mixture, at 0.25 and 0.5 mg/ml, exerted significant 
cytotoxicity in several colorectal cancer cells (Figure 3.1). It was further showed that 
the cytotoxicity was through induction of apoptosis (Figures 3.2 and 3.3). This was in 
line with the effects of flavonoid extracts of many other plants, which have shown 
anti-tumor effects in the range of 0.05-1 mg/ml (Ye et al., 1999; Kim, 2004; Kim et 
al., 2005d).  
As luteolin is the most abundant flavonoid in the EtOAc extract (Figure 3.4), it 
could have played an important role in the anti-tumor effects of chrysanthemum. 
However, the effects of other components in the chrysanthemum can not be excluded. 
For example, apigenin has also been demonstrated to be highly capable of killing 
cancer cells (Figure 3.4) (Way et al., 2004; Shukla et al., 2005; Torkin et al., 2005; 
Zheng et al., 2005). On the other hand, there may be synergistic effects between 
different flavonoids (Liu, 2004). There is evidence that combination of low doses of 
flavonoids may work cooperatively in blocking cell-cycle progression of cancer cells 
(Wang et al., 2004). 
7.2 Luteolin sensitizes TNFα-induced apoptosis in human cancer cells 
 Many cancer therapeutic agents are capable of eliminating cancer cells by 
inducing apoptotic cell death (Ferreira et al., 2002). TNFα has been regarded as a 
cancer therapeutic cytokine due to its potential of inducing apoptosis in cancer cells 
(Tracey and Cerami, 1993). TNFα induces apoptosis through a typical death receptor 
pathway. It binds to TNFR1, a death receptor, and causes recruitment of a number of 
molecules which can subsequently trigger a caspase cascade (Chen and Goeddel, 
2002). However, most cells are resistant to TNFα-induced apoptosis, mainly due to 
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the fact that TNFα simultaneously activates NF-κB, a cell survival signal transduction 
pathway. Activation of NF-κB induces expression of a number of anti-apoptotic 
proteins such as c-IAP-1, c-IAP-2, XIAP, FLIPs, survivin and A20 (Krikos et al., 
1992; Wang et al., 1998; Micheau et al., 2001). On the other hand, the activation of 
NF-κB also suppresses JNK activation, a signal generally regarded as pro-apoptotic in 
TNF signaling (De Smaele et al., 2001; Tang et al., 2001). Therefore, the therapeutic 
value of TNFα alone in cancer therapy is rather limited.  
 As one of the major flavonoids in chrysanthemum, luteolin can inhibit cancer 
cell growth to certain extent (Figure 3.4), and induce apoptosis in certain cancer cell 
lines (Figure 3.5). Interestingly, in the presence of nontoxic concentrations of luteolin, 
TNF could induce apoptosis rapidly in cancer cells (Figure 4.1). This striking 
synergistic effect suggests that luteolin can interfere with the cell survival mechanism 
elicited by TNFα.  
 Further studies showed that the sensitization is via an inhibition on NF-κB 
(Figure 4.9). TNFα-triggered NF-κB activation and over-expression of at least two 
anti-apoptotic proteins, c-IAP-1 and A20, were suppressed by luteolin (Figure 4.14). 
On the other hand, JNK activation was prolonged in the presence of luteolin due to 
removal of the blocking effect of NF-κB (Figure 4.15).  
 It has been reported that luteolin inhibits LPS-induced NF-κB activation in rat 
fibroblasts without affecting IκBα degradation, p65 nuclear translocation and p65-
DNA binding (Xagorari et al., 2001), which is in line with our findings (Figures 4.10 
and 4.11). However, luteolin was found to inhibit LPS-induced NF-κB activation by 
suppressing IκBα degradation in macrophages (Dhanalakshmi et al., 2002), indicating 
that the effect of luteolin on NF-κB may be cell type or stimulus-specific. 
Furthermore, we proved that luteolin inhibits NF-κB activation by disrupting the 
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interaction between p65 and its coactivator, CBP (Gerritsen et al., 1997), one of the 
critical step in p65 transcriptional activation (Kim et al., 2003b).  
 Taken together, data from this part of our study demonstrated a new anti-
cancer function of luteolin: sensitization of human cancer cells to TNFα-induced 
apoptosis. Understanding such an effect of luteolin supports the potential application 
of luteolin as a chemotherapeutic agent against cancer together with TNFα. 
7.3 Luteolin sensitizes TRAIL induced apoptosis in human cancer cells 
 In Chapter 4, we studied the synergistic effect between luteolin and TNFα. In 
our subsequent study, we then focused on the effect of luteolin on TRAIL-induced 
apoptosis. TRAIL is a newly identified member of the TNFR family. The unique 
property of TRAIL is its selectivity: it can kill cancerous or transformed cells but 
spare most of the normal cells (Wang and El Deiry, 2003), thus making TRAIL an 
ideal cancer therapeutic agent. However, one of the major obstacles in its clinical 
application is that many cancer cells are found to be resistant to TRAIL-induced 
apoptosis (Wang and El Deiry, 2003). 
 In this part of study, we observed that luteolin pretreatment greatly enhances 
TRAIL induced-apoptosis in human cancer cells, including those TRAIL-resistant 
cancer cells (Figures 5.2 and 5.3), indicating the potential of using luteolin as a 
chemosensitizer to overcome TRAIL resistance. In search of the molecular 
mechanisms involved in the sensitization, we first excluded the possibility of NF-κB 
inhibition or altered expression of DR4 and DR5, two death receptors for TRAIL 
(Figures 5.7, 5.8 and 5.9). Instead, we found significant reduction of XIAP protein 
level in cells treated with luteolin and TRAIL (Figure 5.11). XIAP is known to be  the 
most important member of IAP family as it can directly bind to and inhibit both 
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caspase 9 and caspase activity (Deveraux et al., 1997; Deveraux and Reed, 1999; 
Riedl et al., 2001).  
 The expression level of XIAP could be regulated at both transcriptional and 
post-transcriptional levels. At transcriptional level, XIAP is known to be one of the 
target genes of NF-κB (Deveraux and Reed, 1999). Since TRAIL fails to activate NF-
κB in our system (Figure 5.9) and there is no change of its mRNA level (Figure 5.14). 
We then focused on the post-transcriptional regulatory mechanisms of XIAP. It is 
known that the RING finger domain of XIAP has ubiquitin protease ligase (E3) 
activity and is responsible for its autoubiquitination and proteasomal degradation 
(Yang et al., 2000b). It is also known that XIAP ubiquitination and degradation 
depends partly on its phosphorylation status as protein kinases such as AKT have 
been shown to block XIAP ubiquitination and degradation via phosphorylation (Dan 
et al., 2004). In this study, we demonstrated a novel PKC signaling mechanism: PKC 
activation contributes to XIAP protein stabilization via enhanced XIAP 
phosphorylation and reduced protein ubiquitination and degradation. More 
importantly, luteolin is probably acting as a PKC inhibitor to inhibit XIAP 
phosphorylation and to promote its ubiquitination and proteasomal degradation. Such 
a finding is important since many cancer cells contain elevated basal PKC level and 
many tumor promoters such as PMA are known to be potent PKC activators (Harper 
et al., 2003b). 
 Combination of TRAIL with other anti-cancer agents has been a promising 
strategy to enhance the therapeutic efficiency of TRAIL and to overcome TRAIL 
resistance (Bagli et al., 2004; Huerta-Yepez et al., 2004; Rosato et al., 2004; von 
Haefen et al., 2004). Our data provide convincing evidence for the potential 
therapeutic application of luteolin in overcoming TRAIL resistance.  
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7.4 Luteolin enhances the anticancer effect of cisplatin in vitro and in vivo 
 Cisplatin has been used successfully as an anti-cancer drug in variety of 
cancers. It has been well established that cisplatin kills the cancer cells via induction 
of DNA damage and p53 activation (Siddik, 2003). However, changes in p53 
signaling pathway, for example, elevation of MDM2 protein level, confer cancer cells 
to resistant to cisplatin (Kondo et al., 1995). 
 In this part of our study, we focused on effect of luteolin on the anti-cancer 
efficacy of cisplatin using both in vitro cell culture and an in vivo animal model. One 
significant finding is that a functional p53 is required for cell death induced by 
combined treatment of luteolin and cisplatin. Moreover, luteolin alone is capable of 
markedly increasing p53 protein level. It has been reported that luteolin activates wild 
type p53 in several cells (Plaumann et al., 1996), without knowing the mechanism 
involved. Here we provided clear evidence that luteolin is capable of stabilizing p53 
protein through suppression of MDM2 gene transcription. Such a finding is indeed 
consistent with a previous report that apigenin could activate p53 through decreasing 
MDM2 protein level, indicating that there might exist a common mechanism by 
which flavonoids activate p53.  
 The chemosensitization effect of luteolin was further tested in a nude mice 
xenograft model. While a relatively low dose of luteolin or cisplatin only marginally 
suppressed the tumor cell growth, the combined treatment of luteolin and cisplatin led 
to significant reduction of tumor size (Figures 6.16 and 6.17). Importantly, higher 
level of p53 protein was also observed in tumor tissues in mice receiving combined 
treatment of luteolin and cisplatin, suggesting that luteolin acts via a similar 
mechanism as observed in vitro to enhance the therapeutic efficacy of cisplatin in vivo. 
Although the combined treatment of luteolin and cisplatin will only be workable in 
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cancers with wild-type p53, luteolin is certainly valuable as a chemosensitizer to 
improve the efficacy of cisplatin or other DNA damaging agents in cancer therapy.  
7.5 Luteolin as a chemosensitizer in cancer therapy 
 One of the focuses of this study is to examine the synergistic effect of luteolin 
with other cancer therapeutic agents, although luteolin alone at a relatively high 
concentration, is capable of inducing apoptotic cell death in cancer cells (Chapter 3). 
Systematic studies were conducted to demonstrate the sensitization activity of luteolin 
on cancer cell apoptosis induced by TNFα (Chapter 4), TRAIL (Chapter 5) and 
cisplatin (Chapter 6).  
 In the summary of the sensitization activity of luteolin, one important point 
emerges: luteolin is capable of utilizing distinct mechanisms depending on the nature 
of the cell death stimuli. For TNFα-induced apoptosis, luteolin acts as a NF-κB 
inhibitor (Chapter 4). In the presence of TRAIL, it promotes XIAP ubiquitination and 
proteasomal degradation by inhibiting PKC (Chapter 5). In cisplatin-treated cells, 
luteolin is able to stabilize p53 protein via inhibition of MDM2 expression (Chapter 
6). Although distinct mechanisms are involved in different parts of our study, it is 
worth mentioning that some of the above mechanisms are functionally interlinked. 
For instance, XIAP is one of the target genes of NF-κB (Deveraux et al., 1997) and 
constitutively active NF-κB activation found in some cancers would render resistance 
to cancer therapy (Baldwin, 2001). Therefore, treatment with luteolin would then 
offer multiple impacts on XIAP: suppression of XIAP expression via reduced NF-κB 
and promotion of XIAP ubiquitination and degradation. On the other hand, it is 
known that NF-κB activation will lead to decreased p53 stabilization (Tergaonkar et 
al., 2002). NF-κB activation is also implicated in resistance to cisplatin-induced 
apoptosis (Chuang et al., 2002). Therefore, treatment with luteolin may increase p53 
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protein stability via multiple mechanisms, including reduced MDM2 expression and 
suppressed NF-κB signaling pathway. Taken together, such a unique property of 
luteolin makes this compound desirable as a chemosensitizer in cancer therapy. The 
significant synergistic effect of luteolin and cisplatin observed in the in vivo animal 
model tends to support the above notion. 
       Based on the literature and our earlier observations that luteolin could have 
multiple functions and effects in cancer cells, possibly with multiple targets and 
affecting different anti-cancer pathways. It was reported that luteolin can directly 
inhibit the activities of several kinases (Ferriola et al., 1989; Huang, 1996; Conseil, 
1998). However, the linkage of the inhibition with the biological effects has not been 
elucidated. Furthermore, it is not clear whether other molecular targets are also 
involved. Sporadic reports have also shown that many flavonoids showed similar 
biological effects as luteolin (Gerritsen et al., 1997; Plaumann et al., 1996; Farah et 
al., 2003; Kim et al., 2003b). Thus, it is worthwhile to explore the structure-activity 
relationship systematically. The identification of the molecular targets of some of the 
flavonoids as well as the structure-activity relationship study will also help to 
optimize its pharmacokinetics and pave a way to its clinical application.  
 
7.6 Conclusions 
 In this study, we carried out systematic investigation on the anti-tumor 
properties of chrysanthemum. We first confirmed that flavonoids are the main active 
components responsible of the anti-cancer effect of chrysanthemum. Subsequently we 
focused on the anti-tumor activity of luteolin by examining its sensitization effect on  
cancer therapeutic agents, including TNFα, TRAIL and cisplatin. 
 The major findings are: 
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 1) Flavonoids are the major anti-tumor components of the chrysanthemum 
water extract; 
 2) Chrysanthemum flavonoids exert their anti-tumor activity by inducing 
caspase-dependent apoptosis; 
 3) Luteolin is the major flavonoid in chrysanthemum, and induces caspase-
dependent apoptosis in human cancer cells; 
 4) Luteolin sensitizes TNFα-induced apoptosis in cancer cells by suppressing 
NF-κB activation and augmenting JNK activation; 
 5) Luteolin sensitizes TRAIL-induced apoptosis in cancer cell by promoting 
XIAP ubiquitination and proteasomal degradation via its inhibitory effect on PKC; 
  6) Luteolin enhances the anti-cancer activity of cisplatin by stabilizing p53 
protein via suppression of MDM2 gene expression;  
 7) Luteolin enhances the anti-cancer activity of cisplatin in a nude mice 
xenograft model.  
 In summary, data from this study clearly demonstrate the anti-tumor activity 
of luteolin, a major flavonoid from chrysanthemum. More importantly, this study 
provides evidence showing that luteolin is highly capable of sensitizing TNFα, 
TRAIL and cisplatin-induced cancer cell apoptosis. Such findings support the 
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